# Patent

## Title
Melanocortin receptor agonists

## Abstract

The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

## Background
TECHNICAL FIELD
The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt or isomer thereof effective as an agonist for melanocortin receptor:




wherein R1, R2, R3, R4 and R5 are as defined below.
The present invention also relates to a process for preparing a compound of the above formula 1.
The present invention also relates to a melanocortin receptor agonistic composition comprising a compound of the above formula 1 as active ingredient, in particular, a composition for the prevention and treatment of obesity, diabetes, inflammation or erectile dysfunction.
BACKGROUND ART
Five subtypes of receptors have been cloned and characterized in the melanocortin family. These G-protein coupled receptors (GPCR) stimulate the cAMP signal transduction pathway in many different tissues, mediating a wide range of physiological functions. Melanocortin 1 receptor (MC1R) is mainly expressed in melanocytes, monocytes, and mast cells, to mediate pigmentation of the hair and skin and to block inflammation. MC2R is expressed in adipocytes and adrenal cells, to mediate steroidogenesis in the adrenal gland. MC3R is present in the brain, hypothalamus, heart, gut, and placenta, and has been associated with energy homeostasis and inflammation. MC4R is uniquely expressed in the brain, and controls feeding behavior, energy homeostasis, and erectile function. MC4R knock-out mice revealed the phenotype of hyperphasia and obesity. MC5R is found in a wide range of tissues and is considered to play a role for the exocrine gland system.
With a plethora of physiological functions of melanocortin receptors, a large number of compounds have been designed and synthesized in search for potent agonists and antagonists. Early examples are synthetic peptides and peptide analogues that have been identified on the basis of endogenous agonist such as MSH. These peptide agonists have been used to characterize the function of these receptors. NDP-MSH is a highly potent and nonselective agonist of MC1R, 3R, 4R and 5R, and has been reported to attenuate food intake and body weight gain in rat models. A cyclic heptapeptide MT-II is an agonist with a similar non-selective profile, and its therapeutic use has been proven in clinical trials for the treatment of erectile dysfunction.
Small molecule agonists for the melanocortin receptors have been reported to have significant activity in drug trials for the treatment of obesity, sexual dysfunction or inflammation. For example, a series of potent and selective MC4R agonists has been identified, one of which demonstrated significant effect for augmenting erectile response in mice (J. Med. Chem. 2002, 45, 4849). A number of MC4R agonists have also been identified, which displayed hyphophasic activity and anti-obesity effect in the rat model (Bioorg. Med. Chem. Lett. 2005, 15, 171, Bioorg. Med. Chem. Lett. 2005, 15, 3430, Bioorg. Med. Chem. Letu. 2005, 15, 3501). A highly potent and selective MC1R agonist has been discovered, which showed efficacy in an acute mouse model of inflammation (J. Med. Chem. 2003, 46, 1123). In addition, a variety of small molecules as MCR agonists have been described in the patent applications (WO 01/55109, WO 01/70337, WO 01/70708, WO 02/018327, WO 02/059095, WO 02/059107, WO 02/059117, WO 02/059108, WO 02/081443, WO 02/085925, WO 02/15909, WO 02/067869, WO 02/068387, WO 02/068388, WO 03/009847, WO 03/009850, WO 2004/087159, WO 2004/078716, WO 2004/078717, WO 2005/040109, WO 2005/047251, WO 2005/077935, WO 2005/077935, WO 2006/019787, WO 2006/020277, WO 2007/041052, WO 2007/041061, WO 2007/047496, WO 2006/072393, WO 2007/015157, WO 2007/015162).
In view of the unresolved deficiencies of the various pharmaceutical compounds as discussed above, there is continuing need in the art for small molecule MCR agonists and pharmacological compositions that have improved pharmacological profiles. It is, therefore, an object of the present invention to provide novel compounds that are useful for the treatment of obesity, diabetes, sexual dysfunction, and inflammation.
DISCLOSURE OF INVENTION
Technical Solution
The present invention provides a compound of formula 1 having agonistic effect against MCRs, in particular, selective agonistic effect against MC4R, pharmaceutically acceptable salt or isomer thereof.
Another object of the present invention is to provide a process for preparing the compound of formula 1.
Another object of the present invention is to provide a melanocortin receptor agonistic composition comprising the compound of the formula 1, pharmaceutically acceptable salt or isomer thereof as active ingredients, together with a pharmaceutically acceptable carrier.
In particular, the composition according to the present invention has potent effect for the prevention and treatment of obesity, diabetes, inflammation or erectile dysfunction.
MODE FOR THE INVENTION
The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt or isomer thereof:




wherein
R1 represents hydrogen, amidino, C1-C4-alkylamidino, C1-C4-alkanoylamidino, C1-C10-alkyl, C3-C7-cycloalkyl, C6-C10-aryl, heterocycle, heteroaryl, C1-C6-alkylcarbonyl, C1-C7-cycloalkylcarbonyl, C1-C4-alkoxycarbonyl, C6-C10-aryl-C1-C4-alkoxycarbonyl, —SO2—C1-C4-alkyl, —C(O)—N(R6)(R7) or —C(S)—N(R6)(R7),
wherein,
R6 and R7 each independently represents hydrogen, C1-C6-alkyl or C3-C7-cycloalkyl, alkyl, cycloalkyl, heterocycle, aryl or heteroaryl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, amino, C1-C4-alkyl, trifluoromethyl, hydroxy, C1-C4-alkoxy and oxo,
R2 represents C6-C10-aryl or heteroaryl, each of which is unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of halogen, hydroxy, C1-C4-alkyl, C1-C4-alkoxy, cyano and amino,
R3 represents hydrogen, cyano, C1-C6-alkyl, C3-C7-cycloalkyl, C2-C6-alkenyl, monocyclic heterocycle, monocyclic heteroaryl, —C(O)R8 or —C(S)—R8,
wherein, R8 represents hydroxy, C1-C4-alkyl, C1-C4-alkyloxy or N(R9)(R10),
R9 and R10 each independently represents hydrogen, C1-C6-alkyl, C3-C7-cycloalkyl, C1-C4-alkyloxy, phenyl or heteroaryl, or
R9 and R10 may combine each other to form single ring or two rings, or further comprise oxygen atom or sulfur atom,
wherein, alkyl, cycloalkyl, heterocycle, phenyl or heteroaryl is unsubstituted or substituted with a substituent selected from the group consisting of methyl, trifluoromethyl, hydroxy, hydroxyimino, amino, acetylamino, (C1-C4-alkyl)amino and (C1-C4-alkyl)(C1-C4-alkyl)amino,
R4 represents C3-C8-cycloalkyl, C6-C10-aryl, heteroaryl or heterocycle,
wherein, C6-C10-aryl or heteroaryl is unsubstituted or mono- or poly-substituted with a substituent selected from the group consisting of halogen, hydroxy, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy and amino,
cycloalkyl or heterocycle is unsubstituted or mono- or poly-substituted with a substituent selected from the group consisting of halogen, hydroxy, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy and oxo,
R5 represents hydrogen, C1-C6-alkyl, —C(O)—R11, C1-C6-alkylsulfonyl, C6-C10-arylsulfonyl, —(CH2)p—C6-C10-aryl, —(CH2)p-heteroaryl or —(CH2)p—C3-C8-cycloalkyl,
wherein, p represents 1 or 2,
R11 represents C1-C10-alkyl, C2-C6-alkenyl, C3-C8-cycloalkyl, C3-C8-cycloalkenyl, amino, C1-C4-alkylamino, (C1-C4-alkyl)(C1-C4-alkyl)amino, C6-C10-aryl, heteroaryl, or heterocycle,
wherein, alkyl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, mercapto, C1-C4-alkoxy, C1-C3-alkylcarboxy, amino, dimethylamino, C1-C4-alkylcarbonylamino, cyano, carbamoyl, dimethylcarbamoyl, hydroxyimino and oxo,
aryl or heteroaryl is unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of halogen, hydroxy, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy and amino,
cycloalkyl, cycloalkenyl or heterocycle is unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy and oxo.
In the radical definitions of the compound of formula (1) according to the present invention, the term “alkyl” means straight-chain or branched hydrocarbon radical when used alone or in combination with “alkyloxy”. The term “cycloalkyl” represents unsaturated aliphatic ring including cyclohexyl.
The term “aryl” represents 6- to 10-membered aromatic group including phenyl, naphthyl, etc.
The term “heteroaryl” includes 1 to 2 heteroatom(s) selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, and represents aromatic 3- to 6-membered ring which can be fused with benzo or C3-C8-cycloalkyl. Examples of monocyclic heteroaryl are, but not limited to, thiazole, oxazole, thiophene, furane, pyrrole, imidazole, isoxazole, pyrazole, triazole, thiadiazole, tetrazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine, and similar group thereto. Examples of bicyclic heteroaryl are, but not limited to, indole, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzisoxazole, benzthiazole, benzthiadiazole, benztriazole, quinoline, isoquinoline, purine, furopyridine, and similar group thereto
The term “heterocycle” includes 1 to 2 heteroatom(s) from the group consisting of nitrogen atom, oxygen atom, and sulfur atom, and represents 4- to 8-membered ring which can be fused with benzo or C3-C8-cycloalkyl, and which is saturated or has 1 or 2 of double bond. Its examples are, but are not limited to, piperidine, morpholine, thiamorpholine, pyrrolidine, imidazolidine, tetrahydrofuran, piperazine, and similar group thereto.
Preferred compounds among the compounds of formula 1 above are those wherein
i) R1 represents hydrogen, amidino, C1-C4-alkylamidino, C1-C4-alkanoylamidino, C1-C6-alkyl, C3-C7-cycloalkyl, phenyl, monocyclic heterocycle, monocyclic heteroaryl, C1-C6-alkylcarbonyl, trifluoroacetyl, C1-C4-alkoxycarbonyl, C6-C10-aryl-C1-C4-alkoxycarbonyl, —SO2—C1-C4-alkyl, carbamoyl, C1-C6-alkylcarbamoyl, (C1-C6-alkyl)(C1-C6-alkyl)carbamoyl, thiocarbamoyl, C1-C6-alkylthiocarbamoyl or (C1-C6-alkyl)(C1-C6-alkyl)thiocarbamoyl,
more preferably, R1 represents hydrogen, amidino, methylamidino, ethylamidino, acetylamidino, methyl, ethyl, trifluoroethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxazolynyl, imidazolynyl, thiazolynyl, piperidinyl, tetrahydropyranyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, pyridinyl, acetyl, trifluoroacetyl, propionyl, butyryl, isobutyryl, pivaloyl, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, methylsulfonyl, carbamoyl, methylcarbamoyl, ethylcarbamoyl, trifluoroethylcarbamoyl, propylcarbamoyl, isopropylcarbamoyl, butylcarbamoyl, t-butylcarbamoyl, thiocarbamoyl, methylthiocarbamoyl, ethylthiocarbamoyl or methylethylcarbamoyl,
ii) R2 represents phenyl unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of F, Cl and methyl,
more preferably, R2 represents phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-methylphenyl or 2,4-difluorophenyl,
iii) R3 represents hydrogen, cyano, C1-C4-alkyl, C1-C4-alkenyl, —CH2C(CH3)2CH2OH, oxazolyl, thiazolyl, oxazolynyl, thiazolynyl, carboxy, C1-C4-alkylcarbonyl, C1-C4-alkyloxycarbonyl, carbamoyl, thiocarbamoyl, C1-C4-alkylcarbamoyl, (C1-C4-alkyl)(C1-C4-alkyl)carbamoyl, (C1-C4-alkyl)(C1-C4-alkyloxy)carbamoyl, C1-C4-alkylthiocarbamoyl or (C1-C4-alkyl)(C1-C4-alkyl)thiocarbamoyl, phenylcarbamoyl, heteroarylcarbamoyl, azetidinecarbonyl, pyrrolidinecarbonyl, piperidinecarbonyl or morpholinecarbonyl,
wherein, alkyl is unsubstituted or substituted with a substituent selected from the group consisting of hydroxy, hydroxyimino, amino, (C1-C4-alkyl)amino and (C1-C4-alkyl)(C1-C4-alkyl)amino,
more preferably, R3 represents hydrogen, cyano, methyl, ethyl, propyl, allyl, —CHNOH, hydroxymethyl, —CH(CH3)OH, aminomethyl, dimethylaminomethyl, oxazolyl, thiazolyl, oxazolynyl, thiazolynyl, carboxy, acetyl, propanoyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, t-butoxycarbonyl, carbamoyl, thiocarbamoyl, ethylcarbamoyl, t-butylcarbamoyl, dimethylcarbamoyl, methylethylcarbamoyl, methylmethoxycarbamoyl, dimethylthiocarbamoyl, phenylcarbamoyl, heteroarylcarbamoyl, —C(O)NH(CH2)2NH2, azetidinecarbonyl, pyrrolidinecarbonyl, piperidinecarbonyl or morpholinecarbonyl.
iv) R4 represents C4-C7-cycloalkyl or monocyclic heterocycle unsubstituted or mono- or poly-substituted with a substituent selected from the group consisting of halogen, hydroxy, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy and oxo; or phenyl or monocyclic heteroaryl unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of halogen, hydroxy, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy and amino,
more preferably, R4 represents cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, 4,4-dimethylcyclohexyl, 4,4-difluorocyclohexyl, 4-trifluoromethylcyclohexyl, 3,4-tetramethylcyclopentyl, tetrahydropyranyl, pyridinyl, N-methylpyridinyl or phenyl,
wherein, phenyl is unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of F, Cl, methyl and methoxy.
v) R5 represents hydrogen, C1-C5-alkyl, trifluoromethyl, C1-C6-alkylcarbonyl, trifluoroacetyl, acryloyl, methacryloyl, C3-C8-cycloalkylcarbonyl, C3-C8-cycloalkenylcarbonyl, carbamoyl, C1-C4-alkylcarbamoyl, (C1-C4-alkyl)(C1-C4-alkyl)carbamoyl, methanesulfonyl, ethanesulfonyl, propanesulfonyl, benzoyl, hydroxybenzoyl, aminobenzoyl, monocyclic heteroarylcarbonyl, heterocyclecarbonyl, benzyl, —CH2-monocyclic heteroaryl, or —CH2—C3-C8-cycloalkyl, more preferably, R5 represents hydrogen, methyl, ethyl, propyl, isobutyl, hydroxyethyl, —CH2C(CH3)2CH2OH, —CH2C(CH3)2CH(CH3)OH, —CH2CH2NHC(O)CH3, aminoethyl, acetyl, trifluoroacetyl, hydroxyacetyl, methoxyacetyl, ethoxyacetyl, propionyl, ethoxypropionyl, isobutyryl, cyanoisobutyryl, hydroxyisobutyryl, carbamoylisobutyryl, 3,3 dimethylbutanoyl, pivaloyl, fluoropivaloyl, difluoropivaloyl, hydroxypivaloyl, mercaptopivaloyl, dihydroxypivaloyl, methoxypivaloyl, ethoxypivaloyl, aminopivaloyl, dimethylaminopivaloyl, hydroxyiminopivaloyl, acetylisobutyryl, —C(O)C(CH3)2CH(CH3)OH, —C(O)C(CH3)2C(CH3)2OH, acryloyl, methacryloyl, cyclopentanecarbonyl, cyclohexylenecarbonyl, carbamoyl, dimethylcarbamoyl, methanesulfonylcarbonyl, benzoyl, thiopenecarbonyl, furoyl, oxazolecarbonyl, thiazolecarbonyl, imidazolecarbonyl, pyrazolecarbonyl, tetrahydrofuroyl, dihydrofuroyl, tetrahydropyrancarbonyl, morpholinecarbonyl, methanesulfonyl, benzyl, furanmethyl, thiazolemethyl or imidazolemethyl.
The compounds according to the present invention also can form pharmaceutically acceptable salts. These pharmaceutically acceptable salts include acid-addition salts formed by acid which contains pharmaceutically acceptable anion to form non-toxic acid addition salt, for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, and the like; organic carboxylic acid such as tartaric, formic, citric, acetic, trichloroacetic, trifluoroacetic, gluconic, benzoic, lactic, fumaric, maleic, and the like; sulfonic acid such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid or naphthalenesulfonic acid, and the like; and more preferably acid-addition salts formed by sulfuric acid, methansulfonic acid or hydrohalic acid, and the like. The compounds of formula 1 according to the present invention can be converted to its salts by conventional method.
Also, the compounds according to the present invention can have asymmetric carbon center, and so can be present as R or S isomeric forms, racemates, diastereomeric mixtures, and individual diasteromers. The present invention encompasses all these isomeric forms and mixtures.
Also, the present invention relates to a process for preparing the compound of formula 1 comprising amide coupling a compound of formula 2 with a compound of formula 3:




wherein, R1, R2, R3, R4 and R5 are as defined above.
Also, the present invention relates to a process for preparing the compound of formula 1 comprising amide coupling a compound of formula 2′ with a compound of formula 3 to form a compound of formula 1′: and deprotecting the compound of formula 1′:




wherein, R1 represents hydrogen,
R3, R4 and R5 are as defined above,
P represent amino protecting groups, preferably t-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz) or fluorenylmethoxycarbonyl (Fmoc).
Also, the present invention relates to a process for preparing the compound of formula 1 comprising deprotecting the compound of formula 1′ in the above process followed by (i) amide coupling with C1-C6-alkyl-CO2H, or (ii) reacting with isocyanate, C1-C4-alkylisocyanate, isothiocyanate or C1-C4-alkylisothiocyanate:




wherein, R1 represents C1-C6-alkylcarbonyl, carbamoyl, thiocarbamoyl, C1-C4-alkylcarbamoyl or C1-C4-thiocarbamoyl,
wherein, alkyl is unsubstituted or substituted with a substituent selected from the group consisting of halogen, amino, C1-C4-alkyl, trifluoromethyl, hydroxy, C1-C4-alkoxy and oxo;
R2, R3, R4 and R5 are as defined above.
It is preferable to carry out each step of the above processes in conventional solvents which do not have significant deleterious effect to the reaction, and particularly preferable to use one or more kinds selected from the group consisting of, but not limited to, dimethylformamide, dimethylacetamide, tetrahydrofuran, methylene chloride, and chloroform.
Deprotection reaction for amino groups can be carried out in the presence of strong acid such as hydrochloric acid (HCl), trifluoroacetic acid (TFA), etc., in the presence of amine base such as triethylamine, diisopropylethylamine (DIPEA), etc., or by hydrogenation. Specific reaction conditions are described in T. W. Green & G. M. Wuts Protective Groups in Organic Synthesis, Chapter 7, pp 309-405.
Known coupling agents usable in coupling reaction are, but are not limited to, carbodiimides such as dicyclohexylcarbodiimide (DCC), 1-(3 dimethylaminopropyl)-3-ethylcarbodiimide (EDC), 1,1′-dicarbonyldiimidazole (CDI), etc. which are used in a mixture with 1-hydroxybenzotriazole (HOBT) or 1-hydroxy-7-azabenzotriazole (HOAT); bis-(2-oxo-3-oxazolidinyl)-phosphinic acid chloride (BOP-Cl), diphenylphosphorylazide (DPPA), N-[dimethylamino-1H-1,2,3-triazol[4,5-b]pyridine-1-ylmethylene]-N-methylmethaneaminum (HATU), etc.
The compounds of formula 1 prepared by the process of the present invention can be converted to its salts by conventional method.
After the above reactions according to the process of the present invention are completed, products can be separated and purified by conventional work-up methods, for example, chromatography, recrystallization, etc.
The compounds of the present invention have potent agonistic effect against melanocortin receptors, and so the present invention provides a melanocortin receptor agonistic composition comprising the compound of formula 1 as active ingredients together with pharmaceutically acceptable carrier. In particular, the composition according to the present invention has potent effect for the prevention and treatment of, but not limited to, diabetes, erectile dysfunction, obesity and inflammation.
When the compounds according to the present invention are administered for clinical purpose, a preferable daily dose would be within the range of 0.01 ̃10 mg/kg body weight as unitary dosage or separated dosage. However, a dosage level specific to individual patients can be varied, depending upon specific compound to be used, weight, sex, health condition, diet, administration time and method of drug, excretion rate, drug mixing, and severity of disease condition.
Any route depending on purpose can administer the compounds according to the present invention. Injection, and oral and nasal administration are preferred, but administration may be made through dermal, intraperitoneal, retroperitoneal, and rectal route.
Injectable preparation, for example, aqueous or oily suspension for sterile injection, can be prepared according to known method by using proper dispersants, wetting agents or suspending agents. Solvents usable for this purpose are water, ringer's solution, and isotonic NaCl solution, and sterilized fixed oil is conventionally used as solvent or suspending media, too. Any non-irritable fixed oil including mono-, diglyceride can be used for this purpose, and aliphatic acid such as oleic acid can be used for injectable preparation.
Solid dosage forms for oral administrations are capsules, tablets, pills, powders and granules, and in particular, capsules and tablets are useful. Tablets and pills are preferable to be prepared as enteric coating. Solid dosage forms can be prepared by mixing the compounds of formula 1 according to the present invention with one or more inert diluents such as sucrose, lactose, starch, etc., and carriers, for example, lubricants like magnesium stearate, disintegrants, binding agents, etc.
Representative compounds of formula 1 according to the present invention include the following listed compounds:

    (4S)-1-{[(3S,4R)-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolinamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-{(4,4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-N,N-ethylmethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-N-ethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2 dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl)}-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl)}-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-N-ethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-methylpyrrolidine-3-yl]carbonyl}-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]-L-prolineamide
    N-[(3S)-1-{[(3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide
    N-[(3S)-1-{[(3S,4R)-1-t-butyl-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-(2,4-fluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(methylsulfonyl)amino]-N,N-dimethyl-L-prolineamide
    N-[(3S)-1-{[(3S,4R)-1-t-butyl-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl](4,4-dimethylcyclohexyl)amino-2,2-dimethylpropane-1-ol
    (3S)-1-{[(3S,4R)-1-tert-butyl(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-N-isobutyl-N-(cis-4-methylcyclohexyl)pyrrolidine-3-amine
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(cis-4,4-methylcyclohexyl)(tetrahydro-2H-pyran-4-ylcarbonyl)amino]-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-thienylcarbonyl)amino]-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(isobutyryl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-[(4,4-dimethylcyclohexyl)(2,2,-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2,-dimethylpropanoyl)amino]-N-ethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2,-dimethylpropanoyl)amino]-N-isopropyl-L-prolineamide
    N-[(3S,5S)-5-(azetidine-1-ylcarbonyl)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethyl propaneamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,5-dihydrofuran-3-ylcarbonyl)(4,4-dimethylcyclohexyl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2,-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(3-hydroxy-2,2,-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2,-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-furoyl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-furoyl)amino]-N-ethyl-N-methyl-L-prolineamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-[(4,4-difluorocyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)[(2S)tetrahydrofuran-2-ylcarbonyl]amino]-N-ethyl-N-methyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(2,2,-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
    (4S)-1-([(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl)-N-ethyl-4-[(3-hydroxy-2,2,-dimethylpropanoyl)-cis-4-methylcyclohexylamino]-N-methyl-L-prolineamide
    N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-{([ethyl(methyl)amino]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(pyrrolidine-1-ylcarbonyl)pyrrolidine-3-yl]-N-(4,4-difluorocyclohexyl)-2,2-dimethylpropaneamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-[-N-ethyl-N-methyl-4-{spiro[2,5]oct-6-yl](2S)-tetrahydrofuran-2-ylcarbonyl]amino}-L-prolineamide
    N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(pyrrolidine-4-ylcarbonyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)acetamide
    (4S)-1-([(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl)-[(4,4-dimethylcyclohexyl)[(2R)-tetrahydrofuran-2-ylcarbonyl]amino]-N-ethyl-N-methyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-N-ethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl})[(4,4-dimethylcyclohexyl)(2,2,-dimethylpropanoyl)amino]-N-phenyl-L-prolineamide
    (2S)—N-[(3S)-1-{[(3S,4R)-1-tert-butyl(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)tetrahydrofuran-2-carboxamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2-methyl-N-[cis-4-(trifluoromethyl)cyclohexyl]propaneamide
    (2S)—N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)tetrahydrofuran-2-carboxamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)tetrahydrofuran-3-carboxamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-cycloheptyl-3-hydroxy-2,2-dimethylpropaneamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{(4,4-dimethylcyclohexyl)[(methylsulfonyl)amino}-N-ethyl-N-methyl-L-prolineamide
    (3S)-1-{[(3S,4R)-1-tert-butyl(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-N-(4,4-dimethylcyclohexyl)-N-3-furylpyrrolidine-3-amine
    N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(4,5-dihydro-1,3-oxazole-2-yl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-{(3S,5S)-1-{[(3S,4R)-1-tert-butyl-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)carbonothionyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2-methylpropaneamide
    N-[(3S,5R)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-(1,3-thiazole-2-yl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(hydroxymethyl)pyrrolidine-3-yl]-N-(4,4-ethylcyclohexyl)-2,2-dimethylpropaneamide
    N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-methylpyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-{(3S,5S)-1-{[(3S,4R)-1-tert-butyl(2,-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(E)-(hydroxyimino)methyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-[(3S,5S)-5-(aminoethyl)-1-{[(3S,4R)-1-tert-butyl(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-[(3S,5S)-5-[(acetylamino)methyl]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-dichlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl(2,4-dichlorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)methyl]pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-cyanopyrrolidine-3-yl]-2,2-dimethyl-N-(cis-4-methylcyclohexyl)propaneamide
    N-[(3S,5R)-5-acetyl-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(1-hydroxymethyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    (4S)-4-[acetyl(4,4-dimethylcyclohexyl)amino]-N-(2-aminoethyl)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-L-prolineamide methyl(4S)-1-{[(3S,4R)-1-tert-butyl(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-L-prolinate
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-L-proline
    N-[(3S,5R)-5-(aminocarbothionyl-1-{[(3S,4R)-1-tert-butyl(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-{(3S,5R)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)carbonothionyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-[(3S,5R)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-propionylpyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-propionylpyrrolidine-3-yl]-N-(4,4-difluorocyclohexyl)-2,2-dimethylpropaneamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylmalonamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-methoxy-2,2-dimethylpropaneamide
    (3E)-N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-(hydroxyimino)-2,2-dimethylpropaneamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylbutaneamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-3-oxobutaneamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2,3-trimethylbutaneamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-fluoro-2,2-dimethylpropaneamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3,3-difluoro-2,2-dimethylpropaneamide
    N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-[(4,4-difluorocyclohexyl)(3-methoxy-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
    (4S)-4-[(3-amino-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl})-4-{[3-(dimethylamino)-2,2-dimethylpropanoyl](4,4-dimethylcyclohexyl)amino}-N,N-dimethyl-L-prolineamide
    N-{(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)carbonyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-diethyl malonamide
    S-(3-{[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-{[ethyl(methyl)amino]carbonyl}pyrrolidine-3-yl](4,4-ethylcyclohexyl)amino}-2,2-dimethyl-3-oxopropyl)ethanethioate
    (4S)-1-{[(3S,4R)-1-tert-butyl(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-mercapto-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(3-methoxy-2,2,-dimethylpropanoyl)amino]-N,N-dimethyl-L-proline amide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(3-ethoxy-2,2,-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,4-difluorophenyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,2,-dimethylpropanoyl)(4-methoxyphenyl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4 {(2,2,-dimethylpropanoyl)[4-(trifluoromethyl)phenyl]amino}-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-tert-butyl(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,2,-dimethylpropanoyl)(4-methylphenyl)amino]-N,N-diethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-tert-butyl(4-chlorophenyl)pyrrolidine-3-yl]carbonyl})-4-{(2,4-difluorophenyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-diethyl-L-prolineamide
    (2S)—N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)tetrahydrofuran-2-carboxamide
    N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(cis-4-methylcyclohexyl)-3-furamide
    N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(cis-4-methylcyclohexyl)-2,2-dihydrofuran-3-carboxamide
    (4S)—N-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,2,-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]-D-prolineamide
    N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(1-hydroxymethyl)pyrrolidine-3-yl]-N-(4,4-diethylcyclohexyl)-2,2-dimethylpropaneamide
    (4S)-1-{[(3S,4R)-1-(aminocarbonyl)4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-diethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
    (3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)pyrrolidine-1-carboxamide
    (3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)pyrrolidine-1-carboxamide
    (4S)-1-({[(3S,4R)-4-(4-chlorophenyl)-1-(ethylamino)carbonyl]pyrrolidine-3-yl}carbonyl)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
    N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-[(ethylamino)carbonothionyl]pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-difluorocyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide
    (3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl) N-ethylpyrrolidine-1-carboxamide
    (3R,4S-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)-N-ethylpyrrolidine-1-carboxamide
    (3R,4S)-3-(4-chlorophenyl-4-({(3S)-3-[(2,4-difluorophenyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)-N-ethylpyrrolidine-1-carboxamide
    (3R,4S)-3-(4-chlorophenyl)-N-ethyl-4-({(3S)-3-[isobutyryl(cis-4-methylcyclohexyl)amino]pyrrolidine-1-yl}carbonyl)-N-methylpyrrolidine-1-carboxamide
    (4S)-1-({[(3S,4R)-1-acetyl(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-propaneamide
    N-[(3S)-1-{[(3S,4R)(4-chlorophenyl)-1-isobutyrylpyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    (4S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-isobutyrylpyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-L-prolineamide
    (4S)-1-({[(3S,4R)-4-(2,4-chlorophenyl)-1-cyclopropylpyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(tetrahydro-2H-pyranyl)pyrrolidine-3-yl]carbonyl}-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-N-ethyl-N-methyl-L-prolineamide
    N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    (4S)-1-{[(3S,4R)(2,4-difluorophenyl)-1-isobutyrylpyrrolidine-3-yl]carbonyl)}[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-cyclobutylpyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
    (4S)-1-{[(3S,4R)-1-cyclopentyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-ethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
    N-{(3S,5S)-1-{[(3S,4R)-4-(2,4-difluorophenyl)-1-isobutyrylpyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)carbonothio]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
    N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(methylsulfonyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2-methyl-N-(cis-4-methylcyclohexyl)propaneamide
    (3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(cis-8-methylcyclohexyl)(2-methylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
    (3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)-N-(2,2,2-trifluoromethyl)pyrrolidine-1-carboxamide
    methyl(3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-methylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)pyrrolidine-1-carboxylate
    N-[(3S)-1-{[(3S,4R)-1-[amino(imino)methyl]-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2-methyl-N-(cis-4-methylcyclohexyl)propaneamide
    N-[(3S)-1-({(3S,4R)-4-(4-chlorophenyl)-1-[(ethylamino)(imino)methyl]pyrrolidine-3-yl}carbonyl)pyrrolidine-3-yl]2-methyl-N-(cis-4-methylcyclohexyl)propaneamide
    N-[(3S)-1-{[(3S,4R)-1-[(acetylamino)(imino)methyl]-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2-methyl-N-(cis-4-methylcyclohexyl)propaneamide
    N-[(3S)-1-{[(3S,4R) (4-chlorophenyl)-1-phenylpyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-propaneamide
    N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-pyridine-2-ylpyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2,2-dimethyl-N-(cis-4-methylcyclohexyl)propaneamide
    N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(4,5-dihydro-1H-imidazole-2-yl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide
    N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(4,5-dihydro-1H-imidazole-2-yl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide.


The present invention is described in more detail by the exemplified compounds in the following Examples, but the scopes of the invention are not be construed to be limited thereby in any manner.
Abbreviations used in the following Preparation Examples and Examples are as follows:













Ac
acetyl


AcOH
acetic acid


Bn
benzyl


n-Bu
n-butyl


t-Bu
t-butyl


BOP
(benzotriazol-1-yl-oxy)tris(dimethylamino-)-



phosphonium hexafluorophosphate


Bu
butyl


CBZ(Cbz)
benzyloxycarbonyl


BOC(Boc)
t-butoxycarbonyl


CDI
N,N′-carbonyldiimidazole


c-Hex
cyclohexyl


c-Bu
cyclobutyl


c-Pen
cyclopentyl


c-Pr
cyclopropyl


DAST
diethylaminosulfur trifluoride


DCC
dicyclohexylcarbodiimide


DCE
dichloroethane


DCM
dichloromethane


diMe
dimethyl


diF
difluoro


DIPEA
diisopropylethylamine


DMAP
4-dismethylaminopyridine


DMF
N,N-dimethylformamide


DMSO
dimethylsulfoxide


DPPA
diphenylphosphorylazide


EDC
1-(3-dimethylaminopropy1)-3-



ethylcarbodiimide hydrochloride


EDTA
ethylenediaminetetraacetic acid


Et
ethyl


EtOAc
ethylacetate


Et2O
diethylether


Fmoc
9-fluorenylmethoxycarbonyl


Hex
normal hexane


HATU
N-[(dimethylarnino)(3H-1,2,3-triazolo[4,5-



b]pyridine-3-yloxy) methylene]-



N-methylenemethaneammonium 



hexafluorophosphate


HOAT
1-hydroxy-7-azabenzotriazole


HOBT
hydroxybenzotriazole


HBTU
2-(1H-benzotriazole-1-y1)-1,1,3,3-tetramethyluronium 



hexafluoro phosphate


i-Pr
isopropyl


i-Bu
isobutyl


KOCN
potassium cyanate


K2CO3
potassium carbonate


LiBH4 
lithium borohydride


Me
methyl


MeOH
methanol


MTBE
methyl t-butyl ether


MgSO4
magnesium sulfate


NaBH4 
sodium borohydride


NaBH(OAc)3
sodium triacetoxyborohydride


NaOtBu
sodium t-butoxide


NaOH
sodium hydroxide


NaN3 
sodium azide


NaH 
sodium hydride


Pyr
pyridine


Ph
phenyl


Pr
propyl


TBAF
tetrabutylammonium fluoride


TEA
triethylamine


TFA
trifluoroacetic acid


TFAA
trifluoroacetic anhydride


THF
tetrahydrofuran


t-Bu
t-butyl









The compounds of the present invention can be prepared according to the following procedures (Schemes A, B, C, D, E, etc.).







The Intermediate A1 compounds can be prepared as follows:


PREPARATION EXAMPLE A1-1
Methyl (2S,4S)-1-Boc-4-aminopyrrolidine-2-carboxylate
Step A: (4R)-1-Boc-4-hydroxy-L-proline
To a solution of (4R)-hydroxy-L-proline (5.08 g, 38.77 mmol) in 1N NaOH (40 ml) and 1,4-dioxane (40 ml) was added dropwise di-t-butyl dicarbonate (9.3 g, 42.6 mmol) at 0° C. The reaction mixture was stirred at rt for 8 h, concentrated in vacuo, acidified with 1N HCl, and extracted with EtOAc. The organic extracts were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo to give the title compound (8.8 g, 99%).
MS[M+H]=232 (M+1)
Step B: methyl (2S,4R)-1-Boc-4-hydroxypyrrolidine-2-carboxylate
To a solution of (4R)-1-Boc-4-hydroxy-L-proline (8 g, 34.63 mmol) prepared in Step A in DMF was added K2CO3 (14 g, 101 mmol) and methyliodide (2.6 ml, 51.9 mmol). The reaction mixture was stirred at rt for 5 h, concentrated in vacuo, and extracted with EtOAc. The organic extracts were washed with water and brine, dried over MgSO4, filtered, and concentrated in vacuo to give the title compound (8.0 g, 95%).
MS[M+H]=246(M+1)
Step C: methyl (2S,4R)-1-Boc-4-[(methylsulfonyl)oxy]pyrrolidine-2-carboxylate
To a solution of methyl (2S,4R)-1-Bochydroxypyrrolidine-2-carboxylate (8 g, 32.65 mmol) prepared in Step B in DCM was added dropwise TEA (11.99 ml, 81.56 mmol) and methanesulfonyl chloride (3.77 ml, 48.9 mmol) at m° C. After the reaction mixture was stirred at rt for 3 h, the organic extracts were washed with a saturated NaHCO3 aqueous solution, 1N HCl and brine, dried over MgSO4, filtered, and concentrated in vacuo to give the title compound (9.4 g, 90%).
MS[M+H]=324(M+1)
Step D: methyl (2S,4S)-1-Boc-4-azidopyrrolidine-2-carboxylate
To a solution of methyl (2S,4R)-1-Boc-4-[(methylsulfonyl)oxy]pyrrolidine-2-carboxylate (9 g, 27.86 mmol) prepared in Step C in DMF was added NaN3 (2.7 g, 41.79 mmol), and stirred at 90° C. for 10 h. The reaction mixture was concentrated in vacuo, extracted with EtOAc. The organic extracts were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc/Hex=1/4) to give the title compound (6 g, 80%).
MS[M+H]=271(M+1)
Step E: methyl (4S,4S)-1-Boc-4-aminopyrrolidine-2-carboxylate
To a solution of methyl (2S,4S)-1-Boc-4-azidopyrrolidine-2-carboxylate (6 g, 22.22 mmol) prepared in Step D in dioxane (10 mL) was added Pd/C (800 mg). The reaction mixture was stirred under hydrogen condition for 24 h, filtered through Celite, and the filtrate was concentrated in vacuo to give the title compound as an oil (5.34 g, 98.5%).
MS[M+H]=245(M+1)
PREPARATION EXAMPLE A1-2
Methyl (2S,4R)-1-Boc-4-aminopyrrolidine-2-carboxylate
The title compound was prepared according to the procedure described in Preparation Example A1-1 using (4S)-hydroxy-1-proline.
MS[M+H]=245(M+1)
PREPARATION EXAMPLE A1-3
Methyl (2R,4S)-1-Boc-4-aminopyrrolidine-2-carboxylate
The title compound was prepared according to the procedure described in Preparation Example A1-1 using (4R)hydroxy-D-proline.
MS[M+H]=245(M+1)
PREPARATION EXAMPLE A1-4
(2S,4S)-1-Boc-2-allyl-4-aminopyrrolidine
Step A: (2S,4R)-1-Boc-2-allyl-4-hydroxypyrrolidine
(3R)-1-BOC-3-hydroxypyrrolidine (1 g, 5.34 mmol) was dissolved in diethylether (50 ml), and filled with nitrogen. The reaction mixture was cooled to −78° C., N,N,N,N′-tetramethylethylenediamine (620 mg, 5.34 mmol) was added, and sec-butyllithium (1.4M cyclohexane solution 4.45 ml, 6.23 mmol) was slowly added. After being stirred for 30 min at the same temperature, dimethylsulfate (1.44 g, 10.68 mmol) was dissolved in diethylether (10 ml). The reaction solution was slowly heated to rt, diluted with water (12 ml), and extracted with diethylether. The organic extracts were dried over MgSO4, and the residue was purified by column chromatography (eluent, EtOAc/Hex=1/4) to give the title compound (840 mg, 70%).
MS[M+H]=228(M+1)
Step B: (2S,4S)-1-Boc-2-allyl-4-azidopyrrolidine
The title compound was prepared according to the procedure described in Steps C ̃D of Preparation Example A1-1 using (2S,4S)-1-Boc-2-allyl-4-hydroxypyrrolidine prepared in Step A.
MS[M+H]=253(M+1)
Step C: (2S,4R)-1-Boc-2-allyl-4-aminopyrrolidine
To a solution of (2S,4R)-1-Boc-2-allyl-4-azidopyrrolidine (450 mg, 1.78 mmol) prepared in Step B in THF was added dropwise trimethylphosphine (135 mg, 1.78 mmol). After the reaction mixture was stirred at rt for 5 h, water (0.03 ml) was added, and stirred for additional 20 min. The reaction mixture was concentrated in vacuo, extracted with EtOAc, washed with water and brine, and concentrated in vacuo. The residue was purified by column chromatography(eluent, MeOH/DCM=1/9) to give the title compound (280 mg, 70%).
MS[M+H]=227(M+1)
PREPARATION EXAMPLE A1-5
(2S,4S)-1-Boc-2-propyl-4-aminopyrrolidine
To a solution of (2S,4S)-1-Boc-2-allyl-4-aminopyrrolidine (450 mg, 1.78 mmol) prepared in Preparation Example A1-4 in dioxane (5 mL) was added Pd/C (40 mg). The reaction mixture was stirred under hydrogen condition for 24 h, filtered through Celite, and the filtrate was concentrated in vacuo to give the title compound as an oil (390 mg, 98.5%).
MS[M+H]=229(M+1)
PREPARATION EXAMPLE A1-6
(2R,4S)-1-Boc-2-propyl-4-aminopyrrolidine
The title compound was prepared according to the procedure described in Preparation Example A1-5 using (2R,4R)-1-Boc-2-allyl-4-hydroxypyrrolidine as starting material.
MS[M+H]=229(M+1)
The Intermediate A2 compounds can be prepared as follows:
PREPARATION EXAMPLE A2-1
4,4-dimethyl-cyclohexanone
4,4-Dimethyl-cyclohexene-1-one (5 g, 40.3 mmol) and n-pentane (15 ml) were placed in a hydrogen reaction vessel, and Pd/C (500 mg) was added. The hydrogen reaction vessel was pressurized with hydrogen (25 psi), and reacted for 30 min. After the reaction finished, the reaction mixture was filtered through Celite, and the filtrate was concentrated in vacuo to give the title compound (5 g, 98%).
MS[M+H]=127(M+1)
PREPARATION EXAMPLE A2-2
4-trifluoromethylcyclohexanone
Step A: 4-trifluoromethyl-cyclohexanol
4-Hydroxybenzotrifluoride (5 g, 30.8 mmol) was placed in a hydrogen reaction vessel, dissolved in acetic acid (15 ml), and Pt−2O (500 mg) was added. The hydrogen reaction vessel was pressurized with hydrogen (50 psi), and reacted for 16 h. After the reaction finished, the reaction mixture was filtered through Celite, and to the filtrate was added 1N-NaOH, extracted with diethylether, dried over MgSO4, and concentrated in vacuo at rt to give the title compound (4.5 g, 87%).
MS[M+H]=169(M+1)
Step B: 4-trifluoromethylcyclohexanone
To a solution of 4-Trifluoromethylcyclohexanol (4.5 g, 26.7 mmol) in DCM (100 ml) was added Dess-Martin periodinane (13.6 g, 32 mmol), and stirred at rt for 2 h. After the reaction finished, the reaction mixture was concentrated in vacuo, sodium thiosulfate aqueous solution and diethylether were added and stirred at rt for 30 min, and extracted with diethylether. The organic layer was dried over MgSO4, concentrated in vacuo at rt to give the title compound (4.2 g, 94.6%).
MS[4+H]=167(M+1)
PREPARATION EXAMPLE A2-3
4,4-difluoro cyclohexanone
Step A: 8,8-difluoro-1,4-dioxospiro-[4,5-]decane
To a solution of commercially available 1,4-cyclohexanedione-mono-ethylene ketal (25 g, 160 mmol) in DCM (500 ml) was added dropwise DAST (52 g, 2.0 mmol) at 0° C. The reaction mixture was slowly heated up to rt, and stirred until the reaction finished. After confirming that all the reaction mixture was disappeared, the reaction solution was added to a saturated NaHCO3 aqueous solution (700 ml) to finish the reaction, and extracted with DCM. The organic extracts were washed with a saturated NaHCO3 aqueous solution and brine, dried over MgSO4, filtered, and concentrated in vacuo. The obtained residue was used in the next reaction without further purification.
Step B: 4,4-difluoro cyclohexanone
The product of Step A, 8,8-difluoro-1,4-dioxospiro[4.5]decane was dissolved in acetone (90 ml) and 3N HCl (900 ml), and stirred until the reaction finished. Then, the reaction mixture was extracted with DCM, washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The obtained residue was used in the next reaction without further purification.
PREPARATION EXAMPLE A2-4
spiro[2,5]octane-6-one
Step A: 4,4-methylene-1,1-ethyleneketal-4-spiro[2,5]octane
To a solution of DMSO (15 mL), filled with nitrogen, was added NaH (60% suspension in mineral oil, 0.42 g, 10.50 mmol), and the reaction mixture was stirred at 50-60° C. for 2 h, methyltriphenylphosphonium bromide (MeP(Ph)3Br) (3.76 g, 10.50 mmol) was added, and stirred at rt for 1 h. Cyclohexanedione monoethyleneketal (1 g, 6.40 mmol) was added, and stirred at 40° C. for 2 h. The reaction solution was cooled to rt, an ice water was added, and extracted with Et2O. The organic extracts were dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc/Hex=1/5) to give the title compound (0.74 g, 74.95%).
Step B: spiro[2.5]octane-one
The product of Step A, 4,4-methylene-1,1-ethyleneketal-4-spiro[2,5]octane (0.74 g, 4.80 mmol) and diiodomethane (1.93 mL, 24.00 mmol) were placed in Et2O (45 mL), Zn—Cu (1.96 g, 30 mmol) was added, and refluxed for 12 h. The reaction solution was cooled to rt, diiodomethane (1.93 mL, 24.00 mmol) and Zn—Cu (1.96 g, 30 mmol) were added again, and refluxed for 20 h. The reaction solution was cooled to rt, filtered, and washed with Et2O. To the filtrate was added 1M HCl (100 mL), reacted at rt for 1 h, and extracted for four (4) times with Et2O. The organic extracts were dried over MgSO4, filtered, and concentrated in vacuo (0.28 g, 46.99%).
The Intermediate A4 compounds can be prepared as follows:
PREPARATION EXAMPLE A4-1
2,2-dimethyl-3-acetyloxypropionyl chloride
Step A: 2,2-dimethyl-3-acetyloxypropionic acid
2,2-Dimethyl-3-hydroxypropionic acid (11.8 g, 100 mmol) was dissolved in pyridine (30 mL), and the reaction solution was cooled to 0° C. Acetyl chloride (11.8 g, 15.0 mmol) was slowed added dropwise, the temperature was increased to rt, and the reaction solution was stirred at rt for 3 h. After the reaction finished, 1N HCl (30 mL) was added, pH adjusted to 3-4, the reaction mixture was extracted with EtOAc. The organic extracts were washed with 1N HCl for 4-5 times, dried over MgSO4, concentrated in vacuo to give the title compound (15.2 g, 95.0%).
MS[M+H]=161(M+1)
Step B: 2,2-dimethyl-3-acetyloxypropionyl chloride
The product of Step A, 2,2-dimethyl-3-acetyloxypropionic acid (11.76 g, 80 mmol) was dissolved in benzene (100 mL), the reaction solution was cooled 0° C., oxalyl chloride (15.0 g, 120 mmol) was slowly added dropwise. After 3 h, the solvent was removed in vacuo, and distilled in vacuo to give the title compound.
MS[M+H]=179(M+1)
PREPARATION EXAMPLE A4-2
2,5-dihydrofuran-3-carboxyl chloride
Step A: t-butyl 4-oxotetrahydrofuran-3-carboxylic acid
Sodium hydride (55% suspension in mineral oil, 0.5 g, 11.46 mmol) was placed in anhydride Et2O (8 mL), and stirred, and ethyl glycolate (0.9 mL, 9.61 mmol) was added dropwise at rt. The reaction solution was stirred for 1 h, concentrated in vacuo, and t-butyl acrylate (1.68 mL, 11.46 mmol) in anhydride DMSO (8 mL) was added at 0-5° C. The reaction solution was stirred for 15 min at 0-5° C., stirred at rt for additional 1 h, and filtered. At 0-5° C., the filtrate was placed in a sulfuric acid solution (5%, 5.6 mL), and extracted with Et2O for 3 times. The organic extracts were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc/Hex=1/5) to give the title compound (0.95 g, 53.11%).
Step B: t-butyl 4-hydroxytetrahydrofuran-3-carboxylate
The product of Step A, tert-butyl 4-oxotetrahydrofuran-3-carboxylate (0.95 g, 5.10 mmol) was placed in isopropylalcohol (14 mL) at 0-5° C., NaBH4 (77 mg, 2.04 mmol) was added, and stirred for 2 h. NaBH (77 mg, 2.04 mmol) was added again, and stirred at rt for 1 h, NaBH4 (39 mg, 1.02 mmol) was added, and stirred for 30 min. The reaction mixture was treated with Et2O to dilute, washed with brine, and extracted with Et2O twice. The organic layer was collected, extracted with a NaHCO3 aqueous solution, dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc/Hex=1/3) to give the title compound (0.83 g, 86.56%).
Step C: t-butyl 2,5-dihydrofuran-3-carboxylate
The product of Step B, t-butyl 4-hydroxytetrahydrofuran-3-carboxylate (0.83 g, 4.41 mmol) and PPh3 (1.74 g, 6.63 mmol) were placed in THF (5 mL), the solution was cooled to 0-5° C., and DIAD (1.13 mL, 5.74 mmol) was added dropwise. After reacting at rt for 12 h, the reaction mixture was filtered, washed with a solution of EtOAc/Hex=1/4, and the filtrate concentrated in vacuo The residue was purified by column chromatography (eluent, EtOAc/Hex=1/7) to give the title compound (0.39 g, 51.34%).
Step D: 2,5-dihydrofuran-3-carboxylic acid
To a solution of t-butyl 2,5-dihydrofuran-3-carboxylate (0.39 g, 2.29 mmol) prepared in Step C in DCM (2 mL) was added TFA (6 mL), and stirred at rt for 12 h. The reaction solution was concentrated in vacuo, the residue was treated with n-Hexane, stirred at rt for 30 min, and filtered to give the title compound (0.19 g, 72.3%).
Step E: 2,5-dihydrofuran-3-carboxyl chloride
The product of Step D, 2,5-dihydrofuran-3-carboxylic acid (0.19 g, 1.66 mmol) was dissolved in benzene (3 mL), the reaction solution was cooled to 0° C., and oxalyl chloride (0.4 g, 3.32 mmol) was slowly added dropwise. After 3 h, the solvent was removed in vacuo, and distilled in vacuo to give the title compound.
PREPARATION EXAMPLE A4-3
2-cyano-2-methylpropanoyl Chloride
To a solution of commercially available ethyl-2-cyano-2-methylpropanoate (3.5 g, 24.8 mmol) in methanol (10 ml) was added LiOH (900 mg, 37.2 mmol) and water (0.5 ml), and reacted at rt for 1 h. After the reaction finished, the solvent was concentrated in vacuo, 1N-HCl (50 ml) was added, and extracted with EtOAc. The extracted organic layer was dried over MgSO4, concentrated in vacuo to give 2-cyano-2-methylpropionic acid (2.67 g, 95%). This compound (2.5 g, 22 mmol) was dissolved in DCM (7 ml), and reacted according to the procedure described in Step B of Preparation Example A4-1 to give the title compound (2.5 g, 86.3%).
MS[M+H]=132 (M+1)
PREPARATION EXAMPLE A4-4 ̃9
The acylchlorides in the following table were prepared according to the procedure described in Preparation Example A4-1 or A4-3 using commercially available carboxylic acid.







TABLE 1













 









Preparation




Example
R5
MS(M + 1)





A4-4




135


 


A4-5




135


 


A4-6




149


 


A4-7




147


 


A4-8




135


 


A4-9




131









PREPARATION EXAMPLE A9-1
(3S,4R)-1-t-butyl-4-(2,4-difluorophenyl)pyridine-3-carboxylic acid
The title compound was prepared according to the procedure described in WO 2004/09126.
PREPARATION EXAMPLE A9-2 ̃7
The compounds in the following table were prepared according to the procedure described in Preparation Example A9-1 using commercially available alpha-halo ketone compounds.







TABLE 2













 












Preparation






Example
A
R2′
M + 1







A9-2
t-Bu
4-Cl
282



A9-3
t-Bu
4-Me
262



A9-4
t-Bu
4-F
266



A9-6
Me
4-Cl
240



A9-7
Me
2,4-diF
242










PREPARATION EXAMPLE A9-8
(3S,4R)-1-Boc-4-(2,4-difluorophenyl)pyrrolidine-3-carboxylic acid
Step A: (4R)-4-(2,4-difluorophenyl)pyrrolidine-3-carbonitrile
To a solution of (4R)-1-t-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-carbonitrile (4 g, 15.15 mmol) prepared according to the procedure described in WO 2004/09126 in DCE (10 ml) was added dropwise 1-chloroethyl chloroformate (2.45 ml, 22.68 mmol) at 0° C. The reaction solution was heated to 70° C., and maintaining this temperature, 1.8-bis(dimethylamino)naphthalene (4.87 g, 22.72 mmol) in DCE (10 ml) was added dropwise for 2 h. After the reaction finished, methanol (10 ml) was added, and maintaining the temperature, the reaction mixture was stirred for additional 1 h, concentrated in vacuo, and the next reaction was carried out without further purification.
MS[M+1]=209(M+1)
Step B: (4R)-1-BOC-4-(2,4-difluorophenyl)pyrrolidine-3-carbonitrile
To a solution of (4R)-4-(2,4-difluorophenyl)pyrrolidine-3-carbonitrile prepared in Step A, DMAP (1.8 g, 15.15 mmol) and TEA (5.56 ml, 15.15 mmol) in DCM (10 ml) was added dropwise di-t-butyl dicarbonate (4.9 g, 22.7 mmol) at 0° C. The reaction mixture was stirred at rt for 8 h, concentrated in vacuo, and extracted with EtOAc. The organic extracts were washed with 1N-HCl and brine, dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/6) to give the title compound (3.3 g, total of Step A and B: 72%).
MS[M+H]=309 (M+1)
Step C: (3S,4R)-1-Boc-4-(2,4-difluorophenyl)pyrrolidine-3-carboxylic acid
To a solution of (4R)-1-BOC-4-(2,4-difluorophenyl)pyrrolidine-3-carbonitrile (3.3 g, 10.6 mmol) prepared in Step B in ethanol (10 ml) was added 6N NaOH solution (5 ml), and stirred at 70° C. for 4 h. After the reaction finished, the solvent was removed, the reaction mixture diluted with ether, the organic solution was sufficiently acidified with 6N HCl, and washed. The organic solution was washed with brine, dried over MgSO4, and concentrated in vacuo to give the title compound (3.43 g, 99.0%).
MS[M+1]=328(M+1)
PREPARATION EXAMPLE A9-9 ̃11
The compounds in the following table were prepared according to the procedure described in Preparation Example A9-8 using phenylpyrrolidine-3-carbonitrile intermediates obtained in Preparation Example A9-2 ̃4.







TABLE 3













 









Preparation




Example
R2′
M + 1





A9-9
4-Cl
326


A9-10
4-Me
306


A9-11
4-F
310









The Examples synthesized by the procedure of Scheme A are as follows.
EXAMPLE A1
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide HCl salt




Step A: methyl-(2S,4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)amino]pyrrolidine-2-carboxylate
To methyl (2S,4S)-1-Boc-4-aminopyrrolidine-2-carboxylate (1.07 g, 4.38 mmol) and dimethylcyclohexanone (0.66 g, 5.25 mmol) in DCE (20 mL) was added dropwise NaBH(OAc) (1.39 g, 6.57 mmol) at rt. The reaction mixture was stirred at rt for 4 h, a saturated NaHCO3 aqueous solution was added, and extracted with DCM (50 mL×2) and EtOAc. The organic extracts were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The obtained residue was purified by column chromatography (eluent, EtOAc/Hex=1/2) to give the title compound (1.16 g, 75%).
MS[M+H]=355(M+1)
Step B: 1-BOC-2-methyl-(2S,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-2-carboxylate
To a solution of methyl (2S,4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)amino]pyrrolidine-2-carboxylate (1.01 g, 2.84 mmol) prepared in Step A in DCE (5 mL) was added dropwise TEA (5 mL) and DMAP (0.34 g, 2.84 mmol), and added commercially available pivaloyl chloride (1.01 g, 8.52 mmol). The reaction solution was heated to 90° C., and stirred for 24 h. After the reaction finished, the solvent was removed in vacuo, the residue treated with a saturated NaHCO3 aqueous solution, and extracted with EtOAc. The organic extracts were washed with 1N HCl, dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/4) to give the title compound (1.02 g, 82%).
MS[M+H]=439(M+1)
Step C: (4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-L-proline
To a solution of 1-BOC 2-methyl (2S,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-2-carboxylate (1.02 g, 2.32 mmol) prepared in Step B in methanol (7 ml) and water (7 ml) was added LiOH (0.15 g, 6.99 mmol). The reaction mixture was stirred at rt for 3 h, concentrated in vacuo, and extracted with EtOAC. The organic extracts were washed with brine, dried over MgSO4, and concentrated in vacuo to give the title compound (0.93 g, 95%).
MS[M+H]=425(M+1)
Step D: BOC(2S,4S)-2-[(dimethylamino)carbonyl]-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine
To a solution of (4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-L-proline (0.93 g, 2.2 mmol) prepared in Step C in DMF (10□) was added dropwise DIPEA (0.95□, 5.5 mmol) followed by dimethylamine-HCl salt (0.21 g, 2.57 mmol) and HBTU (0.83 g, 2.2 mmol). The reaction solution was stirred at rt for 2 h, and concentrated in vacuo. The residue was diluted with EtOAc, washed with a saturated NaHCO3 aqueous solution, water and 1N HCl. The organic solution was dried over MgSO4, concentrated in vacuo, and the residue was purified by column chromatography (eluent: EtOAc:Hex=2/1) to give the title compound (0.92 g, 93%).
MS[M+H]=452(M+1)
Step E: (4S)-4-[(4,4-diethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
To a solution of BOC(2S,4S)-2-[(dimethylamino)carbonyl]-4-[(4,4-dimethyl-cyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine (0.92 g, 2.0 mmol) prepared in Step D in DCM (1□) was added dropwise 4M HCl (1□). The reaction mixture was stirred at rt for 1 h, and concentrated in vacuo. The residue was concentrated in vacuo to give the title compound (705 mg, 99.9%).
MS[M+H]=352(M+1)
Step F: (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide TFA salt
To a solution of (4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide (0.70 g, 2.0 mmol) prepared in Step E in DMF (5□) was added dropwise DIPEA (0.95□, 5.5 mmol). Then, (3S,4R)-1-t-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-carboxylic acid (0.57 g, 2.0 mmol) prepared in Preparation Example A-9-1 was added dropwise followed by HBTU (0.76 g, 2.0 mmol). The reaction mixture was stirred at rt for 2 h, and the solution was concentrated in vacuo. The residue was diluted with EtOAc, and washed with a saturated NaHCO3 aqueous solution and water. The organic solution was dried over MgSO4, concentrated in vacuo, and the residue was purified by HPLC to give the title compound (TFA salt, 1.04 g, 85%).
MS[M+H]=617(M+1)
Step G: (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide HCl salt
TFA salt of the compound prepared in Step F was basified with 1N NaOH, and extracted with EtOAc. The organic solution was dried over MgSO4, concentrated in vacuo, treated with 4M HCl/dioxane, and stirred at rt for 1 h. The reaction solution was concentrated in vacuo without further purification to give HCl salt.
1H NMR (400 MHz, CDCl3) 8.10-8.04 (m, 1H), 6.97-6.93 (m, 1H), 6.79-6.74 (m, 1H), 4.70 (t, 1H), 4.35-4.22 (m, 2H), 3.95-3.90 (m, 2H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 2H), 3.22-3.11 (m, 1H), 2.99 (s, 3H), 2.95 (s, 3H), 2.82-2.68 (m, 1H), 2.19-1.97 (m, 1H), 1.61-1.39 (m, 4H), 1.49 (s, 9H), 1.31-1.15 (m, 4H), 1.22 (s, 9H), 0.95 (s, 3H), 0.91 (s, 3H)
EXAMPLE A2
(4S)-1-[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl)-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-N,N-ethylmethyl-L-prolineamide HCl salt




Step A: 1-boc-2-methyl (2S,4S)-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}pyrrolidine2-carboxylate
To a solution of methyl-(2S,4S)-1-BOCA-4-[(4,4-dimethylcyclohexyl)amino]pyrrolidine-2-carboxylate (1.01 g, 2.84 mmol) prepared in Step A in Example A1 in DCE (5 mL) was added dropwise TEA (5 mL) and DMAP (0.34 g, 2.84 mmol). Then, (S)-tetrahydrofuran-2-carbonyl chloride (1.14 g, 8.52 mmol) prepared in Preparation Example A4-5, was added. The reaction solution was heated 90° C., and stirred for 24 h. After the reaction finished, the solvent was removed in vacuo, and to the residue was added a saturated aqueous NaHCO3 solution, and extracted with EtOAc. The organic extracts were washed with 1N HCl, dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/4) to give the title compound (1.05 g, 82%).
MS[M+H]=453(M+1)
Step B: (4S)-1-BOC-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-L-proline
The title compound was prepared according to the procedure described in Step C of Example A1, using 1-BOC-2-methyl(2S,4S)-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}pyrrolidine2-carboxylate (1.05 g, 2.32 mmol) prepared in Step A (0.96 g, 95%).
MS[M+H]=439(M+1)
Step C: BOC-(2S,4S)-4-{(4,4-dimethylcyclohexyl)[(2S) tetrahydrofuran-2-ylcarbonyl]amino}-2-{[ethyl(methyl)amino]carbonyl}pyrrolidine
The title compound was prepared according to the procedure described in Step D of Example A1, using (4S)-1-BOC-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-L-proline (0.96 g, 2.2 mmol) prepared in Step B and commercially available N-methylethylamine (0.92 g, 93%).
MS[M+H]=480(M+1)
Step D: (4S)-4-[4,4-dimethylcyclohexyl)(tetrahydrofuran-2-ylcarbonyl)amino]-N-ethyl-N-methyl-L-prolineamide
To a solution of BOC-(2S,4S)-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-2-{[ethyl(methyl)amino]carbonyl}pyrrolidine (0.92 g, 2.0 mmol) prepared in Step C in DCM (1□) was added dropwise 4M HCl (1□). The reaction mixture was stirred at rt for 1 h, and concentrated in vacuo. The residue was concentrated in vacuo to give the title compound (750 mg, 99.9%).
MS[M+H]=380(M+1)
Step E: (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-N,N-ethylmethyl-L-prolineamide HCl salt
To a solution of (4S)-4-[(4,4-dimethylcyclohexyl)(tetrahydrofuran-2-ylcarbonyl)amino]-N-ethyl-N-methyl-L-prolineamide (0.76 g, 2.0 mmol) prepared in Step D in DMF (5□) was added dropwise DIPEA (0.95□, 5.5 mmol). Then, the product of Preparation Example A9-2, (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid (0.56 g, 2.0 mmol) was added dropwise followed by HBTU (0.76 g, 2.0 mmol). The reaction mixture was stirred at rt for 2 h, the solution was concentrated in vacuo. The residue was diluted with EtOAc, and washed with a saturated aqueous NaHCO3 solution and water. The organic solution was dried over MgSO4, concentrated in vacuo, and the residue was purified by HPLC to give TFA salt of the compound (1.09 g, 85%). This compound was treated according to the procedure described in Step G of Example A1 to give the title compound.
MS[M+H]=643(M+1)
1H NMR (400 MHz, CDCl3) 7.51 (d, 21), 7.33 (d, 2H), 4.68 (t, 1H), 4.48 (t, 1M), 4.40-4.21 (m, 1H), 4.03-3.90 (m, 3H), 3.90-3.81 (m, 2H), 3.80-3.70 (m, 2H), 3.66-3.46 (m, 3H), 3.45-3.12 (m, 3H), 2.97 (d, 3H), 2.86-2.62 (m, 1H), 2.41-2.28 (m, 1H), 2.13-1.82 (m, 4H), 1.64-1.40 (m, 4H), 1.52 (s, 9H), 1.40-1.22 (m, 2H), 1.26 (t, 3H), 1.20-1.08 (m, 2H), 0.97 (s, 3H), 0.94 (s, 3H)
EXAMPLE A3
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-N-ethyl-L-prolineamide HCl salt




Step A: 1-BOC-(2S,4S)-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-2-[(ethylamino)carbonyl)pyrrolidine
The title compound was prepared according to the procedure described in Step D of Example A1, using (4S)-1-BOC-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-L-proline (0.96 g, 2.2 mmol) prepared in Step B of Example A2 and commercially available ethylamine (0.95 g, 93%).
MS[M+H]=466 (M+1)
Step B: (4S)-4-[(4,4-dimethylcyclohexyl)(tetrahydrofuran-2-ylcarbonyl)amino]-N-ethyl-L-prolineamide
To a solution of 1-BOC-(2S,4S)-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-2-[(ethylamino)carbonyl)pyrrolidine (0.95 g, 2.0 mmol) prepared in Step A in DCM (1□) was added dropwise 4M HCl (1□). The reaction mixture was stirred at rt for 1 h, and concentrated in vacuo. The residue was concentrated in vacuo to give the title compound (730 mg, 99.9%).
MS[M+H]=366(M+1)
Step, C: (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-N-ethyl-L-prolineamide HCl salt
To a solution of (4S)-4-[(4,4-dimethylcyclohexyl)(tetrahydrofuran-2-ylcarbonyl)amino]-N-ethyl-L-proline amide (0.73 g, 2.0 mmol) prepared in Step B in DMF (5□) was added dropwise DIPEA (0.95□, 5.5 mmol). Then, the product of Preparation Example A9-2, (3S,4R)-1-t-butyl-4-(4-(dichlorophenyl)pyrrolidine-3-carboxylic acid (0.56 g, 2.0 mmol) was added dropwise followed by HBTU (0.76 g, 2.0 mmol). The reaction mixture was stirred at rt for 2 h, and the solution was concentrated in vacuo. The residue was diluted with EtOAc, and washed with a saturated aqueous NaHCO3 solution and water. The organic solution was dried over MgSO4, concentrated in vacuo, and the residue was purified by HPLC to give TFA salt of the compound (1.06 g, 85%). This compound was treated according to the procedure described in Step G of Example A1 to give the title compound.
MS[M+H]=629(M+1)
1H NMR (400 MHz, CDCl3) 7.55 (d, 2H), 7.33 (d, 2H), 4.51-4.43 (m, 1H), 4.26 (t, 1H), 4.06-3.98 (m, 1H), 3.97-3.56 (m, 7H), 3.49-3.02 (m, 4H), 2.83-2.74 (m, 1H), 2.49-2.38 (m, 1H), 2.32-2.22 (m, 1H), 2.21-2.11 (m, 1H), 2.02-1.82 (m, 4H), 1.61-1.15 (m, 8H), 1.49 (s, 9H), 1.10 (t, 3H), 0.93 (s, 3H), 0.91 (s, 3H)
EXAMPLE A4
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide HCl salt




Step A: 1-boc-2-methyl-(2S,4S)-4-{[3-(acetyloxy)-2,2-dimethylpropanoyl](4,4-dimethylcyclohexyl)amino}pyrrolidine-2-carboxylate
To a solution of methyl-(2S,4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)amino]pyrrolidine-2-carboxylate (1.01 g, 2.84 mmol) prepared in Step A of Example A1 in DCE (5 mL) was added dropwise TEA (5 mL) and DMAP (0.34 g, 2.84 mmol). Then, the product of Preparation Example A4-1, 2,2-dimethyl-3-acetyloxypropionyl chloride (1.01 g, 5.68 mmol) was added. The reaction solution was heated to 90° C., and stirred for 48 h. After the reaction finished, the solvent was removed in vacuo, to the residue was added a saturated aqueous NaHCO3 solution, and extracted with EtOAc. The organic extracts were washed with 1N HCl, dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/4) to give the title compound (0.88 g, 63%).
MS[M+H]=497(M+1)
Step B: (4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-L-proline
To a solution of 1-BOC-2-methyl-(2S,4S)-4-{[3-(acetyloxy)-2,2-dimethylpropanoyl](4,4-methylcyclohexyl)amino}pyrrolidine-2-carboxylate (1.02 g, 2.05 mmol) prepared in Step A in methanol (10 ml) and water (10 ml), was added NaOH (246 mg, 6.15 mmol), and stiffed for 12 h. After the reaction finished, the reaction solution was concentrated in vacuo, acidified with 1N HCl, and extracted with EtOAc. The organic extracts were washed with 1N HCl, dried MgSO4, and concentrated in vacuo to give the title compound (0.85 g, 95%).
MS[M+H]=441(M+1)
Step C: BOC-(2S,4S)-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-2-{[ethyl(methyl)amino]carbonyl}pyrrolidine
The title compound was prepared according to the procedure described in Step D of Example A1 using (4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-L-pr oline (0.85 g, 1.94 mmol) prepared in Step B and commercially available N-methylethylamine (0.86 g, 93%).
MS[M+H]=482(M+1)
Step D: (4S)-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
The title compound was prepared according to the procedure described in Step E of Example A1 using BOC-(2S,4S)-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-2-{[ethyl(methyl)amino]carbonyl}pyrrolidine (0.86 g, 1.8 mmol) prepared in Step C (0.68 g, 99.9
MS[M+H]=382(M+1)
Step E: (4S)-1-{[(3S,4R)-1-tert-butyl-4-(chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide HCl salt
TFA salt of the compound was prepared according to the procedure described in Step G of Example A1 using (4S)-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-N-ethyl-N-m ethyl-L-prolineamide (0.68 g, 2.0 mmol) prepared in Step D (1 g, 89%). This compound was treated according to the procedure described in Step G of Example A1 to give the title compound.
MS[M+H]=645(M+1)
1H NMR (400 MHz, CDCl3) 7.62 (d, 2H), 7.31 (d, 2H), 4.68 (t, 1H), 4.36-4.19 (m, 1H), 3.96-3.79 (m, 3H), 3.77-3.52 (m, 4H), 3.43-3.08 (m, 6H), 2.94 (s, 3H), 2.74-2.62 (m, 1H), 2.11-1.97 (m, 1H), 1.67-1.36 (m, 14H), 1.35-1.15 (m, 9H), 1.10 (t, 3H), 0.95 (s, 3H), 0.92 (s, 3H)
EXAMPLE A5
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide HCl salt




Step A: 2-methyl-(2S,4S)-1-BOC-4-[(4,4-difluorocyclohexyl)amino]pyrrolidine-carboxylate
To a solution of 4,4-Difluoro cyclohexanone prepared in Preparation Example A2-3, and methyl (2S,4S)-1-Boc-4-aminopyrrolidine-2-carboxylate (29 g, 120 mmol) prepared in Preparation Example A1-1 in DCE was added NaBH(OAc)3 (37 g, 180 mmol), and stirred at rt for 6 h. After the reaction finished, the solvent was concentrated in vacuo, NaHCO3 aqueous solution was added, extracted with EtOAc, and the organic layer was dried over MgSO4, concentrated in vacuo. The residue was purified by column chromatography (eluent: EtOAc/Hex=1/4) to isolate 2-methyl-(2S,4S)-1-BOC-4-[(4-fluorocyclohex-3-ene-1-yl)amino]pyrrolidine-carboxylate, whereby to give the title compound (23 g, 55%).
MS[M+H]=363 (M+1)
Step B: 1-BOC 2-methyl (2S,4S)-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-2-carboxylate
The title compound was prepared according to the procedure described in Step B of Example A1 using 2-methyl-(2S,4S)-1-BOC-4-[(4,4-difluorocyclohexyl)amino]pyrrolidine-carboxylate (1.03 g, 2.84 mmol) prepared in Step A (1.02 g, 82%).
MS[M+H]=447(M+1)
Step C: (4S)-1-BOC-4-[(4,4-difluorocyclohexyl(2,2-dimethylpropanoyl)amino]-L-proline
The title compound was prepared according to the procedure described in Step C of Example A1 using 1-BOC 2-methyl (2S,4S)-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-2-carboxylate (1.02 g, 2.32 mmol) prepared in Step B (0.95 g, 95%).
MS[M+H]=433(M+1)
Step D: BOC-(2S,4S)-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine
The title compound was prepared according to the procedure described in Step D of Example A1 using (4S)-1-BOC-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-L-proline (0.95 g, 2.2 mmol) prepared in Step C (0.93 g, 93%).
MS[M+H]=460 (M+1)
Step E: (4S)-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-diethyl-L-prolineamide
The title compound was prepared according to the procedure described in Step E of Example A1 using BOC-(2S,4S)-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine (0.93 g, 2.0 mmol) prepared in Step D (710 mg, 99.9%).
MS[M+H]=360(M+1)
Step F: (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide HCl salt
The title compound was prepared according to the procedure described in Step F-G of Example A1, using (4S)-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide (0.70 g, 2.0 mmol) prepared in Step E and (3S,4R)-1-t-butyl(4-dichlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (1.06 g, 85%).
MS[M+H]=623(M+1)
1H NMR (400 MHz, CDCl3) 7.60 (d, 2H), 7.31 (d, 2H), 4.69 (t, 1H), 4.33-4.11 (m, 1H), 4.00-3.51 (m, 6H), 3.37-3.08 (m, 3H), 2.99 (d, 6H), 2.45-1.96 (m, 5H), 1.90-1.56 (m, 5H), 1.48 (s, 9H), 1.21 (s, 9H)
EXAMPLE A6
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-N-ethyl-L-prolineamide HCl salt




Step A: BOC-(2S,4S)-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-2-[(ethylamino)carbonyl]pyrrolidine
The title compound was prepared according to the procedure described in Step D of Example A1 using (4S)-1-BOC-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-L-proline (0.95 g, 2.2 mmol) prepared in Step C of Example A5 and commercially available ethylamine (0.93 g, 93%).
MS[M+H]=460 (M+1)
Step B: (4S)-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-N-ethyl-L-prolineamide
The title compound was prepared according to the procedure described in Step E of Example A1 using BOC-(2S,4S)-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-2-[(ethylamino)carbonyl]pyrrolidine (0.93 g, 2.0 mmol) prepared in Step A (710 mg, 99.9%).
MS[M+H]=360(M+1)
Step C: (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-N-ethyl-L-prolineamide HCl salt
The title compound was prepared according to the procedure described in Step F-G of Example A1, using (4S)-4-[(4,4-fluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-N-ethyl-L-prolineamide (0.70 g, 2.0 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-dichlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (1.06 g, 85%).
MS[M+H]=623(M+1)
1H NMR (400 MHz, CDCl3) 7.56 (d, 2H), 7.35 (d, 2H), 4.26 (t, 1H), 4.04-3.57 (m, 61H), 3.57-3.40 (m, 1H), 3.40-3.05 (m, 3H), 2.70-2.50 (m, 1H), 2.43-2.15 (m, 3H), 1.95-1.22 (m, 8H), 1.49 (s, 9H), 1.22 (s, 9H), 1.11 (t, 3H)
EXAMPLE A7
(4S)-1-{[(3S,4R)-4-(4-Chlorophenyl)-1-methylpyrrolidine-3-yl]carbonyl}-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]-L-prolineamide HCl salt




Step A: 1-BOC 2-methyl(2S,4S)-4-[(cis-4-methylcyclohexyl)amino]pyrrolidine-2-carboxylate
To a solution of methyl (2S,4S)-1-Boc-4-aminopyrrolidine-2-carboxylate (1.07 g, 4.38 mmol) prepared in Preparation Example A1-1 and 4-methylcyclohexanone in DCE (30 ml) was added dropwise NaBH(OAc) (1.39 g, 6.57 mmol) at rt. The reaction mixture was stirred at rt for 4 h, a saturated NaHCO3 aqueous solution was added, and extracted with DCM (50 mL×2) and EtOAc. The organic extracts were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by column chromatography (eluent, EtOAc/Hex=1/2) to isolate cis and trans compounds, whereby to give the title compound (0.84 g, 57%).
MS[M+11]=341 (M+1)
Step B: 1-BOC 2-methyl(2S,4S)-4-[(2,2-dimethylpropanoyl)(cis-4-methyl-cyclohexyl)amino]pyrrolidine-2-carboxylate
The title compound was prepared according to the procedure described in Step B of Example A1 using 1-BOC 2-methyl(2S,4S)-4-[(cis-4-methylcyclohexyl)amino]pyrrolidine-2-carboxylate (0.84 g, 2.49 mmol) prepared in Step A (0.92 g, 87%).
MS[M+H]=425(M+1)
Step C: (4S)-1-BOC-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]-L-proline
The title compound was prepared according to the procedure described in Step C of Example A1 using 1-BOC 2-methyl(2S,4S)-4-[(2,2-dimethylpropanoyl)(cis-4-methyl-cyclohexyl)amino]pyrrolidine-2-carboxylate (0.92 g, 2.16 mmol) prepared in Step B (0.84 g, 95%).
MS[M+H]=411(M+1)
Step D: BOC-(2S,4S)-2(aminocarbonyl)-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]pyrrolidine
To a solution of (4S)-1-BOC-4-[(2,2-dimethylpropanoyl)(cis-4-methyl-cyclohexyl)amino]-L-proline (0.83 g, 2.05 mmol) prepared in Step C in THF was added dropwise TEA (0.32 ml, 2.27 mmol). Then, ethylchloroformate (0.24 g, 2.27 mmol) was slowly added dropwise at 0° C., and the reaction solution was stirred at the same temperature for 1 h. 28% Ammonia water (1 equivalent) was slowly added dropwise at 0° C., and stirred at the same temperature for additional 1 h. After the reaction finished, the reaction mixture was concentrated in vacuo, and extracted with EtOAC. The organic extracts were washed with brine, dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=2/1) to give the title compound (0.62 g, 74%).
MS[M+H]=410(M+1)
Step E: (4S)-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]L-prolineamide
The title compound was prepared according to the procedure described in Step E of Example A1 using BOC-(2S,4S)-2(aminocarbonyl)-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]pyrrolidine (0.62 g, 1.53 mmol) prepared in Step D (0.45 g, 95%).
MS[M+H]=310(M+1)
Step F: (4S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-methylpyrrolidine-3-yl]carbonyl}-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]-L-prolineamide HCl salt
The title compound was prepared according to the procedure described in Step F-G of Example A1, using (4S)-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]L-prolineamide (0.45 g, 1.45 mmol) prepared in Step E and (3S,4R)-1-t-methyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-6 (0.67 g, 88%).
MS[M+H]=531(M+1)
1H NMR (400 MHz, CDCl3) 7.51 (d, 2H), 7.33 (d, 2H), 4.69 (t, 1H), 4.35-4.22 (m, 2H), 3.95-3.90 (m, 2H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 2H), 3.22-3.11 (m, 1H), 2.82-2.68 (m, 1H), 2.68-2.56 (m, 3H), 2.19-1.97 (m, 1H), 1.61-1.39 (m, 5H), 1.31-1.15 (m, 4H), 1.22 (s, 9H), 0.90 (d, 3H)
EXAMPLE A8
N-[(3S)-1[(3S,4R)-1-T-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide HCl salt




Step A: (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)amino]pyrrolidine
To a solution of 4,4-dimethylcyclohexanone (3.8 g, 30 mmol) in DCM (200 ml) was added commercially obtained (3S)-1-Boc-3-aminopyrrolidine (5.6 g, 30 mmol), and NaBH(OAc) (12.7 g, 60 mmol) was added, and stirred at rt for 6 h. After the reaction finished, the solvent was concentrated in vacuo, a NaHCO3 aqueous solution was added, and extracted with EtOAc. The organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=2/1) to give the title compound (8.4 g, 94.5%).
MS[M+H]=297 (M+1)
Step B: (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine
To a solution of (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)amino]pyrrolidine (2 g, 6.7 mmol) prepared in Step A in anhydrous THF was added TEA (2.03 g, 20.1 mmol) and DMAP (818 mg, 6.7 mmol). Then, the product of Preparation Example A4-1, 2,2-dimethyl-3-acetyloxypropionyl chloride (3.6 g, 20.1 mmol) was added, and the solution was stirred at 80° C. for 14 h. After the reaction finished, the solvent was concentrated in vacuo, and the residue was diluted with EtOAc, and washed with 1N-NaOH and 1N-HCl. The organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/3) to give (3S)-1-Boc-3-({[3-(acetyloxy)-2,2-dimethylpropanoyl](4,4-dimethylcyclohexyl)amino}pyrrolidine (2.3 g, 78%). This compound was dissolved in methanol (10 ml), and LiOH (187 mg, 7.8 mmol) and water (0.3 ml) were added, and stirred at rt for 3 h. After the reaction finished, the solvent was removed in vacuo, diluted with water (50 ml), and extracted with EtOAc. The organic layer was washed with 1N-HCl, dried over MgSO4, concentrated in vacuo to give the title compound (1.95 g, 94.5%).
MS[M+H]=397 (M+1)
Step C: N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethyl-N-[(3S)pyrrolidine-3-yl]propaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using (3S) 1-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine (484 mg, 1.22 mmol) prepared in Step B (500 mg, 99.9%).
Step D: N-[(3S)-1-{[(3S,4R)-1-t-butyl-4-(4-chlorophenyl) pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide HC salt
The title compound was prepared according to the procedure described in Step F-G of Example A1, using N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]propaneamide (500 mg, 1.21 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (672 mg, 91.9%).
MS[M+H]=560(M+1)
1H NMR (500 MHz, CDCl3) 7.55-7.48 (m, 2H), 7.36-7.28 (m, 2H), 3.95-3.20 (m, 12H), 3.01-2.93 (m, 0.5H), 2.75-2.68 (m, 0.5H), 2.48-2.38 (m, 0.5H), 2.18-2.08 (m, 0.5H), 1.86-1.68 (m, 1H), 1.67-1.53 (m, 6H), 1.53-1.35 (m, 10H), 1.32-1.14 (m, 8H), 0.94 (s, 3H), 0.91 (s, 3H)
EXAMPLE A9
N-[(3S,4R)-1-{[(3S,4R)-1-T-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide HCl salt




Step A: (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine
The title compound was prepared according to the procedure described in Step B of Example A1 using (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)amino]pyrrolidine (2 g, 6.7 mmol) prepared in Step A of Example A8 (2.4 g, 94.5%).
MS[M+H]=381 (M+1)
Step B: N-(4,4 dimethylcyclohexyl)-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]propaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine (460 mg, 1.22 mmol) prepared in Step A (0.33 g, 97%).
MS[M+H]=281(M+1)
Step C: N-[(3S)-1-{[(3S,4R)-1-t-butyl-4-(chlorophenyl)pyrrolidine-3-yl]-carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide HCl salt
The title compound was prepared according to the procedure described in Step F-G of Example A1, using N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]propaneamide (300 mg, 1.06 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (510 mg, 90%).
MS[M+H]=544(M+1)
1H NMR (400 MHz, CDCl3) 7.58-7.47 (m, 2H), 7.37-7.30 (m, 2H), 3.92-3.48 (m, 7H), 3.47-3.22 (m, 3H), 2.77-2.69 (m, 1H), 2.53-2.33 (m, 1H), 1.78-1.57 (m, 8H), 1.52-1.38 (m, 10H), 1.32-1.20 (m, 10H), 0.94 (s, 3H), 0.92 (s, 3H)
EXAMPLE A10
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(methylsulfonyl)amino]-N,N-dimethyl-L-prolineamide HCl salt




Step A: methyl (2S,4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)(methylsulfonyl)amino]pyrrolidine-2-carboxylate
To a solution of methyl (2S,4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)amino]pyrrolidine-2-carboxylate (2.37 g, 6.7 mmol) prepared in Step A of Example A1 in DCM (10 ml) was added TEA (1.36 g, 13.4 mmol), slowly added dropwise methanesulfonylchloride (104 mg, 0.91 mmol) at 0° C., and stirred at rt for 30 min. After the reaction finished, the solvent was concentrated in vacuo, the residue was extracted with water and EtOAc. The organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex ═1/1) to give the title compound (2.08 g, 72%).
MS[M+H]=433 (M+1)
Step B: (4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)(methylsulfonyl)amino]-L-proline
The title compound was prepared according to the procedure described in Step C of Example A1 using methyl (2S,4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)(methylsulfonyl)amino]pyrrolidine-2-carb oxylate (500 mg, 1.19 mmol) prepared in Step A (470 mg, 95%).
MS[M+H]=419(M+1)
Step C: 1-BOC-(2S,4S)-2-[(dimethylaminocarbonyl)-4-[(4,4-dimethylcyclohexyl)(methylsulfonyl)amino]pyrrolidine
The title compound was prepared according to the procedure described in Step D of Example A1 using (4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)(methylsulfonyl)amino]-L-proline (470 mg, 1.13 mmol) prepared in Step B (402 mg, 80%).
MS[M+H]=446 (M+1)
Step D: (4S)-4-[(4,4-dimethylcyclohexyl)(methylsulfonylamino]-N,N-dimethyl-L-prolineamide
The title compound was prepared according to the procedure described in Step E of Example A1 using 1-BOC-(2S,4S)-2-[(dimethylaminocarbonyl)-4-[(4,4-dimethylcyclohexyl)(methylsulfonyl)amino]pyrrolidine (402 mg, 0.90 mmol) prepared in Step C (310 mg, 97%).
MS[M+H]=346(M+1)
Step E: (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenylpyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(methylsulfonyl)amino]-N,N-dimethyl-L-prolineamide HCl salt
The title compound was prepared according to the procedure described in Step F-G of Example A1 using (4S)-4-[(4,4-dimethylcyclohexyl)(methylsulfonyl)amino]-N,N-dimethyl-L-prolineamide (300 mg, 0.86 mmol) prepared in Step D (370 mg, 70%).
MS[M+H]=611(M+1)
1H NMR (400 MHz, CDCl3) 7.85-7.76 (m, 1H), 6.96-6.92 (m, 1H), 6.85-6.79 (m, 11H), 4.66 (t, 11H), 4.21-4.00 (m, 2H), 4.00-3.80 (m, 2H), 3.71-3.52 (m, 2H), 3.48-3.29 (m, 2H), 3.08 (s, 3H), 2.99 (s, 3H), 2.86 (s, 3H), 2.43-2.33 (m, 1H), 2.22-2.11 (m, 1H), 1.99-1.78 (m, 2H), 1.57-1.18 (m, 8H), 1.48 (s, 9H), 0.91 (s, 6H)
EXAMPLE A11
N-[(3S)-1-{[(3S,4R)-1-T-BUTYL-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl](4,4-dimethylcyclohexyl)amino}-2,2-dimethylpropane-1-ol HCl salt




Step A: (3S) 1-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropyl)amino]pyrrolidine
To a solution of (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine (210 mg, 0.53 mmol) prepared in Step B of Example A8 in THF was added dropwise borane-methylsulfide complex (in THF, 2.0M, 0.4 ml, 0.8 mmol), and stirred at 80° C. for 3 h. After the reaction finished, the solvent was concentrated in vacuo, water added, extracted with EtOAc. The organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: DCM/MeOH=9/1) to give the title compound (140 mg, 75%).
MS[M+H]=382 (M+1)
Step B: N-[(3S)-1-{[(3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl](4,4-dimethylcyclohexyl)amino}-2,2-dimethylpropane-1-ol HCl salt
The title compound was prepared according to the procedure described in Step E ̃G of Example A1 using (3S)-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropyl)amino]pyrrolidine (140 mg, 0.36 mmol) prepared in Step A (156 mg, 78%).
MS[M+H]=546 (M+1)
1H NMR (500 MHz, CDCl3) 7.55-7.48 (m, 2H), 7.36-7.28 (m, 2H), 3.95-3.15 (m, 11H), 2.85-2.78 (m, 1H), 2.58-2.38 (m, 2H), 2.28-2.08 (m, 2H), 1.85-1.53 (m, 7H), 1.53-1.35 (m, 10H), 1.32-1.14 (m, 8H), 0.94 (s, 3H), 0.91 (s, 3H)
EXAMPLE A12
(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-N-isobutyl-N-(cis-4-methylcyclohexyl)pyrrolidine-3-amine HCl salt




Step A: (3S)-1-Boc-3-[isobutyl(cis-4-methylcyclohexyl)amino]pyrrolidine
Commercially obtained (3S)-1-Boc-3-aminopyrrolidine (5.6 g, 30 mmol) was reacted according to the procedure described in Step A of Example A7 to give (3S)-1-Boc-3-cis-(4′-methylcyclohexyl)aminopyrrolidine. Then, the title compound was prepared from this compound and isobutylaldehyde via reductive amination as described in Step A of Example A1.
MS[M+H]=339 (M+1)
Step B: (3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-N-isobutyl-N-(cis-4-methylcyclohexyl)pyrrolidine-3-amine HCl salt
The title compound was prepared according to the procedure described in Steps E, F, G of Example A1 using (3S)-1-Boc-3-[isobutyl(cis-4-methylcyclohexyl)amino]pyrrolidine (100 mg, 0.30 mmol) prepared in Step A (115 mg, 78%).
MS[M+H]=502 (M+1)
1H NMR (400 MHz, CDCl3) 7.59-7.48 (m, 2H), 7.35-7.28 (m, 2H), 3.91-3.47 (m, 7H), 3.47-3.22 (m, 3H), 2.80-2.69 (m, 2H), 2.53-2.33 (m, 1H), 1.78-1.57 (m, 8H), 1.52-1.38 (m, 111H), 1.28-1.18 (m, 7H), 0.95 (d, 3H)
EXAMPLE A13 ̃172
The following Examples were prepared according to the procedure described in Example A1 ̃A7, A9, using appropriate compounds among Preparation Example A1, A2, A4, A9 and commercially available amine.







TABLE 4













 























MS


Example
R1
R2′
R3′
R4
R5′
*
**
(M + 1)





A13 
t-Bu
4-Cl
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
S
573


A14 
t-Bu
2,4-diF
C(O)NH2
4,4-diMe-c-Hex
t-Bu
S
S
589


A15 
t-Bu
4-Cl
C(O)NH2
c-Hex
Me
S
S
517


A16 
t-Bu
4-H
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
S
539


A17 
t-Bu
4-Me
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
S
553


A18 
t-Bu
4-F
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
S
557


A19 
t-Bu
2,4-diF
C(O)NH2
4,4-diMe-c-Hex
CH(CH3)2
S
S
575


A20 
t-Bu
2,4-diF
C(O)NH2
4,4-diMe-c-Hex
CH(CH3)2
S
R
575


A21 
t-Bu
4-Cl
C(O)NH2
4,4-diMe-c-Hex
CH(CH3)2
S
S
573


 


A22 
t-Bu
4-Cl
C(O)NH2




CH(CH3)2
S
S
547


 


A23 
t-Bu
4-Cl
C(O)NH2
c-Pen
CH(CH3)2
S
S
531


A24 
t-Bu
2,4-diF
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
S
575


 


A25 
t-Bu
2,4-diF
C(O)NH2
4,4-diMe-c-Hex




S
S
573


 


A26 
t-Bu
2,4-diF
C(O)NH2
4,4-diMe-c-Hex




S
S
603


 


A27 
t-Bu
4-Cl
C(O)NH2
cis-4-Me-c-Hex




S
S
601


 


A28 
t-Bu
2,4-diF
C(O)NH2
cis-4-Me-c-Hex




S
S
585


 


A29 
t-Bu
2,4-diF
C(O)NH2
4,4-diMe-c-Hex




S
S
615


 


A30 
t-Bu
2,4-diF
C(O)NH2
4,4-diMe-c-Hex




S
S
603


 


A31 
t-Bu
2,4-diF
C(O)NH2
4,4-diMe-c-Hex




S
S
603


 


A32 
t-Bu
2,4-diF
C(O)NH2
4,4-diMe-c-Hex




S
S
599


 


A33 
t-Bu
4-Cl
C(O)N(CH3)2
c-Hex
Me
S
S
545


 


A34 
t-Bu
4-Cl
C(O)N(CH3)2
cis-4-Me-c-Hex




S
S
615


 


A35 
t-Bu
4-Cl
C(O)NHEt
c-Hex
Me
S
S
545


A36 
t-Bu
4-Cl
C(O)NHEt
cis-4-Me-c-Hex
t-Bu
S
S
601


A37 
t-Bu
2,4-diF
C(O)NHt-Bu
c-Hex
Me
S
S
575


A38 
t-Bu
2,4-diF
C(O)NHt-Bu
cis-4-Me-c-Hex
t-Bu
S
R
631


A39 
t-Bu
2,4-diF
C(O)NH2
4,4-diF-c-Hex
t-Bu
S
S
597


A40 
t-Bu
4-Cl
C(O)NH2
4,4-diF-c-Hex
t-Bu
S
S
595


A41 
t-Bu
4-Cl
C(O)NH2
4,4-diF-c-Hex
CH(CH3)2
S
S
581


A42 
t-Bu
2,4-diF
C(O)N(CH3)2
4,4-diF-c-Hex
CH(CH3)2
S
S
611


A43 
t-Bu
2,4-diF
C(O)N(CH3)2
4,4-diF-c-Hex
t-Bu
S
S
625


A44 
t-Bu
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
CH(CH3)2
S
S
603


A45 
t-Bu
2,4-diF
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
R
575


 


A46 
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diMe-c-Hex




S
S
629


 


A47 
t-Bu
4-Cl
C(O)NHEt
4,4-diMe-c-Hex
t-Bu
S
S
615


A48 
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
615


A49 
t-Bu
4-Cl
C(O)N(CH3)2
cis-4-Me-c-Hex
t-Bu
S
S
601


A50 
t-Bu
2,4-diF
C(O)N(CH3)2
cis-4-Me-c-Hex
t-Bu
S
S
603


A51 
t-Bu
4-Cl
C(O)NH2
4,4-diMe-c-Hex
t-Bu
S
S
587


A52 
t-Bu
2,4-diF
C(O)NHEt
4,4-diMe-c-Hex
t-Bu
S
S
617


A53 
t-Bu
2,4-diF
C(O)NMeEt
4,4-diMe-c-Hex
t-Bu
S
S
631


A54 
t-Bu
2,4-diF
C(O)NHiPr
4,4-diMe-c-Hex
t-Bu
S
S
631


 


A55 
t-Bu
2,4-diF




4,4-diMe-c-Hex
t-Bu
S
S
629


 


A56 
t-Bu
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex




S
S
627


 


A57 
t-Bu
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex




S
S
631


 


A58 
t-Bu
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
C(CH3)2CH2OH
S
S
633


A59 
i-Pr
2,4-diF
C(O)N(CH3)2
4,4-diF-c-Hex
t-Bu
S
S
611


 


A60 
t-Bu
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex




S
S
629


 


A61 
t-Bu
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
R
617


A62 
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diMe-c-Hex
C(CH3)2CH2OH
S
S
631


 


A63 
t-Bu
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex




S
S
631


 


A64 
t-Bu
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex




S
S
627


 


A65 
t-Bu
2,4-diF
C(O)N(CH3)2
4,4-diF-c-Hex
C(CH3)2CH2OH
S
S
641


 


A66 
t-Bu
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex




S
S
631


 


A67 
t-Bu
2,4-diF
C(O)NMeEt
4,4-diMe-c-Hex
C(CH3)2CH2OH
S
S
647


 


A68 
t-Bu
4-Cl
C(O)NMeEt
4,4-diMe-c-Hex




S
S
639


 


A69 
t-Bu
2,4-diF
C(O)NMeEt
4,4-diMe-c-Hex




S
S
641


 


A70 
t-Bu
2,4-diF
C(O)N(CH3)2
3,3-4,4-tetraMe-c-Pen
t-Bu
S
S
631


A71 
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diF-c-Hex
C(CH3)2CH2OH
S
S
639


A72 
t-Bu
4-Cl
C(O)NMeEt
4,4-diF-c-Hex
C(CH3)2CH2OH
S
S
653


 


A73 
t-Bu
2,4-diF
C(O)NMeEt
4,4-diMe-c-Hex




S
S
645


 


A74 
t-Bu
4-Cl
C(O)N(CH3)2
3,3-4,4-tetraMe-c-Pen
t-Bu
S
S
629


A75 
t-Bu
4-Cl
C(O)NMeEt
4,4-diF-c-Hex
t-Bu
S
S
637


 


A76 
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diF-c-Hex




S
S
637


 


A77 
t-Bu
4-Cl
C(O)NMeEt
4,4-diF-c-Hex




S
S
651


 


A78 
t-Bu
4-Cl
C(O)N(CH3)2
cis-4-Me-c-Hex
C(CH3)2CH2OH
S
S
617


A79 
t-Bu
4-Cl
C(O)NMeEt
cis-4-Me-c-Hex
C(CH3)2CH2OH
S
S
631


A80 
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diF-c-Hex
CH(CH3)2
S
S
609


A81 
t-Bu
4-Cl
C(O)NMeEt
4,4-diF-c-Hex
CH(CH3)2
S
S
623


A82 
t-Bu
4-Cl
C(O)NHtBu
4,4-diMe-c-Hex
t-Bu
S
R
643


A83 
t-Bu
4-Cl
C(O)NMeEt
4,4-diMe-c-Hex
C(CH3)2C(O)NH2
S
S
658


 


A84 
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diMe-c-Hex




S
S
629


 


A85 
t-Bu
4-Cl
C(O)NMeEt
4,4-diMe-c-Hex




S
S
643


 


A86 
t-Bu
4-Cl




4,4-diF-c-Hex
t-Bu
S
S
649


 


A87 
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diF-c-Hex
cBu
S
S
621


A88 
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diF-c-Hex
CH2OCH3
S
S
611


A89 
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diF-c-Hex
cPr
S
S
607


 


A90 
t-Bu
4-Cl
C(O)NMeEt








S
S
641


 


A91 
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diMe-c-Hex
CH3
S
S
573


A92 
t-Bu
4-Cl
C(O)NMeEt
4,4-Me-c-Hex
CH3
S
S
587


 


A93 
t-Bu
4-Cl




4,4-diMe-c-Hex
CH3
S
S
599


 


A94 
t-Bu
4-Cl




4,4-diMe-c-Hex
CH3
S
S
613


 


A95 
t-Bu
2,4-diF




4,4-diMe-c-Hex
CH3
S
S
617


 


A96 
t-Bu
4-Cl




4,4-diMe-c-Hex
CH3
S
S
615


 


A97 
t-Bu
4-Cl
C(O)NMeEt
4,4-diMe-c-Hex




S
S
643


 


A98 
t-Bu
4-Cl
C(O)NEt
4,4-diMe-c-Hex
C(CH3)2CH2OH
S
S
631


 


A99 
t-Bu
4-Cl




4,4-diMe-c-Hex
t-Bu
S
S
663


 


A100
t-Bu
4-Cl




4,4-diMe-c-Hex
t-Bu
S
S
664


 


A101
t-Bu
4-Cl




4,4-diMe-c-Hex
t-Bu
S
S
670


 


A102
t-Bu
4-Cl
C(O)N(CH3)2
cis-4-Me-c-Hex
C(CH3)2CH2OH
R
S
617


A103
Me
4-Cl
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
S
531


A104
Me
4-Cl
C(O)NH2
4,4-diMe-c-Hex
CH(CH3)2
S
S
531


A105
Me
2,4-diF
C(O)NH2
4,4-diMe-c-Hex
t-Bu
S
S
547


 


A106
Me
2,4-diF
C(O)NH2
cis-4-Me-c-Hex




S
S
547


 


A107
Me
4-Cl
C(O)NH2
4,4-diMe-c-Hex




S
S
559


 


A108
Me
2,4-diF
C(O)N(CH3)2
cis-4-Me-c-Hex




S
S
575


 


A109
t-Bu
4-Cl
CO2CH3
4,4-diMe-c-Hex
t-Bu
S
S
602


A110
t-Bu
4-Cl
CO2H
4,4-diMe-c-Hex
t-Bu
S
S
588


A111
t-Bu
4-Cl
H
4,4-diF-c-Hex
C(CH3)2CH2OH
S

568


A112
t-Bu
4-Cl
H
4,4-diMe-c-Hex
CH(CH3)2
S

530


A113
t-Bu
4-Cl
H
4,4-diMe-c-Hex
CH2C(CH3)3
S

558


A114
t-Bu
4-Cl
H
4,4-diMe-c-Hex
Ph
S

564


 


A115
t-Bu
4-Cl
H
4,4-diMe-c-Hex




S

558


 


A116
t-Bu
4-Cl
H
4,4-diMe-c-Hex




S

558


 


A117
t-Bu
4-Cl
H
4,4-diMe-c-Hex




S

558


 


A118
t-Bu
4-Cl
H
4,4-diMe-c-Hex




S

572


 


A119
t-Bu
4-Cl
H
4,4-diMe-c-Hex




S

556


 


A120
t-Bu
4-Cl
H
4,4-diMe-c-Hex




S

568


 


A121
t-Bu
4-Cl
H
4,4-diMe-c-Hex




S

528


 


A122
t-Bu
4-Cl
H
cis-4-Me-c-Hex
CH3
S

488


 


A123
t-Bu
4-Cl
H
4,4-diMe-c-Hex




S

554


 


A124
t-Bu
4-Cl
H
4,4-diMe-c-Hex




S

554


 


A125
t-Bu
4-Cl
H
4,4-diMe-c-Hex




S

571


 


A126
t-Bu
4-Cl
H
4,4-diMe-c-Hex
CH2OCH3
S

532


A127
t-Bu
4-Cl
H
4,4-diMe-c-Hex
CH2OCH2CH3
S

546


A128
t-Bu
4-Cl
H
4,4-diMe-c-Hex
C(CH3)2OH
S

546


A129
t-Bu
4-Cl
H
cis-4-Me-c-Hex
CH2CH3
S

502


A130
t-Bu
4-Cl
H
cis-4-Me-c-Hex
CH2OCH3
S

518


A131
t-Bu
4-Cl
H
cis-4-Me-c-Hex
t-Bu
S

530


A132
t-Bu
4-Cl
H
cis-4-Me-c-Hex
cyclopentyl
S

542


 


A133
t-Bu
4-Cl
H
cis-4-Me-c-Hex




S

540


 


A134
t-Bu
4-Cl
H
cis-4-Me-c-Hex




S

556


 


A135
t-Bu
4-Cl
H
cis-4-Me-c-Hex
C(CH3)2CH2OH
S

546


A136
t-Bu
4-Cl
H
cis-4-Me-c-Hex
C(CH3)2CH(CH3)OH
S

560


A137
t-Bu
4-Cl
H
cis-4-Me-c-Hex
C(CH3)2C(CH3)2OH
S

574


A138
t-Bu
4-Cl
H
cis-4-Me-c-Hex
C(CH3)2CN
S

541


 


A139
t-Bu
4-Cl
H
cis-4-Me-c-Hex




S

514


 


A140
t-Bu
4-Cl
H
cis-4-Me-c-Hex
CH2C(CH3)2
S

544


A141
t-Bu
4-Cl
H
Trans-4-Me-c-Hex
CH(CH3)2
S

516


A142
t-Bu
4-Cl
H
Trans-4-Me-c-Hex
t-Bu
S

530


A143
t-Bu
2,4-diF
H
Trans-4-Me-c-Hex
t-Bu
S

532


A144
t-Bu
4-Cl
H
cyclopentyl
C(CH3)2CH2OH
S

518


 


A145
t-Bu
4-Cl
H




C(CH3)2CH2OH
S

534


 


A146
t-Bu
4-Cl
H
4,4-diF-c-Hex
CH(CH3)2
S

538


A147
t-Bu
4-Cl
H
4,4-diF-c-Hex
t-Bu
S

552


 


A148
t-Bu
4-Cl
H
4,4-diF-c-Hex




S

566


 


A149
t-Bu
4-Cl
H
4,4-diF-c-Hex




S

566


 


A150
t-Bu
4-Cl
H
4,4-diF-c-Hex
CH3


510


A151
t-Bu
4-Cl
H
Cis-4-CF3-c-Hex
CH(CH3)2
S

570


A152
t-Bu
4-Cl
H
Cis-4-CF3-c-Hex
t-Bu
S

584


A153
t-Bu
4-Cl
H
Trans-4-CF3-c-Hex
t-Bu
S

584


A154
t-Bu
2,4-diF
H
4,4-diMe-c-Hex
CH(CH3)2
S

532


A155
t-Bu
2,4-diF
H
4,4-diMe-c-Hex
t-Bu
S

546


 


A156
t-Bu
2,4-diF
H
4,4-diMe-c-Hex




S

558


 


A157
t-Bu
2,4-diF
H
4,4-diMe-c-Hex




S

560


 


A158
t-Bu
2,4-diF
H
4,4-diMe-c-Hex




S

560


 


A159
t-Bu
2,4-diF
H
4,4-diMe-c-Hex
C(CH3)2CH2OH
S

562


A160
t-Bu
2,4-diF
H
4,4-diMe-c-Hex
CH2CH2OCH2CH3
S

562


A161
t-Bu
2,4-diF
H
cis-4-Me-c-Hex
t-Bu
S

532


 


A162
t-Bu
2,4-diF
H
cis-4-Me-c-Hex




S

542


 


A163
t-Bu
2,4-diF
H
4,4-diF-c-Hex
C(CH3)3
S

554


A164
t-Bu
2,4-diF
H
4,4-diF-c-Hex
C(CH3)2CH2OH
S

570


 


A165
t-Bu
2,4-diF
H
4,4-diF-c-Hex




S

568


 


A166
t-Bu
4-F
H
Cis-4-Me-c-Hex
CH(CH3)2
S

500


A167
t-Bu
4-Me
H
4,4-diMe-c-Hex
t-Bu
S

524


A168
t-Bu
4-Cl
H
cyclobutyl
C(CH3)2CH2OH
S

504


A169
t-Bu
4-Cl
H
cycloheptyl
C(CH3)2CH2OH
S

546


 


A170
Me
4-Cl
H
4,4-diMe-c-Hex




S

516


 


A171
Me
4-Cl
H
4,4-diMe-c-Hex




S

516


 


A172
t-Bu
4-Cl
H
4,4-diMe-c-Hex
CH2OH
S

518









(A44) (TFA Salt)
1H NMR (500 MHz, CDCl3) 7.60-7.52 (m, 1H), 6.92-6.85 (m, 1H), 6.82-6.74 (m, 1H), 4.72 (t, 1H), 4.23-4.10 (m, 2H), 4.06-3.93 (m, 2H), 3.74-3.40 (m, 5H), 3.35-3.25 (m, 1H), 2.99 (s, 3H), 2.95 (s, 3H), 2.81-2.66 (m, 2H), 2.17-2.06 (m, 1H), 1.68-1.14 (m, 611), 1.44 (s, 9H), 1.14-1.00 (m, 2H), 1.07 (dd, 6H), 0.95 (s, 3H), 0.92 (s, 3H)
(A50) (TFA Salt)
1H NMR (500 MHz, CDCl3) 7.61-7.54 (m, 1H), 6.92-6.86 (m, 1H), 6.81-6.75 (m, 1H), 4.71 (t, 1H), 4.25-4.07 (m, 2H), 4.04-3.93 (m, 2H), 3.84-3.71 (m, 1H), 3.70-3.55 (m, 2H), 3.55-3.45 (m, 1H), 3.45-3.35 (m, 1H), 3.35-3.25 (m, 1H), 3.11 (s, 6H), 2.81-2.70 (m, 1H), 2.01-1.90 (T, 1H), 1.60-1.39 (m, 5H), 1.44 (s, 9H), 1.28-1.13 (m, 4H), 1.21 (s, 9H), 0.97 (d, 3H)
(A52) (HCl Salt)
1H NMR (400 MHz, CDCl3) 8.10-8.04 (m, 1H), 6.97-6.93 (m, 1H), 6.79-6.74 (m, 1H), 4.70 (t, 1H), 4.35-4.22 (m, 2H), 3.95-3.40 (m, 2H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 2H), 3.26-3.11 (m, 3H), 2.82-2.68 (m, 1H), 2.19-1.97 (m, 1H), 1.61-1.39 (m, 4H), 1.49 (s, 9H), 1.32-1.15 (m, 7H), 1.22 (s, 9H), 0.95 (s, 3H), 0.91 (s, 3H)
(A53) (HCl Salt)
1H NMR (400 MHz, CDCl3) 8.10-8.04 (m, 1H), 6.97-6.93 (m, 1H), 6.79-6.74 (m, 1H), 4.70 (t, 1H), 4.35-4.22 (m, 2H), 3.95-3.40 (m, 2H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 2H), 3.26-3.11 (m, 3H), 2.99 (s, 3H), 2.82-2.68 (m, 1H), 2.19-1.97 (m, 1H), 1.61-1.39 (m, 4H), 1.49 (s, 9H), 1.32-1.15 (m, 7H), 1.22 (s, 9H), 0.95 (s, 3H), 0.91 (s, 3H)
(A54) (HCl Salt)
1H NMR (400 MHz, CDCl3) 8.10-8.04 (m, 1H), 6.97-6.93 (m, 1H), 6.79-6.74 (m, 1H), 4.70 (t, 1H), 4.35-4.22 (m, 2H), 3.98-3.93 (m, 1H), 3.95-3.81 (m, 2H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 2H), 3.26-3.11 (m, 1H), 2.82-2.68 (m, 1H), 2.19-1.97 (m, 1H), 1.61-1.39 (m, 4H), 1.49 (s, 9H), 1.34-1.15 (m, 10H), 1.22 (s, 9H), 0.95 (s, 3H), 0.91 (s, 3H)
(A55) (HCl Salt)
1H NMR (400 MHz, CDCl3) 8.10-8.04 (m, 1H), 6.97-6.93 (m, 1H), 6.79-6.74 (m, 1H), 4.70 (t, 1H), 4.35-4.22 (m, 2H), 3.97-3.81 (m, 6H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 2H), 3.22-3.11 (m, 1H), 2.82-2.68 (m, 1H), 2.35-2.20 (m, 2H), 2.19-1.97 (m, 1H), 1.61-1.39 (m, 4H), 1.49 (s, 9H), 1.31-1.15 (m, 4H), 1.22 (s, 9H), 0.95 (s, 3H), 0.91 (s, 3H)
(A60) (HCl Salt)
1H NMR (400 MHz, CDCl3) 8.14-8.00 (m, 1H), 7.03-6.91 (m, 1H), 6.83-6.72 (m, 1H), 5.94 (s, 1H), 4.89-4.66 (m, 5H), 4.30-4.12 (m, 2H), 4.12-3.99 (m, 1H), 3.99-3.88 (m, 1H), 3.74-3.47 (m, 4H), 3.42-3.26 (m, 2H), 3.00 (s, 3H), 2.95 (s, 3H), 2.76-2.52 (m, 1H), 2.24-2.09 (m, 1H), 1.57-1.34 (m, 4H), 1.49 (s, 9H), 1.34-1.16 (m, 4H), 0.93 (s, 3H), 0.90 (s, 3H)
A62) (HCl Salt)
1H NMR (400 MHz, CDCl3) 7.62 (d, 2H), 7.31 (d, 2H), 4.70 (t, 1H), 4.36-4.19 (m, 1H), 3.97-3.80 (m, 3H), 3.78-3.64 (m, 2H). 3.63-3.52 (m, 2H), 3.39-3.21 (m, 3H), 3.19-3.10 (m, 1H), 2.99 (s, 6H), 2.74-2.62 (m, 1H), 2.11-1.97 (m, 1H), 1.67-1.36 (m, 14H), 1.35-1.15 (m, 9H), 0.95 (s, 3H), 0.92 (s, 3H)
(A63) (HCl Salt)
1H NMR (400 MHz, CDCl3) 8.08-8.02 (m, 1H), 6.96-6.92 (m, 1H), 6.78-6.73 (m, 1H), 4.68 (t, 1H), 4.48 (t, 1H), 4.40-4.21 (m, 1H), 4.04-3.81 (m, 5H), 3.80-3.71 (m, 2H), 3.66-3.46 (m, 3H), 3.22-3.12 (m, 1H), 2.97 (s, 6H), 2.86-2.62 (m, 1H), 2.41-2.28 (m, 1H), 2.13-1.82 (m, 4H), 1.64-1.39 (m, 4H), 1.49 (s, 9H), 1.39-1.22 (m, 2H), 1.20-1.08 (m, 2H), 0.97 (s, 3H), 0.94 (s, 3H)
(A67) (HCl Salt)
1H NMR (400 MHz, CDCl3) 8.10-8.04 (m, 1H), 6.97-6.93 (m, 1H), 6.79-6.74 (m, 1H), 4.69 (t, 1H), 4.38-4.19 (m, 2H), 4.03-3.80 (m, 2H), 3.76-3.50 (m, 4H), 3.43-3.08 (m, 6H), 2.94 (s, 3H), 2.74-2.62 (m, 1H), 2.11-1.97 (m, 1H), 1.67-1.36 (m, 14H), 1.35-1.15 (m, 9H), 1.10 (t, 3H), 0.95 (s, 3H), 0.92 (s, 3H)
(A68) (HCl Salt)
1H NMR (500 MHz, CDCl3) 8.13-8.03 (m, 1H), 7.62 (s, 1H), 7.40 (s, 1H), 6.99-6.92 (m, 1H), 6.78-6.71 (m, 1H), 6.43 (s, 1H), 4.75-4.67 (m, 1H), 4.31-4.18 (m, 2H), 4.11-4.01 (m, 1H), 3.96-3.89 (m, 1H), 3.78-3.66 (m, 1H), 3.66-3.48 (m, 4H), 3.42-3.24 (m, 4H), 2.93 (d, 3H), 2.23-2.12 (m, 1H), 1.88-1.06 (m, 8H), 1.48 (s, 9H), 1.20 (t, 3H), 0.91 (s, 3H), 0.90 (s, 3H)
(A72) (HCl Salt)
1H NMR (500 MHz, CDCl3) 7.64-7.56 (m, 2H), 7.35-7.29 (m, 2H), 4.70-4.61 (m, 1H), 4.32-4.16 (m, 1H), 3.97-3.50 (m, 7H), 3.41-3.14 (m, 5H), 2.93 (s, 3H), 2.76-2.56 (m, 1H), 2.40-2.28 (m, 1H), 2.23-2.12 (m, 1H), 1.70-1.14 (m, 8H), 1.48 (s, 9H), 1.30-1.16 (m, 6H), 1.10 (t, 3H)
(A73) (HCl Salt)
1H NMR (400 MHz, CDCl3) 8.08-8.02 (m, 1H), 6.96-6.92 (m, 1H), 6.78-6.73 (m, 1H), 4.68 (t, 1H), 4.48 (t, 1H), 4.40-4.21 (m, 1H), 4.04-3.81 (m, 51), 3.80-3.71 (m, 2H), 3.66-3.46 (m, 3H), 3.45-3.12 (m, 3H), 2.97 (d, 3H), 2.86-2.62 (m, 1H), 2.41-2.28 (m, 1H), 2.13-1.82 (m, 4H), 1.64-1.39 (m, 4H), 1.49 (s, 9H), 1.39-1.22 (m, 2H), 1.26 (t, 3H), 1.20-1.08 (m, 2H), 0.97 (s, 3H), 0.94 (s, 3H)
(A75) (HCl Salt)
1H NMR (400 MHz, CDCl3) 7.60 (d, 2H), 7.31 (d, 2H), 4.65 (t, 1H), 4.33-4.11 (m, 1H), 4.00-3.51 (m, 5H), 3.37-3.08 (m, 6H), 2.95 (d, 3H), 2.45-1.96 (m, 51), 1.90-1.56 (m, 5H), 1.48 (s, 9H), 1.21 (s, 9H), 1.10 (t, 3H)
(A83) (TFA Salt)
1H NMR (500 MHz, CDCl3) 7.36 (d, 2H), 7.29 (d, 2H), 4.60 (t, 1H), 4.38-4.25 (m, 1H), 4.25-4.14 (m, 1H), 3.92-3.78 (m, 1H), 3.72-3.27 (m, 8H), 3.19-3.12 (m, 1H), 2.96 (d, 3H), 2.85-2.68 (m, 1H), 2.13-1.99 (m, 1H), 1.62-1.11 (m, 1111), 1.43 (s, 9H), 1.39 (s, 3H), 1.33 (s, 3H), 0.90 (s, 3H), 0.87 (s, 3H)
(A90) (HCl Salt)
1H NMR (400 MHz, CDCl3) 7.50 (d, 2H), 7.32 (d, 2H), 4.68 (t, 1H), 4.48 (t, 1H), 4.40-4.21 (m, 1H), 4.03-3.90 (t, 3H), 3.90-3.81 (m, 2H), 3.80-3.70 (m, 2H), 3.66-3.46 (m, 3H), 3.45-3.12 (m, 3H), 2.97 (d, 3H), 2.86-2.62 (m, 1H), 2.41-2.28 (m, 1H), 2.13-1.82 (m, 4H), 1.64-1.40 (m, 4H), 1.52 (s, 9H), 1.40-1.22 (m, 2H), 1.26 (t, 3H), 1.20-1.08 (m, 2H), 0.39-0.11 (m, 4H)
(A96) (TFA Salt)
1H NMR (500 MHz, CDCl3) 7.40 (d, 2H), 7.29 (d, 2H), 4.69 (t, 1H), 4.12-4.00 (m, 2H), 3.89-3.75 (m, 2H), 3.74-3.53 (m, 9H), 3.51-3.30 (m, 4H), 3.28-3.18 (M, 1H), 2.72-2.63 (m, 1H), 2.07 (s, 3H), 1.60-1.38 (m, 15H), 1.32-1.21 (m, 3H), 0.92 (s, 3H), 0.90 (s, 3H)
(A97) (TFA Salt)
1H NMR (400 MHz, CDCl3) 7.40 (d, 2H), 7.31 (d, 2H), 4.66 (t, 1H), 4.51 (t, 1H), 4.26-4.13 (m, 1H), 4.09-3.96 (m, 1H), 3.96-3.65 (m, 5H), 3.65-3.21 (m, 7H), 2.94 (d, 3H), 2.88-2.27 (m, br, 2H), 2.19-1.82 (m, 4H), 1.62-1.39 (m, 4H), 1.44 (s, 9H), 1.35-1.12 (m, br, 2H), 1.23 (t, 3H), 1.12-1.06 (m, 2H), 0.94 (s, 3H), 0.91 (s, 3H)
(A98) (TFA Salt)
1H NMR (500 MHz, CDCl3) 7.37 (d, 2H), 7.32 (d, 2H), 4.34-4.21 (m, 1H), 4.02-3.86 (m, 2H), 3.85-3.12 (m, 1H), 2.95-2.83 (m, 1H), 2.53-2.40 (m, 1H), 2.31-2.19 (m, 1H), 1.60-1.14 (m, 8H), 1.44 (s, 9H), 1.21 (s, 6H), 1.11 (t, 3H), 0.94 (s, 3H), 0.91 (s, 3H)
(A99) (TFA Salt)
1H NMR (500 MHz, CDCl3) 7.66 (d, 2H), 7.39-7.22 (m, 6H), 7.06 (t, 1H), 4.34 (t, 1H), 3.93-3.84 (m, 2H), 3.84-3.75 (m, 2H), 3.74-3.35 (m, 4H), 3.32-3.23 (m, 1H), 3.04-2.96 (m, 1H), 2.56-2.46 (m, 1H), 2.35-2.25 (m, 1H), 1.68-1.17 (m, 8H), 1.40 (s, 9H), 1.25 (s, 9H), 0.95 (s, 3H), 0.93 (s, 3H)
(A158) (TFA Salt)
1H NMR (500 MHz, CDCl3) 7.57-7.41 (m, 1H), 6.95-6.86 (m, 1H), 6.86-6.75 (m, 1H), 4.17-3.72 (m, 9H), 3.72-3.36 (m, 6H), 3.36-3.26 (m, 1H), 3.26-3.09 (m, 2H), 2.55-2.41 (m, 1H), 2.22-1.98 (m, 2H), 1.94-1.77 (m, 1H), 1.73-1.23 (m, 7H), 1.44 (s, 9H), 0.95 (s, 3H), 0.92 (s, 3H)
EXAMPLE A173 ̃177
The following Examples were prepared according to the procedure described in Example A10, using appropriate compounds among Preparation Example A1, A2, A4, A9 and commercially available amine.







TABLE 5













 














Example
R1
R2′
R3
R4
*
**
MS (M + 1)





A173
t-Bu
4-Cl
H
4,4-diMe-c-Hex
S

538


A174
t-Bu
4-Cl
H
cis-4-Me-c-Hex
S

524


A175
t-Bu
2,4-diF
H
cis-4-Me-c-Hex
S

526


A176
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diMe-c-Hex
S
S
609


A177
t-Bu
4-Cl
C(O)NMeEt
4,4-diMe-c-Hex
S
S
623









EXAMPLE A178 ̃188
The following Examples were prepared according to the procedure described in Example A11, A12, using appropriate compounds of Preparation Example A1, A2, A4, A9 and commercially available amine.







TABLE 6













 





















MS


Example
R1
R2′
R3′
R4
R5
*
(M + 1)





A178
t-Bu
4-Cl
H
4,4-diMe-c-Hex
CH2OH
S
518


 


A179
t-Bu
4-Cl
H
4,4-diMe-c-Hex




S
571


 


A180
t-Bu
4-Cl
H
4,4-diMe-c-Hex
Ph
S
564


 


A181
t-Bu
4-Cl
H
4,4-diMe-c-Hex




S
554


 


A182
t-Bu
4-Cl
H
Cis-4-Me-c-Hex
CH2OH
S
504


A183
t-Bu
4-Cl
H
Cis-4-Me-c-Hex
CH2NH2
S
503


A184
t-Bu
4-Cl
H
Cis-4-Me-c-Hex
CH2NHC(O)CH3
S
545


A185
t-Bu
4-Cl
H
Cis-4-Me-c-Hex
Ph
S
550


 


A186
t-Bu
4-Cl
H
Cis-4-Me-c-Hex




S
540


 


A187
t-Bu
4-Cl
H
Cis-4-Me-c-Hex




S
557


 


A188
t-Bu
4-Cl
H
Cis-4-Me-c-Hex




S
540













The preparation process of the Intermediate B1 compounds, and the Examples synthesized by the procedure of Scheme B are as follows.
EXAMPLE B1
N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(4,5-dihydro-1,3-oxazole-2-yl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide HCl salt




Step A (2S,4S)-1-Boc-2-{[(2-hydroxyethyl)amino]carbonyl}-4-[dimethylpropanoyl(4,4-dimethylcyclohexyl)amino]pyrrolidine
The title compound was prepared according to the procedure described in Step D of Example A1 using (4S)-1-BOC-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-L-proline (410 mg, 0.9 mmol) prepared in Step C of Example A1 and hydroxy ethyl amine (273 mg, 65%).
MS[M+H]=468 (M+1)
Step B: (2S,4S)-1-Boc-2-(4,5-dihydro-1,3-oxazole-2-yl)-4-[dimethylpropanoyl(4,4-dimethylcyclohexyl)amino]pyrrolidine
The product of Step A, (2S,4S)-1-Boc-2-{[(2-hydroxyethyl)amino]carbonyl}-4-[dimethylpropanoyl(4,4-dimethylcyclohexyl)amino]pyrrolidine (410 mg, 0.58 mmol) together with DMAP (70.7 mg, 0.58 mmol) and DIPEA (0.39 ml, 2.32 mmol) were dissolved in toluene (3 ml), and phosgene (20% in toluene, 0.31 ml, 0.87 mmol) was added dropwise. After the reaction solution was stirred at 30 ̃40° C. for 48 h, the solution was concentrated in vacuo. The residue was diluted with EtOAc, and washed with a saturated NaHCO3 aqueous solution, water and 1N HCl. The organic solution was dried over MgSO4, concentrated in vacuo, and the residue was purified by column chromatography (eluent: EtOAc) to give the title compound (160 mg, 62%).
MS[M+H]=450(M+1)
Step C: N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(4,5-dihydro-1,3-oxazole-2-yl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide HCl salt
The title compound was prepared according to the procedure described in Step E-G of Example A1 using (2S,4S)-1-Boc-2-(4,5-dihydro-1,3-oxazole-2-yl)-4-[dimethylpropanoyl(4,4-dimethylcyclohexyl)amino]pyrrolidine (100 mg, 0.2 mmol) prepared in Step B (95 mg, 82%).
MS[M+H]=613(M+1)
1H NMR (400 MHz, CDCl3) 7.36 (d, 2H), 7.29 (d, 2H), 4.35-4.22 (m, 2H), 3.95-3.90 (m, 2H), 3.80-3.51 (m, 6H), 3.42-3.29 (m, 2H), 3.22-3.11 (m, 1H), 2.82-2.68 (m, 1H), 2.19-1.97 (m, 1H), 1.61-1.39 (m, 6H), 1.49 (s, 9H), 1.31-1.15 (m, 4H), 1.22 (s, 9H), 0.95 (s, 3H), 0.91 (s, 3H)
EXAMPLE B2
N-{(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)carbonothionyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2-methylpropaneamide TFA salt




Step A: 1-BOC-2-methyl(2S,4S)-4-[(4,4-dimethylcyclohexyl)(isobutyryl)amino]pyrrolidine-2-carboxylate
The title compound was prepared according to the procedure described in Step B of Example A1, using methyl-(2S,4S)-4-BOC-4-[(4,4-dimethylcyclohexyl)amino]pyrrolidine-2-carboxylate (1 g, 2.82 mmol) prepared in Step A of Example A1□ Step A and isobutyryl chloride (1.1 g, 93%).
MS[M+H]=425(M+1)
Step B: (4S)-BOC-4-[(4,4-dimethylcyclohexyl)(isobutyryl)amino]-L-proline
The title compound was prepared according to the procedure described in Step C of Example A1 using 1-BOC-2-methyl(2S,4S)-4-[(4,4-dimethylcyclohexyl)(isobutyryl)amino]pyrolidine-2-carboxylate (1.1 g, 2.62 mmol) prepared in Step A (1.0 g, 93%).
MS[M+H]=411(M+1)
Step C: BOC-(2S,4S)-2-[(dimethylamino)carbonyl]-4-[(4,4-dimethylcyclohexyl)(isobutyryl)amino]pyrrolidine
The title compound was prepared according to the procedure described in Step D of Example A1 using (4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)(isobutyryl)amino]-L-proline (1.0 g, 2.43 mmol) prepared in Step B (0.97 g, 92%).
MS[M+H]=438(M+1)
Step D: BOC (2S,4S)2-[(dimethylamino)carbonothionyl]-4-[(4,4-dimethylcyclohexyl)(isobutyryl)amino]pyrrolidine
To a solution of BOC-(2S,4S)-2-[(dimethylamino)carbonyl]-4-[(4,4-dimethylcyclohexyl)(isobutyryl)amino]pyrrolidine (615 mg, 1.41 mmol) prepared in Step C in benzene (3 ml) was added Lawson s reagents (570 mg, 1.47 mmol). The reaction solution was heated to 80° C., and stirred for 1 h. After the reaction finished, the solution was concentrated in vacuo. The residue was diluted with EtOAc, and washed with brine. The organic solution was dried over MgSO4, concentrated in vacuo, and the residue was purified by column chromatography (eluent: EtOAc:Hex=1/2) to give the title compound (409 mg, 64%).
MS[M+H]=454(M+1)
Step E: N-{(3S,5S)-5-[(dimethylamino)carbonothionyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2-methylpropaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using BOC (2S,4S)-2-[(dimethylamino)carbonothionyl]-4-[(4,4-dimethylcyclohexyl)(isobutyryl)amino]pyrrolidine (50 mg, 0.11 mmol) prepared in Step D (38 mg, 98%).
MS[M+H]=354 (M+1)
Step F: N-{(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)carbonothionyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2-methylpropaneamide TFA salt
The title compound was prepared according to the procedure described in Step F of Example A1 using N-{(3S,5S)-5-[(dimethylamino)carbonothionyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2-methylpropaneamide (38 mg, 0.10 mmol) prepared in Step E and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (55 mg, 89%).
MS[M+H]=617(M+1)
1H NMR (500 MHz, CDCl3) 7.55-7.50 (m, 1H), 6.92-6.85 (m, 1H), 6.82-6.75 (m, 1H), 5.02-4.95 (t, 1H), 4.20-4.08 (m, 1H), 4.08-3.90 (m, 2H), 3.68-3.26 (m, 5H), 3.46 (s, 3H), 3.31 (s, 3H), 3.15-2.88 (m, 3H), 2.79-2.68 (m, 1H), 2.20-2.00 (m, 1H), 1.75-1.60 (m, 1H), 1.60-1.52 (m, 1H), 1.52-1.38 (m, 4H), 1.44 (s, 9H), 1.38-1.25 (m, 2H), 1.10 (dd, 6H), 0.94 (s, 3H), 0.92 (s, 3H)
EXAMPLE B3
N-[(3S,5R)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-(1,3-thiazole-2-yl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropanamide HCl salt




Step A: BOC (2R,4S)-2-(aminocarbonothionyl)-4-[(4,4-dimethylcyclohexy(2,2-dimethylproanoyl)amino pyrrolidine
The title compound was prepared according to the procedure described in Step A-C of Example A1 and Step D of Example B2, using methyl (2R,4S)-1-Boc-4-aminopyrrolidine-2-carboxylate prepared in Preparation Example A1-3 as starting material (880 mg, 2 mmol).
MS[M+H]=440 (M+1)
Step B: BOC(2R,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-(1,3-thiazole-2-yl)pyrrolidine
To a solution of BOC (2R,4S)-2-(aminocarbonothionyl)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino pyrrolidine (880 mg, 2 mmol) prepared in Step A in dimethoxyethane (10 ml) was added 50 wt % chloroacetaldehyde (0.38 ml, 3 mmol) and NaHCO3 (504 mg, 6 mmol), and stiffed at rt for 2 h. After the reaction finished, the reaction solution was concentrated in vacuo, and extracted with EtOAC. The organic extracts were washed with water and brine, dried over MgSO4, concentrated in vacuo, and the residue was purified by column chromatography (eluent: EtOAc:Hex=1/1). This compound (510 mg, 1.24 mmol) was dissolved in pyridine (0.9 ml, 11.1 mmol), and TFAA (1.0 g, 4.96 mmol) was added dropwise at 0° C. At the same temperature, the solution was stirred for 1.5 h, concentrated in vacuo, and extracted with EtOAc. The organic extracts were washed with 0.5N HCl solution and brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography (eluent: EtOAc/Hex=2/1) to give the title compound (249 mg, 51.0%).
MS[M+H]=464 (M+1)
Step C: N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-N-[(3S,5R)-5-(1,3-thiazole-2-yl)pyrrolidine-3-yl]propaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using BOC (2R,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-(1,3-thiazole-2-yl)pyrrolidine (80 mg, 0.17 mmol) prepared in Step B (60 mg, 98%).
MS[M+H]=364 (M+1)
Step D: N-[(3S,5R)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-(1,3-thiazole-2-yl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide HCl salt
The title compound was prepared according to the procedure described in Step F, G of Example A1 using N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-N-[(3S,5R)-5-(1,3-thiazole-2-yl)pyrrolidine-3-yl]propaneamide (60 mg, 0.16 mmol) prepared in Step C (55 mg, 89%).
MS[M+H]=629(M+1)
1H NMR (400 MHz, CDCl3) 8.10-8.04 (m, 1H), 7.92-7.86 (m, 1H), 7.21-7.15 (m, 1H), 6.97-6.93 (m, 1H), 6.79-6.74 (m, 1H), 4.94 (t, 1H), 4.35-4.22 (m, 2H), 3.95-3.90 (m, 2H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 2H), 3.22-3.11 (m, 1H), 2.82-2.68 (m, 1H), 2.19-1.97 (m, 1H), 1.61-1.39 (m, 4H), 1.49 (s, 9H), 1.31-1.15 (m, 4H), 1.22 (s, 9H), 0.95 (s, 3H), 0.91 (s, 3H)
EXAMPLE B4
N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(hydroxymethyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide TFA salt




Step A: BOC(2S,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-(hydroxymethyl)pyrrolidine
To a solution of 1-BOC-2-methyl-(2S,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-2-carboxylate (1.18 g, 2.71 mmol) prepared in Step B of Example A1 in THF (10 ml) was added LiBH4 (177 mg, 8.13 mmol). The solution was stirred at 70° C. for 2 h, concentrated in vacuo, and extracted with EtOAc. The organic extracts were washed with a saturated NaHCO3 aqueous solution and brine, dried over MgSO4, and concentrated in vacuo to give the title compound (0.88 g, 81%).
MS[M+H]=411(M+1)
Step B: N-(4,4-dimethylcyclohexyl)-N-[(3S,5S)-5-(hydroxymethyl)pyrrolidine-3-yl]-2,2-dimethylpropaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using BOC (2S,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-(hydroxymethyl)pyrrolidine (120 mg, 0.29 mmol) prepared in Step A (89 mg, 98%).
MS[M+H]=311 (M+1)
Step C: N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(hydroxymethyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide TFA salt
The title compound was prepared according to the procedure described in Step F of Example A1, using N-(4,4-dimethylcyclohexyl)-N-[(3S,5S)-5-(hydroxymethyl)pyrrolidine-3-yl]-2,2-dimethylpropaneamide (60 mg, 0.28 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (144 mg, 90%).
MS[M+H]=574(M+1)
1H NMR (400 MHz, CDCl3) 7.49-7.21 (m, 4H), 4.28-3.21 (m, 12H), 3.17-3.04 (m, 1H), 2.46-2.29 (m, 1H), 2.06-1.92 (m, 1H), 1.72-1.04 (m, 8H), 1.45 (s, 9H), 1.21 (s, 9H), 0.93 (s, 3H), 0.90 (s, 3H)
EXAMPLE B5
N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-methylpyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide TFA salt




Step A: BOC-(2R,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-(hydroxymethyl)pyrrolidine
The title compound (1.11 g) was prepared according to the procedure described in Step A ̃C of Example A1 and Step A of Example B4, using methyl (2R,4S)-1-Boc-4-aminopyrrolidine-2-carboxylate prepared in Preparation Example A1-3 as starting material.
MS[M+H]=411(M+1)
Step B: BOC-(2R,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-{[(methylsulfonyl)oxy]methyl}pyrrolidine
The title compound was prepared according to the procedure described in Step C of Preparation Example A1-1A using BOC-(2R,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-(hydroxymethyl)pyrrolidine (1.11 g, 2.71 mmol) prepared in Step A (1.1 g, 85%).
MS[M+H]=489 (M+1)
Step C: BOC-(2R,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-methylpyrrolidine
To a solution of BOC-(2R,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-{[(methylsulfonyl)oxy]methyl}pyrrolidine (580 mg, 1.19 mmol) prepared in Step B in THF (5 ml) was added dropwise LiBH4 (77 mg, 3.57 mmol) at 70° C. The solution was stirred at 70° C. for 5 h, concentrated in vacuo, and extracted with EtOAC. The organic extracts were washed with a saturated NaHCO3 aqueous solution and brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography (eluent: EtOAc:Hex=1/4) to give the title compound (258 mg, 53%).
MS[M+H]=395(M+1)
Step D: N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-N-[(3S,5S)-5-methylpyrrolidine-3-yl]propaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using BOC-(2R,4S)-4-[(4,4-dimethyl-cyclohexyl)(2,2-dimethylpropanoyl)amino]-2-methylpyrrolidine (50 mg, 0.12 mmol) prepared in Step C (36 mg, 98%).
MS[M+H]=295(M+1)
Step E: N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-methylpyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide TFA salt
The title compound was prepared according to the procedure described in Step F of Example A1, using N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-N-[(3S,5S)-5-methylpyrrolidine-3-yl]propaneamide (36 mg, 0.12 mmol) prepared in Step D and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (144 mg, 90%).
MS[M+H]=558(M+1)
1H NMR (400 MHz, CDCl3) 7.48-7.20 (m, 4H), 4.28-3.25 (m, 10H), 3.17-3.04 (m, 1H), 2.46-2.29 (m, 1H), 2.06-1.92 (m, 1H), 1.72-1.04 (m, 8H), 1.45 (s, 9H), 1.27 (m, 3H), 1.21 (s, 9H), 0.93 (s, 3H), 0.90 (s, 3H)
EXAMPLE B6
N-{(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(E)-(hydroxyimino)methyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide HCl salt




Step A: (2S,4S)-1-Boc-4-[(4,4-methylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-formylpyrrolidine
To a solution of BOC (2S,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-(hydroxymethyl)pyrrolidine (602 mg, 1.47 mmol) prepared in Step A of Example B4 in DCM (5 ml) was added dropwise 15 wt % Dess-Martin/DCM reagent (2.2 mmol) at 70′. The solution was stirred at rt for 3 h, concentrated in vacuo, and extracted with EtOAC. The organic extracts were washed with water and brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography (eluent: EtOAc:Hex=1/4) to give the title compound (312 mg, 60%).
MS[M+H]=423 (M+1)
Step B: BOC (2S,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-[(E)-(hydroxyimino)methyl]pyrrolidine
To a solution of (2S,4S)-1-Boc-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-formylpyrrolidine (312 mg, 0.88 mmol) prepared in Step A in methanol (5 ml) and TEA (0.64 ml, 4.4 mmol) was added hydroxylamine hydrochloride (305 mg, 4.4 mmol), and stirred at rt for 2 h. After the reaction finished, the solution was concentrated in vacuo, and extracted with EtOAC. The organic extracts were washed with water and brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography (eluent: EtOAc:Hex=1/2) to give the title compound (208 mg, 67%).
MS[M+H]=424 (M+1)
Step C: N-(4,4-dimethylcyclohexyl)-N-{(3S,5S)-5-[(E)-hydroxyimino)methyl]pyrrolidine-3-yl}-2,2-dimethylpropaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using BOC (2S,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-[(E)-(hydroxyimino)methyl]pyrrolidine (200 mg, 0.47 mmol) prepared in Step B (150 mg, 98%).
MS[M+H]=324(M+1)
Step D: N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(E)-(hydroxyimino)methyl]pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide HCl salt
The title compound was prepared according to the procedure described in Step F, G of Example A1 using N-(4,4-dimethylcyclohexyl)-N-{(3S,5S)-5-[(E)-(hydroxyimino)methyl]pyrrolidine-3-yl}-2,2-dimethylpropaneamide (150 mg, 0.46 mmol) prepared in Step C (144 mg, 90%).
MS[M+H]=589(M+1)
1H NMR (500 MHz, CDCl3) 8.06-8.01 (m, 1H), 7.36-7.30 (m, 1H), 6.97-6.93 (m, 1H), 6.79-6.74 (m, If), 4.34-4.25 (m, 1H), 3.82-3.69 (m, 3H), 3.69-3.44 (m, 3H), 3.19-3.10 (m, 21), 3.08-2.98 (m, 1H), 2.88 (d, 1H), 2.34-2.25 (m, 1H), 2.13-2.03 (m, 1H), 1.61-1.37 (m, 4H), 1.45 (s, 9H), 1.36-1.17 (m, 4H), 1.23 (s, 91), 0.94 (s, 3H), 0.90 (s, 3H)
EXAMPLE B7
N-[(3S,5S)-5-(aminoethyl)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide TFA salt




Step A: (2S,4S)-1-BOC-2-(aminomethyl)4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine
The title compound was prepared according to the procedure described in Step C-E of Preparation Example A1-1 using BOC (2S,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-(hydroxymethyl)pyrrolidine (2 g, 4.87 mmol) prepared in Step A of Example B40 Step A (1.69 g, 85%).
MS[M+H]=410 (M+1)
Step B: (2S,4S)-1-BOC-2-({[(benzyloxy)carbonyl]amino}methyl)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine
To a solution of (2S,4S)-1-BOC-2-(aminomethyl)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine (410 mg, 1 mmol) prepared in Step A in DCM (10 ml) was slowly added dropwise benzyl chloroformate (200 mg, 1.2 mmol) at 0° C., and stirred at rt for 3 h. After the reaction finished, the solvent was concentrated in vacuo, the residue was extracted with water and EtOAc, and the organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/1) to give the title compound (310 g, 72%).
MS[M+H]=544 (M+1)
Step C: benzyl({(2S,4S)-4-[(4,4-methylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-2-yl}methyl)carbamate
The title compound was prepared according to the procedure described in Step E of Example A1 using (2S,4S)-1-BOC-2-({[(benzyloxy)carbonyl]amino}methyl)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine (150 mg, 0.27 mmol) prepared in Step B (120 mg, 98%).
MS[M+H]=444(M+1)
Step D: benzyl({(2S,4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-2-yl}methyl)carbamate
The title compound was prepared according to the procedure described in Step F of Example A1 using benzyl({(2S,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-2-yl}methyl)carbamate (120 mg, 0.27 mmol) prepared in Step C (170 mg, 90%). Only, the reaction proceeded to next step without further purification, and in Step E, HPLC was used for purification.
MS[M+H]=709(M+1)
Step E: N-[(3S,5S)-5-(aminoethyl)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide TFA salt
The title compound was prepared according to the procedure described in Step E of Preparation Example A1-1 using benzyl({(2S,4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-fluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-2-yl)methyl)carbamate (170 mg, 0.27 mmol) prepared in Step D, and purification via HPLC (108 mg, 70%).
MS[M+H]=575(M+1)
1H NMR (500 MHz, CDCl3) 7.61-7.54 (m, 1H), 6.92-6.86 (m, 1H), 6.81-6.75 (m, 1H), 4.34-4.24 (m, 1H), 3.84-3.69 (m, 4H), 3.69-3.54 (m, 2H), 3.19-3.10 (m, 2H), 3.08-2.90 (m, 3H), 2.88 (d, 1H), 2.34-2.25 (m, 1H), 2.13-2.03 (m, 1H), 1.61-1.37 (m, 4H), 1.45 (s, 9H), 1.36-1.17 (m, 4H), 1.23 (s, 9H), 0.94 (s, 3H), 0.90 (s, 3H)
EXAMPLE B8
N-[(3S,5S)-5-[(acetylamino)methyl]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-dichlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide TFA salt




Step A: (2S,4S)-1-BOC-2-[(acetylamino)methyl]4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine
To a solution of (2S,4S)-t-BOC-2-(aminomethyl)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine (500 mg, 1.21 mmol) prepared in Step A of Example B7 in DMF was added dropwise acetic acid (80 mg, 1.3 mmol), HBTU (490 mg, 1.28 mmol) and DIPEA (0.56 ml, 3.22 mmol) in order. After the reaction mixture was stirred at rt for 5 h, the solution was concentrated in vacuo. The residue was diluted with EtOAc, and washed with a saturated NaHCO3 aqueous solution, water and 1N HCl. The organic solution was dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography (eluent: EtOAc:Hex=1/2) to give the title compound (508 mg, 93%).
MS[M+H]=452(M+1)
Step B: N-{(3S,5S)-5-[(acetylamino)methyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using (2S,4S)-1-BOC-2-[(acetylamino)methyl]-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine (100 mg, 0.22 mmol) prepared in Step A (75 mg, 98%).
MS[M+H]=352(M+1)
Step C: N-[(3S,5S)-5-[(acetylamino)methyl]-1-{[(3S,4R)-1-tert-butyl(2,4-dichlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide TFA salt
The title compound was prepared according to the procedure described in Step F of Example A1, using N-{(3S,5S)-5-[(acetylamino)methyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide (75 mg, 0.21 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (113 mg, 89%).
MS[M+H]=615(M+1)
1H NMR (500 MHz, CDCl3) 7.41 (d, 2H), 7.30 (d, 2H), 4.34-4.24 (m, 2H), 3.82-3.69 (m, 3H), 3.69-3.54 (m, 2H), 3.42-3.27 (m, 2H), 3.19-3.10 (m, 2H), 3.08-2.98 (m, 1H), 2.88 (d, 1H), 2.34-2.25 (m, 1H), 2.13-2.03 (m, 1H), 2.08 (s, 3H), 1.61-1.37 (m, 4H), 1.45 (s, 9H), 1.36-1.17 (m, 4H), 1.23 (s, 9H), 0.94 (s, 3H), 0.90 (s, 3H)
EXAMPLE B9
N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-dichlorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)methyl]pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide HCl salt




Step A: (2S,4S)-1-Boc 2-[(dimethylamino)methyl]-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine
The title compound was prepared according to the procedure described in Step A of Example A1, using (2S,4S)-1-BOC-2-(aminomethyl)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine (440 mg, 1 mmol) prepared in Step A of Example B7 and formaldehyde via reductive amination (300 mg, 70%).
MS[M+H]=438 (M+1)
Step B: N-{(3S,5S)-5-[(dimethylamino)methyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using (2S,4S)-1-Boc-2-[(dimethylamino)methyl]-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine (100 mg, 0.22 mmol) prepared in Step A (75 mg, 98%).
MS[M+H]=338(M+1)
Step C: N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-dichlorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)methyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2 dimethylpropaneamide HCl salt
The title compound was prepared according to the procedure described in Step F, G of Example A1 using N-{(3S,5S)-5-[(dimethylamino)methyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide (75 mg, 0.21 mmol) prepared in Step B (113 mg, 89%).
MS[M+H]=603(M+1)
1H NMR (500 MHz, CDCl3) 8.05-7.90 (m, 1H), 6.97-6.93 (m, 1H), 6.79-6.74 (m, 1H), 4.67-4.48 (m, 1H), 3.84-3.69 (m, 4H), 3.69-3.54 (m, 2H), 3.19-3.10 (m, 2H), 3.08-2.97 (m, 1H), 2.88-2.58 (m, 3H), 2.34-2.27 (m, 1H), 2.25 (s, 3H), 2.23 (s, 3H), 2.13-2.03 (m, 1H), 1.61-1.37 (m, 4H), 1.45 (s, 9H), 1.36-1.17 (m, 4H), 1.23 (s, 9H), 0.94 (s, 3H), 0.90 (s, 3H)
EXAMPLE B10
N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-cyanopyrrolidine-3-yl]-2,2-dimethyl-N-(cis-4-methylcyclohexyl)propaneamide HCl salt




Step A: 1-BOC (2S,4S)-2-cyano-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]pyrrolidine
To a solution of BOC-(2S,4S)-2(aminocarbonyl)-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]pyrrolidine (576 mg, 1.41 mmol) prepared in Step D of Example A7 in DCM (5 ml) was added dropwise TFAA (0.2 ml, 1.41 mmol), and the solution was stirred at rt for 2 h. After the reaction finished, the solution was concentrated in vacuo. The residue was diluted with EtOAc, and washed with brine. The organic solution was dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography (eluent: EtOAc:Hex=1/2) to give the title compound (514 mg, 93%).
MS[M+H]=392 (M+1)
Step B: N-[(3S,5S)-5-cyanopyrrolidine-3-yl]-2,2-dimethyl-N-(cis-4-methylcyclohexyl)propaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using 1-BOC (2S,4S)-2-cyano-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]pyrrolidine (50 mg, 0.13 mmol) prepared in Step A (37 mg, 98%).
MS[M+H]=292(M+1)
Step C: N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-cyanopyrrolidine-3-yl]-2,2-dimethyl-N-(cis-4-methylcyclohexyl)propaneamide HCl salt
The title compound was prepared according to the procedure described in Step F, G of Example A1 using N-[(3S,5S)-5-cyanopyrrolidine-3-yl]-2,2-dimethyl-N-(cis-4-methylcyclohexyl)propaneamide (37 mg, 0.12 mmol) prepared in Step B (58 mg, 89%).
MS[M+H]=557(M+1)
1H NMR (400 MHz, CDCl3) 8.10-8.04 (m, 1H), 6.97-6.93 (m, 1H), 6.79-6.74 (m, 1H), 4.76 (t, 1H), 4.35-4.22 (m, 2H), 3.95-3.90 (m, 2H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 2H), 3.22-3.11 (m, 1H), 2.82-2.68 (m, 1H), 2.28-2.10 (m, 1H), 1.61-1.39 (m, 5H), 1.49 (s, 9H), 1.31-1.15 (m, 4H), 1.22 (s, 9H), 0.86 (d, 3H)
EXAMPLE B11
N-[(3S,5R)-5-acetyl-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide TFA salt




Step A: (4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-D-proline
The title compound was prepared according to the procedure described in Step A-C of Example A1 using Preparation Example A1-3 as starting material.
Step B: BOC (2R,4S)[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-{[methoxy(methyl)amino]carbonyl}pyrrolidine
To a solution of (4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-D-proline (1.08 g, 2.57 mmol) prepared in Step A in DMF (10 D) was added dropwise DIPEA (1.15□, 6.70 mmol), and N,O-dimethylhydroxylamine hydrochloride (292 mg, 3 mmol) and HBTU (1.1 g, 3 mmol) were added dropwise in order. After the reaction mixture was stirred at rt for 1 h, the solution was concentrated in vacuo. The residue was diluted with EtOAc, and washed with a saturated NaHCO3 aqueous solution, water and 1N HCl. The organic solution was dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography (eluent: EtOAc:Hex=3/1) to give the title compound (600 mg, 50%).
MS[M+H]=468(M+1)
Step C: 1-BOC-(2R,4S)-2-acetyl-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine
To a solution of BOC (2R,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-{[methoxy(methyl)amino]carbonyl}pyrrolidine (670 mg, 1.44 mmol) prepared in Step B in THF (5 ml) was added methylmagnesium bromide 3M in ether solution (1.2 ml, 3.66 mmol), and the solution was stirred for 3 h. After the reaction finished, the solution was concentrated in vacuo. The residue was diluted with EtOAc, and washed with water and brine. The organic solution was dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography (eluent: EtOAc:Hex=3/1) to give the title compound (280 mg, 46%).
MS[M+H]=423(M+1)
Step D: N-[(3S,5R)-5-acetylpyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using 1-BOC-(2R,4S)-2-acetyl-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine (200 ng, 0.47 mmol) prepared in Step C (149 mg, 98%).
MS[M+H]=323(M+1)
Step E: N-[(3S,5R)-5-acetyl-1-{[(3S,4R)-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide TFA salt
The title compound was prepared according to the procedure described in Step F of Example A1, using N-[(3S,5R)-5-acetylpyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide (149 mg, 0.46 mmol) prepared in Step D and (3S,4R)-1-t-butyl(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (230 mg, 89%).
MS[M+H]=587(M+1)
1H NMR (500 MHz, CDCl3) 7.44-7.37 (m, 2H), 7.36-7.28 (m, 2H), 4.80-4.74 (m, 1H), 4.01-3.26 (m, 10H), 2.81-2.71 (m, 1H), 2.64 (t, 1H), 2.11 (s, 3H), 1.70-1.13 (m, 8H), 1.45 (s, 9H), 1.20 (s, 9H), 0.93 (s, 3H), 0.91 (s, 3H)
EXAMPLE B12
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(1-hydroxymethyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide TFA salt




Step A: 1-boc-(4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-(1-hydroxymethyl pyrrolidine
To a solution of 1-BOC-(2R,4S)-2-acetyl-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine (270 mg, 0.66 mmol) prepared in Step C of Example B11 in methanol (5 ml) was added NaBH4 (49.9 mg, 1.32 mmol). The solution was stirred at rt for 2 h, concentrated in vacuo, and extracted with EtOAC. The organic extracts were washed with brine, dried over MgSO4, and concentrated in vacuo to give the title compound (225 mg, 80%).
MS[M+H]=425(M+1)
Step B: N-(4,4-dimethylcyclohexyl)-N-[(3S)-5-(1-hydroxyethyl)pyrrolidine-3-yl]-2,2-dimethylpropaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using 1-boc-(4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-2-(1-hydroxymethyl)pyrrolidine (100 mg, 0.23 mmol) prepared in Step A (75 mg, 98%).
MS[M+H]=325(M+1)
Step C: N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(1-hydroxymethyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide TFA salt
The title compound was prepared according to the procedure described in Step F of Example A1, using N-(4,4-dimethylcyclohexyl)-N-[(3S)-5-(1-hydroxyethyl)pyrrolidine-3-yl]-2,2-dimethylpropaneamide (75 mg, 0.22 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (113 mg, 88%).
MS[M+H]=588(M+1)
1H NMR (400 MHz, CDCl3) 7.49-7.21 (m, 4H), 4.30-3.24 (m, 111H), 3.17-3.04 (m, 1H), 2.46-2.29 (m, 1H), 2.06-1.92 (m, 1H), 1.72-1.04 (m, 8H), 1.45 (s, 9H), 1.21 (s, 9H), 1.18 (d, 3H), 0.93 (s, 3H), 0.90 (s, 3H)
EXAMPLE B13
(4S)-4-[acetyl(4,4-dimethylcyclohexyl)amino]-N-(2-aminoethyl)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-L-prolinamide TFA salt




Step A: 1-BOC (2S,4S)-4-[acetyl(4,4-dimethylcyclohexyl)amino]-2-{[(2-{[(benzyloxy)carbonyl]amino}ethyl)amino]carbonyl}pyrrolidine
Methyl-(2S,4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)amino]pyrrolidine-2-carboxylate (1.77 g, 5 mmol) prepared in Step A of Example A1 and acetyl chloride were reacted according to the procedure described in Step B ̃C of Example A1, and then reacted according to the procedure described in Step D of Example A1 using CBZ-ethylamine to give the title compound (1.5 g, 55%).
MS[M+H]=559(M+1)
Step B: (4S)-4-[acetyl(4,4-dimethylcyclohexyl)amino]-N-(2-{[(benzyloxy)carbonyl]amino}ethyl)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-L-prolinamide
The title compound was prepared according to the procedure described in Step E-F of Example A1 using 1-BOC (2S,4S)-4-[acetyl(4,4-dimethylcyclohexyl)amino]-2-{[(2-{[(benzyloxy)carbonyl]amino}ethyl)amino]carbonyl}pyrrolidine (560 mg, 1 mmol) prepared in Step A (0.56 g, 78%).
MS[M+H]=724(M+1)
Step C: 4S)-4-[acetyl(4,4-dimethylcyclohexyl)amino]-N-(2-aminoethyl)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-L-prolineamide TFA salt
The title compound was prepared according to the procedure described in Step E of Preparation Example A1-1 using (4S)-4-[acetyl(4,4-dimethylcyclohexyl)amino]-N-(2-{[(benzyloxy)carbonyl]amino}ethyl)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-L-prolineamide (100 mg, 0.13 mmol) prepared in Step B and purification via HPLC (65 mg, 80%).
MS[M+H]=590(M+1)
1H NMR (500 MHz, CDCl3) 7.71-7.61 (m, 1H), 6.99-6.79 (m, 2H), 4.67-4.48 (m, 1H), 4.22-3.94 (m, 2H), 3.94-3.84 (m, 1H), 3.83-3.00 (m, 1H), 2.59-2.29 (m, 2H), 1.99 (d, 3H), 1.69-1.17 (m, 8H), 1.43 (s, 9H), 0.94 (s, 3H), 0.91 (s, 3H)
EXAMPLE B14
methyl (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-L-prolinate HCl salt




The title compound was prepared according to the procedure described in Step E-G of Example A1 using 1-BOC-2-methyl-(2S,4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-2-carboxylate (200 mg, 0.45 mmol) prepared in Step B of Example A1 (230 mg, 87%).
MS[M+H]=602(M+1)
1H NMR (500 MHz, CDCl3) 7.57 (d, 2H), 7.32 (d, 2H), 4.45 (t, 1H), 4.05-3.94 (m, 1H), 3.89-3.54 (m, 6H), 3.72 (s, 3H), 3.39-3.21 (m, 2H), 3.04-2.95 (m, 1H), 2.74-2.62 (m, 1H), 2.15-2.05 (m, 1H), 1.54-1.35 (m, 4H), 1.48 (s, 9H), 1.27-1.12 (m, 4H), 1.19 (s, 9H), 0.93 (s, 3H), 0.90 (s, 3H)
EXAMPLE B15
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-L-proline TFA salt




The title compound was prepared according to the procedure described in Step C of Example A1 using methyl (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-L-prolinate TFA salt prepared in Example B14 (230 mg, 82%).
MS[M+H]=588(M+1)
1H NMR (500 MHz, CDCl3) 7.38 (d, 2H), 7.30 (d, 2H), 4.37 (t, 1H), 4.10-3.56 (m, 8H), 3.36-3.18 (m, 2H), 2.51-2.42 (m, 1H), 2.40-2.30 (m, 1H), 1.61-1.37 (m, 5H), 1.50 (s, 9H), 1.32-1.08 (m, 3H), 1.22 (s, 9H), 0.94 (s, 3H), 0.90 (s, 3H)
EXAMPLE B16 ̃41
The following Examples were prepared according to the procedure described in Example B1 ̃15, using the intermediates which are prepared in a series of Example A by the reactions between appropriate compounds among Preparation Example A1, A2, A4, A9 and appropriate amines.







TABLE 7













 























MS


Example
R1
R2′
R3′
R4
R5′
*
**
(M + 1)





B16
t-Bu
4-Cl
Me
c-Hex
Me
S
S
488


B17
t-Bu
2,4-diF
C(S)NH2
c-Hex
Me
S
R
535


 


B18
t-Bu
2,4-diF
C(S)NH2
cis-4-Me-c-Hex




S
R
605


 


B19
t-Bu
2,4-diF
CH2OH
c-Hex
Me
S
S
506


B20
t-Bu
2,4-diF
CH2OH
cis-4-Me-c-Hex
t-Bu
S
S
562


 


B21
t-Bu
2,4-diF




c-Hex
Me
S
R
519


 


B22
t-Bu
2,4-diF




cis-4-Me-c-Hex
t-Bu
S
R
575


 


B23
t-Bu
2,4-diF




cis-4-Me-c-Hex
CH(CH3)2
S
R
603


 


B24
t-Bu
4-Cl




cis-4-Me-c-Hex
CH(CH3)2
S
S
585


 


B25
t-Bu
4-Cl
CH2NH2
c-Hex
Me
S
S
505


B26
t-Bu
2,4-diF
CH2N(CH3)2
c-Hex
Me
S
S
533


B27
t-Bu
2,4-diF
Ac
cis-4-Me-c-Hex
t-Bu
S
R
503


B28
t-Bu
2,4-diF
C(S)NH2
cis-4-Me-c-Hex
t-Bu
S
R
591


B29
t-Bu
4-Cl
C(S)NH2
cis-4-Me-c-Hex
t-Bu
S
R
589


B30
t-Bu
2,4-diF
C(S)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
633


B31
t-Bu
2,4-diF
CH2OH
4,4-diMe-c-Hex
CH(CH3)2
S
S
562


 


B32
t-Bu
2,4-diF




4,4-diMe-c-Hex
CH(CH3)2
S
R
575


 


B33
t-Bu
2,4-diF




4,4-diMe-c-Hex
CH(CH3)2
S
S
575


 


B34
t-Bu
2,4-diF
Ac
4,4-diMe-c-Hex
CH(CH3)2
S
S
574


B35
t-Bu
2,4-diF
Ac
4,4-diMe-c-Hex
t-Bu
S
S
588


B36
t-Bu
4-Cl
C(S)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
631


B37
t-Bu
2,4-diF
C(S)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
R
633


B38
t-Bu
2,4-diF
C(O)Et
4,4-diMe-c-Hex
t-Bu
S
R
602


B39
t-Bu
4-Cl
C(O)Et
4,4-diF-c-Hex
t-Bu
S
S
608


 


B40
t-Bu
4-Cl




4,4-diMe-c-Hex
t-Bu
S
S
629


 


B41
t-Bu
2,4-diF
C(O)NH(CH2)2NH2
4,4-diMe-c-Hex
CH3
S
R
590













EXAMPLE C1
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylmaloneamide TFA salt




Step A: (3S)-1-Boc-[(2-cyano-2-methylpropanoyl)(4,4-dimethylcyclohexyl)amino]pyrrolidine
The title compound was prepared according to the procedure described in Step B of Example A1, using (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)amino]pyrrolidine (1.5 g, 5 mmol) prepared in Step A of Example A8 and 2-cyano-2-methylpropanoyl chloride (2 g, 15 mmol) prepared in Preparation Example A4-3 (1.5 g, 76.6%).
MS[M+H]=392 (M+1)
Step B: (3S)-1-Boc-3-[(3-amino-2,2-dimethyl-3-oxopropanoyl)(4,4-dimethylcyclohexyl)amino]pyrrolidine
To a solution of (3S)-1-Boc-[(2-cyano-2-methylpropanoyl)(4,4-dimethylcyclohexyl)amino]pyrrolidine (900 mg, 2.3 mmol) prepared in Step A in methanol (10 ml) was added 10N-NaOH (5 ml), and the solution was stirred at 80° C. for 2 h. After the reaction finished, the solvent was concentrated in vacuo, diluted with water, and extracted with EtOAc. The extracted organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=3/1) to give the title compound (828 mg, 88%).
MS[M+H]=410 (M+1)
Step C: N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]-maloneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using (3S)-1-Boc-3-[(3-amino-2,2-dimethyl-3-oxopropanoyl)(4,4-dimethylcyclohexyl)amino]pyrrolidine (192 mg, 0.47 mmol) prepared in Step B (142 mg, 98%).
MS[M+H]=310(M+1)
Step D: N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylmaloneamide TFA salt
The title compound was prepared according to the procedure described in Step F of Example A1, using N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]maloneamide (142 mg, 0.46 mmol) prepared in Step C and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (234 mg, 89%).
MS[M+H]=573(M+1)
1H NMR (500 MHz, CDCl3) 7.29-7.25 (m, 4H), 4.58-4.50 (m, 1H), 4.34-4.26 (m, 1H), 4.20-4.14 (m, 1H), 4.04-3.96 (m, 1H), 3.84-3.75 (m, 1H), 3.69-3.60 (m, 1H), 3.55-3.40 (m, 2H), 3.40-3.32 (m, 1H), 3.19-3.10 (m, 2H), 2.96-2.87 (m, 1H), 2.28-2.17 (m, 1H), 1.87-1.78 (m, 1H), 1.72-1.56 (m, 2H), 1.53-1.38 (m, 3H), 1.43 (s, 9H), 1.40 (s, 3H), 1.36-1.21 (m, 3H), 1.30 (s, 3H), 0.89 (s, 3H), 0.87 (s, 3H)
EXAMPLE C2
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-methoxy-2,2-dimethylpropaneamide TFA salt




Step A: (3S)-1-Boc-3-{[3-(methoxy)-2,2-dimethylpropanoyl](4,4-dimethylcyclohexyl)amino}pyrrolidine
To a solution of (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine (800 mg, 2.02 mmol) prepared in Step B of Example A8 in THF was added NaH (73 mg, 3.03 mmol) and iodomethane (430 mg, 3.03 mmol) at 0° C., and the solution was stirred at rt for 2 h. After the reaction finished, the solution was concentrated in vacuo, extracted with 1N-HCl and EtOAc. The organic layer was washed with brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography (eluent: EtOAc/Hex=1/2) to give the title compound (784 mg, 94.6%).
MS[M+H]=411 (M+1)
Step B: N-(4,4-dimethylcyclohexyl)-3-methoxy-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]propaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using (3S)-1-Boc-3-{[3-(methoxy)-2,2-dimethylpropanoyl](4,4-dimethylcyclohexyl)amino}pyrrolidine (193 mg, 0.47 mmol) prepared in Step A (141 mg, 98%).
MS[M+=311(M+1)
Step C: N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-methoxy-2,2-dimethylpropaneamide TFA salt
The title compound was prepared according to the procedure described in Step F of Example A1, using N-(4,4-dimethylcyclohexyl)-3-methoxy-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]propaneamide (141 mg, 0.46 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (232 mg, 89%).
MS[M+H]=574 (M+1)
1H NMR (500 MHz, CDCl3) 7.37-7.33 (d, 2H), 7.31-7.25 (d, 2H), 3.91-3.81 (m, 2H), 3.80-3.65 (m, 4H), 3.64-3.55 (m, 2H), 3.54-3.46 (m, 1H), 3.44-3.26 (m, 3H), 3.29 (s, 3H), 3.24-3.17 (m, 1H), 3.08-3.01 (m, 0.3H), 2.94-2.88 (m, 0.7H), 2.42-2.32 (m, 1H), 1.80-1.71 (m, 1H), 1.65-1.50 (m, 2H), 1.49-1.32 (m, 12H), 1.30-1.15 (m, 9H), 0.95-0.85 (m, 6H)
EXAMPLE C3
(3E)-N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-(hydroxyimino)-2,2-dimethylpropaneamide HCl salt




Step A: (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(2,2-dimethyl-3-oxopropanoyl)amino]pyrrolidine
To a solution of (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine (1.05 g, 2.7 mmol) prepared in Step B of Example A8 in DCM was added Dess-Martin periodinane (1.35 g, 3.17 mmol), and stirred at rt for 2 h. After the reaction finished, the solvent was concentrated in vacuo, sodium thiosulfate aqueous solution and EtOAc were added and stirred at rt for 30 min, and extracted with EtOAc. The organic layer was dried over MgSO4, concentrated in vacuo at rt, and purified by column chromatography (eluent: EtOAc/Hex=1/3) to give the title compound (960 mg, 90%).
MS[M+H]=395 (M+1)
Step B: 1-Boc-(3S)-3-[(4,4-dimethylcyclohexyl)(2,2-dimethyl-3-oxopropanoyl)amino]pyrrolidine
To a solution of (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(2,2-dimethyl-3-oxopropanoyl)amino]pyrrolidine (250 mg, 0.63 mmol) prepared in Step A in methanol (5 ml) was added hydroxyammoniumchloride (49 mg, 1.27 mmol) and TEA (127 mg, 1.26 mmol), and the solution was stirred at 80° C. for 1 h. After the reaction finished, the solvent was concentrated in vacuo, diluted with water (20 ml), and extracted with EtOAc. The organic layer was washed with 1N-HCl, dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/2) to give the title compound (206 mg, 80%).
MS[M+H]=410 (M+1)
Step C: (3E)-N-(4,4-dimethylcyclohexyl)-3-(hydroxyamino)-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]propaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using 1-Boc-(3S)-3-[(4,4-dimethylcyclohexyl)(2,2-dimethyl-3-oxopropanoyl)amino]pyrrolidine (192 mg, 0.47 mmol) prepared in Step B (142 mg, 98%).
MS[M+H]=310(M+1)
Step D: (3E)-N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxyimino)-2,2-dimethylpropaneamide HCl salt
The title compound was prepared according to the procedure described in Step F, G of Example A1, using (3E)-N-(4,4-dimethylcyclohexyl)-3-(hydroxyimino)-2,2-methyl-N-[(3S)-pyrrolidine-3-yl]propaneamide (142 mg, 0.46 mmol) prepared in Step C and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (234 mg, 89%).
MS[M+H]=573(M+1)
1H NMR (400 MHz, CDCl3) 7.45-7.39 (m, 2H), 7.37-7.30 (m, 2H), 6.72 (s, 1H), 4.12-3.52 (m, 7H), 3.40-3.19 (m, 3H), 2.77-2.69 (m, 1H), 2.53-2.33 (m, 1H), 1.78-1.57 (m, 8H), 1.55-1.41 (m, 10H), 1.35-1.22 (m, 7H), 0.94 (s, 3H), 0.92 (s, 3H)
EXAMPLE C4
N-[(3S)-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylbutanamide HCl salt




Step A: (3S) 1-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylbutanoyl)amino]pyrrolidine
To a solution of (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(2,2-dimethyl-3-oxopropanoyl)amino]pyrrolidine (250 mg, 0.63 mmol) prepared in Step A of Example C3 in THF was slowly added dropwise methylmagnesium bromide (in diethylether, 3.0M, 0.25 ml, 0.76 mmol) at 0° C., and the solution was stirred at rt for 2 h. After the reaction finished, to the solution was added 1N-HCl at 0° C., and extracted with EtOAc. The organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/2) to give the title compound (238 mg, 92%).
MS[M+H]=425 (M+1)
Step B: 1-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]butaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using (3S) 1-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylbutanoyl)amino]pyrrolidine (100 mg, 0.23 mmol) prepared in Step A (73 mg, 98%).
MS[M+H]=325 (M+1)
Step C: N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylbutaneamide HCl salt
The title compound was prepared according to the procedure described in Step F, G of Example A1, using N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]butaneamide (73 mg, 0.23 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (232 mg, 89%).
MS[M+H]=574 (M+1)
1H NMR (400 MHz, CDCl3) 7.58-7.48 (m, 2H), 7.37-7.29 (m, 2H), 3.92-3.48 (m, 7H), 3.47-3.22 (m, 4H), 2.77-2.69 (m, 1H), 2.53-2.33 (m, 1H), 1.80-1.55 (m, 8H), 1.52-1.38 (m, 10H), 1.32-1.20 (m, 10H), 0.94 (s, 3H), 0.92 (s, 3H)
EXAMPLE C5
N-[(3S)-1-{[(3S,4R)-1-tert butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-3-oxobutaneamide HCl salt




Step A: (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(2,2-dimethyl-3-oxobutanoyl)amino]pyrrolidine
To a solution of (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylbutanoyl)amino]pyrrolidine (150 mg, 0.36 mmol) prepared in Step A of Example C4 in DCM was added Dess-Martin periodinane (230 mg, 0.54 mmol), and stirred at rt for 2 h. After the reaction finished, the solvent was concentrated in vacuo, sodium thiosulfate aqueous solution and EtOAc were added and stirred at rt for 30 min, and extracted with EtOAc. The organic layer was dried over MgSO4, concentrated in vacuo at rt, and purified by column chromatography (eluent: EtOAc/Hex=1/3) to give the title compound (132 mg, 90%).
MS[M+H]=409 (M+1)
Step B: N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-3-oxo-N-[(3S)-1-pyrrolidine-3-yl]butaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(2,2-dimethyl-3-oxobutanoyl)amino]pyrrolidine (50 mg, 0.12 mmol) prepared in Step A (36 mg, 98%).
MS[M+H]=309(M+1)
Step C: N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-3-oxobutaneamide HCl salt
The title compound was prepared according to the procedure described in Step F, G of Example A1, using N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-3-oxo-N-[(3S)-pyrrolidine-3-yl]butaneamide (50 mg, 0.11 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (56 mg, 89%).
MS[M+H]=572 (M+1)
1H NMR (500 MHz, CDCl3) 7.60-7.51 (m, 2H), 7.35-7.30 (m, 2H), 3.95-3.48 (m, 7H), 3.47-3.22 (m, 3H), 2.77-2.69 (m, 1H), 2.53-2.33 (m, 1H), 2.11 (s, 3H), 1.78-1.57 (m, 8H), 1.50-1.37 (m, 10H), 1.35-1.25 (m, 7H), 0.94 (s, 3H), 0.92 (s, 3H)
EXAMPLE C6
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2,3-trimethylbutaneamide HCl salt




Step A: (3S) 1-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2,3-trimethylbutanoyl)amino]pyrrolidine
To a solution of (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(2,2-dimethyl-3-oxobutanoyl)amino]pyrrolidine (100 mg, 0.25 mmol) prepared in Step A of Example C5 in THF was slowly added dropwise methylmagnesium bromide (in diethylether, 3.0M, 0.1 ml, 0.3 mmol) at 0° C., and the solution was stirred at rt for 2 h. After the reaction finished, to the solution was added 1N-HCl at 0° C., and extracted with EtOAc. The organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/3) to give the title compound (97 mg, 92%).
MS[M+H]=425 (M+1)
Step B: N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2,3-trimethyl-N-[(3S)-pyrrolidine-3-yl]butaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2,3-trimethylbutanoyl)amino]pyrrolidine (80 mg, 0.19 mmol) prepared in Step A (60.5 mg, 98%).
MS[M+H]=325(M+1)
Step C: N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2,3-trimethylbutaneamide HCl salt
The title compound was prepared according to the procedure described in Step F, G of Example A1, using N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2,3-trimethyl-N-[(3S)-pyrrolidine-3-yl]butaneamide (62 mg, 0.19 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (99 mg, 89%).
MS[M+H]=588 (M+1)
1H NMR (400 MHz, CDCl3) 7.60-7.49 (m, 2H), 7.39-7.30 (m, 2H), 3.93-3.48 (m, 7H), 3.47-3.21 (m, 3H), 2.77-2.69 (m, 1H), 2.53-2.33 (m, 1H), 1.80-1.55 (m, 8H), 1.52-1.38 (m, 10H), 1.34-1.21 (m, 13H), 0.94 (s, 3H), 0.92 (s, 3H)
EXAMPLE C7
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-fluoro-2,2-dimethylpropaneamide HCl salt




Step A: (3S)-1 Boc-3-[(4,4-dimethylcyclohexyl)(3-fluoro-2,2-dimethylpropanoyl)amino]pyrrolidine
To a solution of (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine (300 mg, 0.76 mmol) prepared in Step B of Example A8 in DCM was added TEA (192 mg, 1.9 mmol), slowly added dropwise methanesulfonylchloride (104 mg, 0.91 mmol) at 0° C., and the solution was heated to rt, and stirred for 1 h. After the reaction finished, the solvent was concentrated in vacuo, and washed with water and EtOAc. The organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/2) to give (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl){2,2-dimethyl-3-[(methylsulfonyl)oxy]propanoyl}amino]pyrrolidine (250 mg, 75%). A solution of this compound (200 mg, 0.42 mmol) in THF was added dropwise TBAF (in THF, 1.0M 0.5 ml, 0.5 mmol), and the solution was stirred at 80° C. for 3 h. After the reaction finished, the solvent was concentrated in vacuo, and extracted with 1N-HCl and EtOAc. The organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/4) to give the title compound (147 mg, 89%).
MS[M+H]=399 (M+1)
Step B: N-(4,4-dimethylcyclohexyl)-3-fluoro-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]propaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(3-fluoro-2,2-dimethylpropanoyl)amino]pyrrolidine (147 mg, 0.37 mmol) prepared in Step A (108 mg, 98%).
MS[M+H]=299(M+1)
Step C: N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-fluoro-2,2-dimethylpropaneamide HCl salt
The title compound was prepared according to the procedure described in Step F, G of Example A1, using N-(4,4-dimethylcyclohexyl)-3-fluoro-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]propaneamide (100 mg, 0.47 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (230 mg, 89%).
MS[M+H]=562 (M+1)
1H NMR (400 MHz, CDCl3) 7.58-7.47 (m, 2H), 7.37-7.30 (m, 2H), 4.39-4.28 (m, 2H), 3.92-3.48 (m, 7H), 3.47-3.22 (m, 3H), 2.77-2.69 (m, 1H), 2.53-2.33 (m, 1H), 1.78-1.57 (m, 8H), 1.52-1.38 (m, 10H), 1.35-1.23 (m, 7H), 0.94 (s, 3H), 0.92 (s, 3H)
EXAMPLE C8
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3,3-difluoro-2,2-dimethylpropaneamide HCl salt




Step A: (3S)-1-Boc-[(3,3-difluoro-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]pyrrolidine
To (3S)-1-Boc-3-[(4,4-dimethylcyclohexyl)(2,2-dimethyl-3-oxopropanoyl)amino]pyrrolidine (1 g, 2.53 mmol) prepared in Step A of Example C3 was added DCM (20 ml), cooled to 78° C., and DAST (0.67 ml, 5.06 mmol) was slowly added dropwise. The mixture was stirred at −78° C. for 1 h, and stirred at rt for 10 h. After the reaction finished, the solvent was concentrated in vacuo, and extracted with water and EtOAc. The organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/1) to give the title compound (630 mg, 60%).
MS[M+H]=417(M+1)
Step B: N-(4,4-dimethylcyclohexyl)-3,3-difluoro-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]propaneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using (3S)-1-Boc-[(3,3-difluoro-2,2-dimethylpropanoyl)(4,-dimethylcyclohexyl)amino]pyrrolidine (100 mg, 0.24 mmol) prepared in Step A (73 mg, 98%).
MS[M+H]=317(M+1)
Step C: N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrroline-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3,3-difluoro-2,2-dimethylpropaneamide HCl salt
The title compound was prepared according to the procedure described in Step F, G of Example A1, using N-(4,4-dimethylcyclohexyl)-3,3-difluoro-2,2-dimethyl-N-[(3S)-pyrrolidine-3-yl]propaneamide (73 mg, 0.23 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (118 mg, 89%).
MS[M+H]=580 (M+1)
1H NMR (400 MHz, CDCl3) 7.59-7.49 (m, 2H), 7.38-7.31 (m, 2H), 5.59 (s, 1H), 3.92-3.48 (m, 7H), 3.47-3.22 (m, 3H), 2.77-2.69 (m, 1H), 2.53-2.33 (m, 1H), 1.78-1.57 (m, 8H), 1.52-1.38 (m, 10H), 1.34-1.23 (m, 7H), 0.94 (s, 3H), 0.92 (s, 3H)
EXAMPLE C9
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-[(4,4-difluorocyclohexyl)(3-methoxy-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide TFA salt




Step A: 2-methyl-(2S,4S)-1-BOC-4-{[3-(acetyloxy)-2,2-dimethylpropanoyl](4,4-difluorocyclohexyl)amino}pyrrolidine-carboxylate
To a solution of 2-methyl-(2S,4S)-1-BOC-4-[(4,4-difluorocyclohexyl)amino]pyrrolidine-carboxylate (1.01 g, 2.84 mmol) prepared in Step A of Example A5 in DCE (5 mL) was added dropwise TEA (5 mL) and DMAP (0.34 g, 2.84 mmol), and added 2,2-dimethyl-3-acetyloxypropionyl chloride (1.01 g, 5.68 mmol) prepared in Preparation Example A4-1. The reaction solution was heated to 90° C., and stirred for 48 h. After the reaction finished, the solvent was removed in vacuo, and to the residue was added a saturated aqueous NaHCO3 solution, and extracted with EtOAc. The organic extracts were washed with 1N HCl, dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=1/4) to give the title compound (0.89 g, 62.9%).
MS[M+H]=505(M+1)
Step B: (4S)-1-BOC-4-[(4,4-difluorocyclohexyl)amino(3-hydroxy-2,2-dimethylpropanoyl)amino]-proline
To a solution of 2-methyl-(2S,4S)-1-BOC-4-{[3-(acetyloxy)-2,2-dimethylpropanoyl](4,4-difluorocyclohexyl)amino}pyrrolidine-carboxylate (0.89 g, 1.78 mmol) prepared in Step A in 1N NaOH (5 ml) and water (5 ml), and stirred until the reaction finished. The reaction solution was concentrated in vacuo, acidified with 1N HCl, and extracted with EtOAc. The organic extracts were washed with 1N HCl, dried over MgSO4, concentrated in vacuo to give the title compound (1.1 g, 90%).
MS[M+H]=449(M+1)
Step C: (2S,4S)-1-BOC-4-[(4,4-difluorocyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-2-[(dimethylethylamino)carbonyl]pyrrolidine
To a solution of (4S)-1-BOC-4-[(4,4-difluorocyclohexyl)amino(3-hydroxy-2,2-dimethylpropanoyl)amino]-L-proline (1.1 g, 2.6 mmol) prepared in Step B in DMF (5□) was added dropwise DIPEA (0.08□, 0.5 mmol), and added dropwise 2M dimethylamine-THF solution (1.8 ml, 3.6 mmol), HOBT (0.5 g, 3.6 mmol) and EDC (0.7 g, 3.6 mmol) were added dropwise in order. After the reaction mixture was stirred at rt for 12 h, the solution was concentrated in vacuo. The residue was diluted with EtOAc, and washed with a saturated NaHCO3 aqueous solution, water and 1N HCl. The organic solution was dried over MgSO4, concentrated in vacuo, and the residue was purified by column chromatography (eluent: EtOAc:Hex=1/2) to give the title compound (1.1 g, 93%).
MS[M+H]=490(M+1)
Step D: (2S,4S)-1-BOC-4-[(4,4-difluorocyclohexyl(3-methoxy-2,2-dimethylpropanoyl)amino]-2-[(dimethylethylamino)carbonyl]pyrrolidine
To a solution of (2S,4S)-1-BOC-4-[(4,4-difluorocyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine (1.1 g, 2.3 mmol) prepared in Step C in THF was added NaH (83 mg, 3.45 mmol) and iodomethane (490 mg, 3.45 mmol) at 0° C., and the solution was stirred at rt for 2 h. After the reaction finished, the solution was concentrated in vacuo, and extracted with 1N-HCl and EtOAc. The organic layer was washed with brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography (eluent: EtOAc/Hex=1/2) to give the title compound (1.06 mg, 94.6%).
MS[M+H]=504 (M+1
Step E: (4S)-4-[(4,4-difluorocyclohexyl)(3-methoxy-2,2-dimethylpropanol)amino]-N-ethyl-N-methyl-L-prolineamide
The title compound was prepared according to the procedure described in Step E of Example A1 using (2S,4S)-1-BOC [(4,4-difluorocyclohexyl)(3-methoxy-2,2-dimethylpropanoyl)amino]-2-[(dimethylethylamino)carbonyl]pyrrolidine (100 mg, 0.20 mmol) prepared in Step D (79 mg, 98%).
MS[M+H]=404(M+1)
Step F: N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-[(4,4-difluorocyclohexyl)(3-methoxy-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide TFA salt
The title compound was prepared according to the procedure described in Step F of Example A1, using (4S)-4-[(4,4-difluorocyclohexyl)(3-methoxy-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide (79 mg, 0.19 mmol) prepared in Step E and (3S,4R)-1-t-butyl-4-(chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (112 mg, 89%).
MS[M+H]=667(M+1)
1H NMR (400 MHz, CDCl3) 7.38 (d, 2H), 7.31 (d, 2H), 4.65-4.59 (m, 1H), 4.22-4.02 (m, br, 1H), 4.00-3.93 (m, 1H), 3.86-3.74 (m, 2H), 3.71-3.57 (m, 2H), 3.56-3.19 (m, 9H), 2.96 (d, 3H), 2.86-2.63 (m, br, 1H), 2.33-2.21 (m, 1H), 2.21-2.10 (m, 1H), 2.10-1.96 (m, 1H), 1.86-1.14 (m, 8H), 1.44 (s, 9H), 1.22 (m, 6H), 1.11 (t, 3H)
EXAMPLE C10
(4S)-4-[(3-amino-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-N,N-dimethyl-L-prolineamide HCl salt




Step A: 1-BOC-(2S,4S)-4-[(2-cyano-2-methylpropanoyl)(4,4-dimethylcyclohexyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine
The title compound was prepared according to the procedure described in Step B ̃D of Example A1, using methyl-(2S,4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)amino]pyrrolidine-2-carboxylate (1.46 g, 4.14 mmol) prepared in Step A of Example A1 and 2-cyano-2-methylpropanoyl chloride prepared in Preparation Example A4-3 as starting materials (1.07 g, 56%).
MS[M+H]=463 (M+1)
Step B: 1-BOC-(2S,4S)-4-[(3-amino-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine
To a solution of 1-BOC-(2S,4S)-4-[(2-cyano-2-methylpropanoyl)(4,4-dimethylcyclohexyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine (1.07 g, 2.31 mmol) prepared in Step A in methanol was added Pd/C (9 mg), and carried out hydrogen reaction at rt for 10 h. After the reaction finished, the reaction mixture was filtered through Celite, and the filtrate was concentrated in vacuo, and purified by HPLC to give the title compound (0.84 g, 78%).
MS[M+H]=467(M+1)
Step C: 1-BOC-(2S,4S)-4-[(3-{[(benzyloxy)carbonyl]amino}-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine
The title compound was prepared according to the procedure described in Step E of Example B7 using 1-BOC-(2S,4S)-4-[(3-amino-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine (200 mg, 0.43 mmol) prepared in Step A (201 mg, 80%).
MS[M+H]=601(M+1)
Step D: (4S) [(3-{[(benzyloxy)carbonyl]amino}-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-N,N-dimethyl-L-prolineamide
The title compound was prepared according to the procedure described in Step E of Example A1 using 1-BOC-(2S,4S)-4-[(3-{[(benzyloxy)carbonyl]amino}-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine (200 mg, 0.33 mmol) prepared in Step C (162 mg, 98%).
MS[M+H]=501(M+1)
Step E: (4S)-4-[(3-{[(benzyloxy)carbonyl]amino}-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-1-{[(3S,4R)-1-tert-butyl-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-N,N-dimethyl-L-prolineamide
The title compound was prepared according to the procedure described in Step F of Example A1 using (4S)-4-[(3-{[(benzyloxy)carbonyl]amino}-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-N,N-dimethyl-L-prolineamide (162 mg, 0.32 mmol) prepared in Step D (217 mg, 89%). The reaction proceeded to next step without further purification, and in Step F, HPLC was used for purification.
MS[M+H]=766(M+1)
Step F: (4S)-4-[(3-amino-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-N,N-dimethyl-L-prolineamide HCl salt
The title compound was prepared according to the procedure described in Step E of Preparation Example A1-1 using (4S)-4-[(3-{[(benzyloxy)carbonyl]amino}-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-N,N-diethyl-L-prolineamide (217 mg, 0.28 mmol) prepared in Step E and purification via HPLC (160 mg, 91%).
MS[M+H]=632(M+1)
1H NMR (400 MHz, CDCl3) 8.10-8.04 (m, 1H), 6.97-6.93 (m, 1H), 6.79-6.74 (m, 1H), 4.70 (t, 1H), 4.35-4.22 (m, 2H), 3.95-3.90 (m, 2H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 2H), 3.22-3.11 (m, 1H), 2.99 (s, 3H), 2.95 (s, 3H), 2.92-2.70 (m, 3H), 2.19-1.97 (m, 1H), 1.61-1.39 (m, 4H), 1.49 (s, 9H), 1.31-1.15 (m, 4H), 1.27 (s, 6H), 0.95 (s, 3H), 0.91 (s, 3H)
EXAMPLE C11
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{[3-(dimethylamino)-2,2-dimethylpropanoyl](4,4-dimethylcyclohexyl)amino}-N,N-dimethyl-L-prolineamide HCl salt




Step A: 1-BOC(2S,4S)-2-[(diethylamino)carbonyl]-4-{[3-(dimethylamino)-2,2-dimethylpropanoyl](4,4-dimethylcyclohexyl)amino}pyrroline
The title compound was prepared according to the procedure described in Step A of Example A1 using 1-BOC-(2S,4S)-4-[(3-amino-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine (142 mg, 0.3 mmol) prepared in Step B of Example C10 and formaldehyde (105 mg, 71%).
MS[M+H]=495(M+1)
Step B: (4S)-4-{[3-(dimethylamino)-2,2-dimethylpropanoyl](4,4-dimethylcyclohexyl)amino}-N,N-dimethyl-prolineamide
The title compound was prepared according to the procedure described in Step E of Example A1 using 1-BOC(2S,4S)-2-[(dimethylamino)carbonyl]-4-{[3-(dimethylamino)-2,2-dimethylpropanoyl](4,4-dimethylcyclohexyl)amino}pyrrolidine (105 mg, 0.21 mmol) prepared in Step A (82 mg, 98%).
MS[M+H]=395(M+1)
Step C: (4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{[3-(dimethylamino)-2,2-dimethylpropanoyl](4,4-dimethylcyclohexyl)amino}-N,N dimethyl-L-prolineamide HCl salt
The title compound was prepared according to the procedure described in Step F, G of Example A1, using (4S)-4-{[3-(dimethylamino)-2,2-dimethylpropanoyl](4,4-dimethylcyclohexyl)amino)}-N,N-dimethyl-L-prolineamide (82 mg, 0.18 mmol) prepared in Step B and (3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (105 mg, 89%).
MS[M+H]=658(M+1)
1H NMR (400 MHz, CDCl3) 7.50 (d, 2H), 7.32 (d, 2H), 4.70 (t, 1H), 4.35-4.22 (m, 2H), 3.95-3.90 (m, 2H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 2H), 3.22-3.11 (m, 1H), 2.99 (s, 3H), 2.95 (s, 3H), 2.88-2.55 (m, 3H), 2.30-2.01 (m, 7H), 1.61-1.39 (m, 4H), 1.49 (s, 9H), 1.31-1.15 (m, 4H), 1.27 (s, 6H), 0.95 (s, 3H), 0.91 (s, 3H)
EXAMPLE C12
N-{(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)carbonyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylmaloneamide TFA salt




Step A: 1-BOC-(2S,4S)-4-[(2-cyano-2-methylpropanoyl)(4,4-dimethylcyclohexyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine
The title compound was prepared according to the procedure described in Step B ̃D of Example A1, using methyl-(2S,4S)-1-BOC-4-[(4,4-dimethylcyclohexyl)amino]pyrrolidine-2-carboxylate (1.77 g, 5 mmol) prepared in Step A of Example A1 and 2-cyano-2-methylpropanoyl chloride prepared in Preparation Example A4-3 as starting materials (1.3 g, 56%).
MS[M+H]=463 (M+1)
Step B: 1-BOC-(2S,4S)-4-[(3-amino-2,2-diethyl-3-oxopropanoyl)(4,4-dimethylcyclohexyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine
To a solution of 1-BOC-(2S,4S)-4-[(2-cyano-2-methylpropanoyl)(4,4-dimethylcyclohexyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine (1.06 g, 2.3 mmol) prepared in Step A in methanol (10 ml) was added 10N-NaOH (5 ml), and stirred at 80° C. for 2 h. After the reaction finished, the solvent was concentrated in vacuo, diluted with water, and extracted with EtOAc. The extracted organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent: EtOAc/Hex=3/1) to give the title compound (970 mg, 88%).
MS[M+H]=481 (M+1)
Step C: N-{(3S,5S)-5-[(dimethylamino)carbonyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylmaloneamide
The title compound was prepared according to the procedure described in Step E of Example A1 using 1-BOC-(2S,4S)-4-[(3-amino-2,2-dimethyl-3-oxopropanoyl)(4,4-methylcyclohexyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine (226 mg, 0.47 mmol) prepared in Step B (166 mg, 98%).
MS[M+H]=381 (M+1)
Step D: N-{(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)carbonyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylmaloneamide TFA salt
dried over MgSO4, concentrated F of Example A1, using N-{(3S,5S)-5-[(dimethylamino)carbonyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylmaloneamide (166 mg, 0.53 mmol) prepared in Step C and (3S,4R)-1-t-butyl(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-2 (273 mg, 89%).
MS[M+H]=644 (M+1)
1H NMR (500 MHz, CDCl3) 7.36 (d, 21), 7.29 (d, 2H), 4.60 (t, 1H), 4.38-4.25 (m, 1H), 4.25-4.14 (m, 1H), 3.92-3.78 (m, 1H), 3.72-3.27 (m, 6H), 3.19-3.12 (m, 1H), 2.98 (d, 3H), 2.94 (d, 3H), 2.85-2.68 (m, 1H), 2.13-1.99 (m, 1H), 1.62-1.11 (m, 8H), 1.43 (s, 9H), 1.39 (s, 3H), 1.33 (s, 3H), 0.90 (s, 3H), 0.87 (s, 3H)
EXAMPLE C13
S-(3-{[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-{[ethyl(methyl)amino]carbonyl}pyrrolidine-3-yl](4,4-dimethylcyclohexyl)amino}-2,2-dimethyl-3-oxopropyl)ethanethioate HCl salt




Step A: 1-BOC-(2S,4S)-4-{[3-(acetylthio)-2,2-dimethylpropanoyl](4,4-dimethylcyclohexyl)amino}-2-{[ethyl(methyl)amino]carbonyl}pyrrolidine
The product of Step C of Example A4, BOC-(2S,4S)-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-2-{[ethyl(methyl)amino]carbonyl}pyrrolidine (1 g, 2.1 mmol) was reacted according to the procedure described in Step C of Preparation Example A1-1 to give 1-BOC-(2S,4S)-4-[(4,4-dimethylcyclohexyl){2,2-dimethyl-3-[(methylsulfonyl)oxy]propanoyl}amino]-2-{[ethyl(methyl)amino]carbonyl}pyrrolidine (0.72 g, 61%). This compound (200 mg, 0.36 mmol) and potassium thioacetate (411 mg, 3.6 mmol) was dissolved in methanol (3.6 mL), and the solution was stirred for 8 h. After the reaction finished, the solution was concentrated in vacuo, and extracted with EtOAc. The organic extracts were washed with water, dried over MgSO4, and concentrated in vacuo to give the title compound (0.14 g, 76%).
MS[M+H]=540 (M+1)
Step B: S-(3-{[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4 difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-{[ethyl(methyl)amino]carbonyl}pyrrolidine-3-yl](4,4-dimethylcyclohexyl)amino}-2,2-dimethyl-3-oxopropyl)ethanethioate HCl salt
The title compound was prepared according to the procedure described in Step E-G of Example A1 using 1-BOC-(2S,4S)-4-{[3-(acetylthio)-2,2-dimethylpropanoyl](4,4-methylcyclohexyl)amino}-2-{[ethyl(methyl)amino]carbonyl}pyrrolidine (100 mg, 0.19 mmol) prepared in Step A (60 mg, 44%).
MS[M+H]=705 (M+1)
1H NMR (400 MHz, CDCl3) 8.10-8.03 (m, 1H), 6.9&6.93 (m, 1H), 6.79-6.74 (m, 1H), 4.70 (t, 1H), 4.35-4.22 (m, 2H), 3.95-3.40 (m, 2H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 2H), 3.26-3.10 (m, 3H), 2.99 (s, 3H), 2.82-2.63 (m, 3H), 2.19-1.97 (m, 1H), 1.61-1.39 (m, 4H), 1.49 (s, 9H), 1.32-1.15 (m, 7H), 1.27 (s, 6H), 0.95 (s, 3H), 0.91 (s, 3H)
EXAMPLE C14
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-mercapto-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide HCl salt




To a solution of S-(3-{[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-{[ethyl(methyl)amino]carbonyl}pyrrolidine-3-yl](4,4-dimethylcyclohexyl)amino}-2,2-dimethyl-3-oxopropyl)ethanethioate (32 mg, 0.045 mmol) prepared in Example C13 in methanol/water (5:1, 1 mL) was added potassioumcarbonate (38 mg, 0.28 mmol), and the solution was stirred for 5 h. The methanol in the reaction solution was concentrated in vacuo, purified by prep-TLC without further process, and treated according to the procedure described in Step G of Example A1 to give the compound (7 mg, 23%).
MS[M+H]=663 (M+1)
1H NMR (400 MHz, CDCl3) 8.10-8.03 (m, 1H), 6.96-6.93 (m, 1H), 6.79-6.74 (m, 1H), 4.70 (t, 1H), 4.35-4.22 (m, 21), 3.95-3.40 (m, 2H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 21), 3.26-3.07 (m, 5H), 2.99 (s, 3H), 2.82-2.30 (m, 4H), 2.19-1.97 (m, 1H), 1.61-1.39 (m, 4H), 1.49 (s, 9H), 1.32-1.15 (m, 7H), 1.27 (s, 6H), 0.95 (s, 3H), 0.91 (s, 3H)
EXAMPLE C15 ̃25
The following Examples were prepared according to the procedure described in Example C1 ̃14, using the intermediates which are prepared in a series of Example A by the reactions between appropriate compounds among Preparation Example A1, A2, A4, A9 and appropriate amines.







TABLE 8













 























MS


Example
R1
R2′
R3′
R4
R5′
*
**
(M + 1)





C15
t-Bu
2,4-diF
H
4,4-diMe-c-Hex
C(CH3)2CH2NH2
S

561


C16
t-Bu
4-Cl
H
4,4-diMe-c-Hex
N(CH3)2
S

531


C17
t-Bu
4-Cl
H
4,4-diMe-c-Hex
CH2CH2OCH2CH3
S

560


C18
t-Bu
4-Cl
H
4,4-diMe-c-Hex
C(CH3)2CH2OCH2
S

588







CH3


C19
t-Bu
4-Cl
H
cis-4-Me-c-Hex
C(CH3)2C(O)CH3
S

558


C20
t-Bu
4-Cl
H
cis-4-Me-c-Hex
C(CH3)2CH(═NOH)
S

559


C21
t-Bu
4-Cl
H
cis-4-Me-c-Hex
C(CH3)2CH2F
S

548


C22
t-Bu
4-Cl
H
cis-4-Me-c-Hex
C(CH3)2C(O)NH2
S

559


C23
t-Bu
2,4-diF
H
cis-4-Me-c-Hex
C(CH3)2C(O)NH2
S

561


C24
t-Bu
4-Cl
C(O)N(CH3)2
4,4-diF-c-Hex
C(CH3)2CH2OCH3
S
S
653


C25
t-Bu
4-Cl
C(O)N
4,4-diF-c-Hex
C(CH3)2CH2O
S
S
681





MeEt

CH2CH3













The preparation process of the Intermediate D1 compounds, and the Examples synthesized by the procedure of Scheme D are as follows.
EXAMPLE D1
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,4-difluorophenyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide TFA salt




Step A: (2S,4S)-1-Boc-4-azidopyrrolidine-2-carboxylic acid
To a solution of methyl (2S,4S)-1-Boc-4-azidopyrrolidine-2-carboxylate (10 g, 37 mmol) prepared in Step D of Preparation Example A1-1 in methanol (100 ml) and water (100 ml) was added LiOH (2.5 g, 111 mmol). The solution was stirred at rt for 3 h, concentrated in vacuo, acidified with 1N HCl, and extracted with EtOAC. The organic extracts were washed with brine, dried over MgSO4, and concentrated in vacuo to give the title compound (9.5 g, 95%).
MS[M+H]=257(M+1)
Step B: (2S,4S) 1-Boc-4-azido[(dimethylamino)carbonyl]pyrrolidine
To a solution of (2S,4S)-1-Boc-4-azidopyrrolidine-2-carboxylic acid (9.5 g, 35 mmol) prepared in Step A in DMF (30□) was added dropwise DIPEA (1.15□, 6.70 mmol), and added dropwise 2M dimethylamine-THF solution (26.3 ml, 52.5 mmol), HOBT (7 g, 52.5 mmol) and EDC (10.2 g, 52.5 mmol) in order. The reaction mixture was stirred at rt for 12 h, and concentrated in vacuo. The residue was diluted with EtOAc, and washed with a saturated NaHCO3 aqueous solution, water and 1N HCl. The organic solution was dried over MgSO4, concentrated in vacuo, and the residue was purified by column chromatography (eluent: EtOAc:Hex=1/2) to give the title compound (9.1 g, 93%).
MS[M+H]=284(M+1)
Step C: (2S,4S)-1-Boc-4-amino[(dimethylamino)carbonyl]pyrrolidine
To a solution of (2S,4S)-1-Boc-4-azido[(dimethylamino)carbonyl]pyrrolidine (9 g, 32 mmol) prepared in Step B in dioxane (30 mL) was added dropwise Pd/C (900 mg). The reaction mixture was stirred under hydrogen condition for 24 h, filtered through Celite, and concentrated in vacuo to give the title compound as an oil (8.1 g, 98.5%).
MS[M+H]=258(M+1)
Step D: (2S,4S)-1-Boc-4-[(2,4-difluorophenyl)amino]-2[(dimethylamino)carbonyl]pyrrolidine
To a solution of (2S,4S)-1-Boc-4-amino[(dimethylamino)carbonyl]pyrrolidine (8 g, 31.5 mmol) prepared in Step C in toluene (100 ml) was added sodium t-butoxide (3.46 g, 36 mmol), 2-(di-t-butylphosphino)biphenyl (800 mg, 2.68 mmol), tris(dibenzylideneacetone)dipalladium(0) (1.6 g, 1.79 mmol) and 1-bromo-2,4-difluorobenzene (6.94 g, 36 mmol), and the solution was stirred at 110° C. for 10 h. After the reaction finished, the solution was filtered through Celite, and extracted with water and EtOAc. The organic layer was dried over MgSO4, concentrated in vacuo, and purified by column chromatography (eluent, EtOAc/Hex=1/4) to give the title compound (1.5 g, 78%).
MS[M+H]=370 (M+1)
Step E: (4S)-1-{[(3S,4R)-1-tert butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,4-difluorophenyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide TEA salt
The title compound was prepared according to the procedure described in Step B, E, F, G of Example A1 using (2S,4S)-1-Boc-4-[(2,4-difluorophenyl)amino]-2-[(dimethylamino)carbonyl]pyrrolidine (0.5 g, 1.34 mmol) prepared in Step D as starting material (0.46 g, 55%).
MS[M+H]=617 (M+1)
1H NMR (500 MHz, CDCl3) 7.57 (d, 21), 7.41 (d, 2H), 7.35-7.14 (m, 1H), 7.13-7.00 (m, 1H), 6.99-6.89 (m, 1H), 4.82-4.71 (m, 1H), 4.61-4.53 (m, 1H), 3.92-3.49 (m, 5H), 3.29-3.20 (m, 1H), 3.14-2.85 (m, 2H), 3.04 (d, 3H), 2.93 (d, 3H), 2.59-2.42 (m, 1H), 2.21-2.10 (m, 1H), 1.40 (s, 9H), 0.97 (s, 9H)
EXAMPLE D2 ̃39
The following Examples were prepared according to the procedure described in Example D1, using the intermediates which are prepared in a series of Example A by the reactions between appropriate compounds among Preparation Example A1, A2, A4, A9 and appropriate amines.







TABLE 9













 























MS


Example
R1
R2′
R3′
R4
R5′
*
**
(M + 1)





D2
t-Bu
4-Cl
H
2,4-diF-Ph
CH(CH3)2
S

532


D3
t-Bu
4-Cl
H
2,4-diF-Ph
t-Bu
S

546


D4
t-Bu
4-Cl
H
2,4-diF-Ph
CF3
S

558


D5
t-Bu
4-Cl
H
2-F-Ph
CH(CH3)2
S

514


D6
t-Bu
4-Cl
H
2,3-diF-Ph
CH(CH3)2
S

532


D7
t-Bu
2,4-diF
H
2,4-diF-Ph
CH(CH3)2
S

534


D8
t-Bu
4-Cl
H
2-F-Ph
t-Bu
S

528


D9
t-Bu
4-Cl
H
2,3-diF-Ph
t-Bu
S

546


D10
t-Bu
4-Cl
H
3,4-diF-Ph
t-Bu
S

546


D11
t-Bu
4-Cl
H
3,5-diF-Ph
t-Bu
S

546


D12
t-Bu
4-Cl
H
4-Cl-Ph
t-Bu
S

544


D13
t-Bu
4-Cl
H
3-Cl-Ph
t-Bu
S

544


D14
t-Bu
4-Cl
H
4-Me-Ph
t-Bu
S

524


D15
t-Bu
4-Cl
H
3-Me-Ph
t-Bu
S

524


 


D16
t-Bu
4-Cl
H




t-Bu
R

511


 


D17
t-Bu
4-Cl
H




t-Bu
R

517


 


D18
t-Bu
2,4-diF
H




t-Bu
R

519


 


D19
t-Bu
4-Cl
H
2,4-diF-Ph
CH(CH3)2
R

532


D20
t-Bu
4-Cl
H
2,4-diF-Ph
t-Bu
R

546


 


D21
t-Bu
4-Cl
H
2,4-diF-Ph




R

556


 


D22
t-Bu
4-Cl
H
Ph
t-Bu
S

510


D23
t-Bu
4-Cl
C(O)NH2
2,4-diF-Ph
CH(CH3)2
S
S
575


D24
t-Bu
4-Cl
C(O)NH2
4-Cl-Ph
CH(CH3)2
S
S
573


 


D25
t-Bu
2,4-diF
C(O)N(CH3)2
2,4-diF-Ph
t-Bu
S
S
619


D26
t-Bu
4-Cl
C(O)N(CH3)2
2,4-diF-Ph
CH(CH3)2
S
S
603


D27
t-Bu
4-Cl
C(O)N(CH3)2
4-OMe-Ph
t-Bu
S
S
611


D28
t-Bu
4-Cl
C(O)N(CH3)2
2,4-diF-Ph
t-Bu
R
S
617


D29
t-Bu
4-Cl
C(O)N(CH3)2
4-CF3-Ph
t-Bu
S
S
650


D30
t-Bu
4-Cl
C(O)N(CH3)2
2,4-diF-Ph
t-Bu
S
R
617


D31
t-Bu
4-Cl
C(O)N(CH3)2
4-CH3-Ph
t-Bu
S
S
595


 


D32
t-Bu
4-Cl
C(O)N(CH3)2
2,4-diF-Ph




S
S
631


 


D33
t-Bu
4-Cl
C(O)N(CH3)2
4-Cl-Ph




S
S
629


 


D34
t-Bu
4-Cl
C(O)N(CH3)2
2,4-diF-Ph




S
S
627


 


D35
t-Bu
4-Cl
C(O)N(CH3)2
2,4-diF-Ph




S
S
627


 


D36
t-Bu
4-Cl
C(O)N(CH3)2
2,4-diF-Ph




S
S
631


 


D37
t-Bu
4-Cl
C(O)N(CH3)2
2,4-diF-Ph




S
S
631


 


D38
t-Bu
4-Cl
C(O)N(CH3)2
CH3-(2,4-diF-Ph)
t-Bu
S
S
631


 


D39
t-Bu
4-Cl
H
2,4-diF-Ph




R

575













EXAMPLE E1-1
(4S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide




Step A 1-BOC-(3R,4S)-3-(4-chlorophenyl)-4-({(2S,4S)-2-[(dimethylamino)carbonyl]-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)pyrrolidine
The title compound was prepared according to the procedure described in Step F of Example A1, using (4S)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide (350 mg, 11.0 mmol) prepared in Step E of Example A1 and (3S,4R)-1-(tert-butoxycarbonyl)-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-9 (593 mg, 90%).
MS[M+H]=659(M+1)
Step B: (4S)-1-{[(3S,4R)(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
1-BOC-(3R,4S)-3-(4-chlorophenyl)-4-({(2S,4S)-2-[(dimethylamino)carbonyl]-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)pyrrolidine (100 mg, 0.15 mmol) prepared in Step A was treated according to the procedure described in Step E of Example A1, and purified by HPLC. This TFA salt of the compound was basified with 1N NaOH, and extracted with EtOAc. The organic layer was dried over MgSO4, and concentrated in vacuo to give the title compound (75 mg, 90%).
MS[M+H]=559(M+1)
1H NMR (500 MHz, CDCl3) 7.30 (d, 2H), 7.24 (d, 2H), 4.71 (t, 1H), 4.29-4.19 (m, 1H), 3.78-3.60 (m, br, 2H), 3.45-3.19 (m, 4H), 3.59-3.50 (m, 1H), 3.06 (s, 3H), 2.96 (s, 3H), 2.96-2.74 (m, 2H), 2.50-2.41 (m, 1H), 2.09-1.95 (m, 1H), 1.63-1.04 (m, 8H), 1.18 (s, 9H), 0.95 (s, 3H), 0.92 (s, 3H)
EXAMPLE E1-2 ̃58
The following Examples were prepared according to the procedure described in Example E1-1, using the intermediates which are prepared in a series of Example A, B, C, D by the reactions between appropriate compounds among Preparation Example A1, A2, A4, A9 and appropriate amines.







TABLE 10













 























MS


Example
R1
R2′
R3′
R4
R5′
*
**
(M + 1)





E1-2
H
4-Cl
H
Cis-4-Me-c-Hex
CH(CH3)2
S

460


E1-3
H
4-Cl
H
4,4-diMe-c-Hex
CH(CH3)2
S

474


E1-4
H
4-Cl
H
4,4-diMe-c-Hex
t-Bu
S

488


 


E1-5
H
4-Cl
H
4,4-diMe-c-Hex




S

498


 


E1-6
H
4-Cl
H
4,4-diMe-c-Hex
CH2OCH2CH3
S

490


E1-7
H
4-Cl
H
4,4-diMe-c-Hex
CF3
S

500


E1-8
H
4-Cl
H
4,4-diMe-c-Hex
C(CH3)2CN
S

499


E1-9
H
4-Cl
H
4,4-diMe-c-Hex
C(CH3)2CH2F
S

506


E1-10
H
4-Cl
H
4,4-diMe-c-Hex
C(CH3)2CH2OCH2
S

532







CH3


 


E1-11
H
4-Cl
H
4,4-diMe-c-Hex




S

502


 


E1-12
H
4-Cl
H
4,4-diMe-c-Hex




S

502


 


E1-13
H
4-Cl
H
cis-4-Me-c-Hex
t-Bu
S

474


 


E1-14
H
4-Cl
H
cis-4-Me-c-Hex




S

484


 


E1-15
H
4-Cl
H
cis-4-Me-c-Hex
C(CH3)2
S

504







CH(CH3)OH


E1-16
H
4-Cl
H
cis-4-Me-c-Hex
C(CH3)2C(CH3)2O
S

518







H


E1-17
H
4-Cl
H
cis-4-Me-c-Hex
C(CH3)2C(O)CH3
S

502


E1-18
H
4-Cl
H
cis-4-Me-c-Hex
C(CH3)2C(O)NH2
S

503


E1-19
H
2,4-diF
H
cis-4-Me-c-Hex
C(CH3)2C(O)NH2
S

505


E1-20
H
4-Cl
H
4,4-diF-c-Hex
CH(CH3)2
S

482


E1-21
H
4-Cl
H
4,4-diF-c-Hex
t-Bu
S

496


E1-22
H
4-Cl
H
4,4-diF-c-Hex
CF3
S

508


 


E1-23
H
4-Cl
H
cis-4-Me-c-Hex




S

486


 


E1-24
H
4-Cl
H
4,4-diF-c-Hex




S

510


 


E1-25
H
2,4-diF
H
4,4-diMe-c-Hex




S

500


 


E1-26
H
4-Cl
CONH2
cis-4-Me-c-Hex
t-Bu
S
S
517


E1-27
H
4-Cl
Pr
c-Hex
Me
S
S
460


E1-28
H
4-Cl
Pr
c-Hex
t-Bu
S
S
502


E1-29
H
4-Cl
allyl
c-Hex
t-Bu
S
S
500


 


E1-30
H
2,4-diF
C(O)NH2
cis-4-Me-c-Hex




S
S
533


 


E1-31
H
4-Cl
C(O)NH2
cis-4-Me-c-Hex




S
S
531


 


E1-32
H
4-Cl
C(O)NH2
cis-4-Me-c-Hex




S
S
527


 


E1-33
H
4-Cl
C(O)NH2
4,4-diMe-c-Hex




S
S
545


 


E1-34
H
2,4-diF
C(O)NHEt
cis-4-Me-c-Hex
t-Bu
S
S
547


E1-35
H
4-Cl
C(O)NHt-Bu
cis-4-Me-c-Hex
t-Bu
S
R
573


 


E1-36
H
4-Cl




c-Hex
Me
S
R
501


 


E1-37
H
4-Cl




cis-4-Me-c-Hex
CH(CH3)2
S
R
543


 


E1-38
H
4-Cl
CH2NH2
4,4-diMe-c-Hex
t-Bu
S
S
517


E1-39
H
4-Cl
CH2N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
545


E1-40
H
4-Cl
CN
c-Hex
Me
S
R
443


E1-41
H
4-Cl
CN
cis-4-Me-c-Hex
t-Bu
S
R
499


E1-42
H
4-Cl
Ac
c-Hex
Me
S
R
460


E1-43
H
2,4-diF
Ac
cis-4-Me-c-Hex
t-Bu
S
R
518


E1-44
H
4-Cl
Ac
4,4-diMe-c-Hex
t-Bu
S
R
530


E1-45
H
4-Cl
CH(OH)CH3
c-Hex
Me
S
R,
462









S


E1-46
H
4-Cl
CH(OH)CH3
4,4-diMe-c-Hex
t-Bu
S
R,
532









S


E1-47
H
4-Cl
C(O)NHEt
cis-4-Me-c-Hex
t-Bu
S
S
545


E1-48
H
4-Cl
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
S
517


E1-49
H
2,4-diF
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
S
519


E1-50
H
4-Cl
C(O)N(CH3)2
cis-4-Me-c-Hex
t-Bu
S
S
545


E1-51
H
4-Cl
CH(OH)CH3
cis-4-Me-c-Hex
t-Bu
S
R,
518









S


 


E1-52
H
4-Cl
C(O)NH2
cis-4-Me-c-Hex




S
R
527


 


E1-53
H
4-Cl
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
R
517


E1-54
H
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
561


E1-55
H
2,4-diF
C(S)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
577


E1-56
H
4-Cl
C(O)N(CH3)2
2,4-diF-Ph
CH(CH3)2
S
S
547


E1-57
H
4-Cl
H
4,4-diMe-c-Hex
C(CH3)2CH2OH
S

504









EXAMPLE E2-1
(4S)-1-{[(3S,4R)-1-(aminocarbonyl)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide




To a solution of (4S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide (84 mg, 0.15 mmol) prepared in Example E1-1 in DMF was added dropwise KOCN (24 mg, 0.3 mmol) and a catalytic amount of acetic acid. The reaction mixture was stirred at rt for 1 h, extracted with EtOAc, washed with excessive amount of water and brine, and the organic solution was dried over MgSO4. The residue was purified by HPLC to give the title compound.
MS[M+H]=602(M+1)
1H NMR (500 MHz, CDCl3) 7.30 (d, 2H), 7.24 (d, 2H), 4.71 (t, 1H), 4.29-4.19 (m, 1H), 4.05-3.77 (m, 4H), 3.76-3.60 (m, 2H), 3.59-3.50 (m, 1H), 3.06 (s, 3H), 2.96 (s, 3H), 2.99-2.71 (m, 2H), 2.50-2.40 (m, 1H), 2.09-1.95 (m, 1H), 1.63-1.04 (m, 8H), 1.18 (s, 9H), 0.95 (s, 3H), 0.94 (s, 3H)
EXAMPLE E2-2 ̃25
The following Examples were prepared according to the procedure described in Example E2-1, using the intermediates which are prepared in a series of Example A, B, C, D by the reactions between appropriate compounds among Preparation Example A1, A2, A4, A9 and appropriate amines.







TABLE 11













 























MS


Example
R1
R2′
R3′
R4
R5′
*
**
(M + 1)





E2-2
NH2C(O)
4-Cl
H
4,4-diMe-c-Hex
C(CH3)2CH2
S

547







OH


E2-3
NH2C(O)
4-Cl
H
4,4-diMe-c-Hex
t-Bu
S

531


E2-4
NH2C(O)
4-Cl
H
4,4-diMe-c-Hex
CH(CH3)2
S

517


 


E2-5
NH2C(O)
4-Cl
H
4,4-diMe-c-Hex




S

545


 


E2-6
NH2C(O)
4-Cl
H
4,4-diMe-c-Hex




S

545


 


E2-7
NH2C(O)
4-Cl
H
4,4-diMe-c-Hex
C(CH3)(CH2OH)2
S

563


 


E2-8
NH2C(O)
4-Cl
H
cis-4-Me-c-Hex
CH(CH3)2
S

503


E2-9
NH2C(O)
4-Cl
H
cis-4-Me-c-Hex
t-Bu
S

517


 


E2-10
NH2C(O)
4-Cl
H
cis-4-Me-c-Hex




S

501


 


E2-11
NH2C(O)
4-Cl
H
cis-4-Me-c-Hex
C(CH3)(CH2OH)3
S

549


E2-12
NH2C(O)
2,4-diF
H
4,4-diMe-c-Hex
t-Bu
S

533


 


E2-13
NH2C(O)
2,4-diF
H
4,4-diMe-c-Hex




S

547


 


E2-14
NH2C(O)
4-Cl
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
S
560


E2-15
NH2C(O)
4-Cl
C(O)NH2
cis-4-Me-c-Hex
CH(CH3)2
S
S
546


E2-16
NH2C(O)
2,4-diF
C(O)NH2
4,4-diMe-c-Hex
t-Bu
S
S
576


 


E2-17
NH2C(O)
2,4-diF
C(O)NH2
cis-4-Me-c-Hex




S
S
576


 


E2-18
NH2C(O)
4-Cl
C(O)NH2
cis-4-Me-c-Hex




S
S
574


 


E2-19
NH2C(O)
2,4-diF
C(O)NH2
cis-4-Me-c-Hex




S
S
572


 


E2-20
NH2C(O)
2,4-diF
C(O)N(CH3)2
cis-4-Me-c-Hex




S
S
604


 


E2-21
NH2C(O)
4-Cl
C(O)N(CH3)2
4,4-diMe-c-Hex




S
S
616


 


E2-22
NH2C(O)
4-Cl
C(O)NH(CH2)2NH2
cis-4-Me-c-Hex
t-Bu
S
S
603


E2-23
NH2C(O)
2,4-diF
C(O)NH(CH2)2NH2
cis-4-Me-c-Hex
t-Bu
S
S
605


E2-24
NH2C(O)
2,4-diF
C(O)NH(CH2)3NH2
4,4-diMe-c-Hex
t-Bu
S
S
633


E2-25
NH2C(S)
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
620









EXAMPLE E3-1
(4S)-1-({[(3S,4R)-4-(4-chlorophenyl)-1-(ethylamino)carbonyl]pyrrolidine-3-yl}carbonyl)-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide




To a solution of (4S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}[(4,4-dimethylcyclohexyl)(2,2-methylpropanoyl)amino]-N,N-dimethyl-L-prolineamide (84 mg, 0.15 mmol) prepared in Example E1-1 and TEA (0.04 ml, 0.3 mmol) in DCM, was added dropwise ethylisocyanate (16 mg, 0.22 mmol). The reaction mixture was stirred at rt for 1 h, extracted with EtOAc, washed with excessive amount of water and brine, and the organic solution was dried over MgSO4. The residue was purified by HPLC to give the title compound.
MS[M+H]=630(M+1)
1H NMR (500 MHz, CDCl3) 7.28 (d, 2H), 7.23 (d, 2H), 4.71 (t, 1H), 4.26-4.13 (m, 1H), 4.08-3.98 (m, 1H), 3.87-3.62 (m, br, 3H), 3.58-3.37 (m, br, 3H), 3.37-3.21 (m, 3H), 3.10-2.96 (m, 1H), 3.05 (s, 3H), 2.94 (s, 3H), 2.74-2.60 (m, 1H), 2.09-1.98 (m, 1H), 1.63-1.04 (m, 8H), 1.18 (s, 9H), 1.14 (t, 3H), 0.95 (s, 3H), 0.93 (s, 3H)
EXAMPLE E3-2
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-[(ethylamino)carbonothioyl]pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-difluorocyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide




To a solution of N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl)-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide (93 mg, 0.15 mmol) prepared in Example E1-57 and TEA (0.04 ml, 0.3 mmol) in DCM, was added dropwise ethylisocyanate (19 mg, 0.22 mmol). The reaction mixture was stirred at rt for 1 h, extracted with EtOAc, washed with excessive amount of water and brine, and the organic solution was dried over MgSO4. The residue was purified by HPLC to give the title compound (74.4 mg, 84%).
MS[M+H]=591(M+1)
1H NMR (500 MHz, CDCl3) 7.55-7.48 (m, 2H), 7.36-7.28 (m, 2H), 3.95-3.20 (m, 12H), 3.12-2.89 (m, 4H), 1.86-1.68 (m, 1H), 1.67-1.53 (m, 6H), 1.52-1.14 (m, 9H), 0.94 (s, 3H), 0.91 (s, 3H), 0.88 (t, 3H)
EXAMPLE E3-3 ̃37
The following Examples were prepared according to the procedure described in Example E3-1,2, using the intermediates which are prepared in a series of Example A, B, C, D by the reactions between appropriate compounds among Preparation Example A1, A2, A4, A9 and appropriate amines.







TABLE 12













 























MS


Example
R1
R2′
R3′
R4
R5′
*
**
(M + 1)





E3-3
EtNHC(O)
4-Cl
H
4,4-diMe-c-Hex
C(CH3)2CH2OH
S

575


E3-4
EtNHC(O)
4-Cl
H
4,4-diMe-c-Hex
CH(CH3)2
S

545


 


E3-5
EtNHC(O)
4-Cl
H
4,4-diMe-c-Hex




S

573


 


E3-6
EtNHC(O)
4-Cl
H
4,4-diMe-c-Hex




S

573


 


E3-7
EtNHC(O)
4-Cl
H
4,4-diMe-c-Hex
t-Bu
S

559


 


E3-8
EtNHC(O)
4-Cl
H
Cis-4-Me-c-
CH(CH3)2
S

531






Hex


 


E3-9
EtNHC(O)
4-Cl
H
Cis-4-Me-c- Hex




S

529


 


E3-10
EtNHC(O)
4-Cl
H
2,4-diF-Ph
CH(CH3)2
R

547


E3-11
EtNHC(O)
4-Cl
H
2,4-diF-Ph
t-Bu
R

561


 


E3-12
EtNHC(O)
2,4-diF
H
2,4-diF-Ph
t-Bu
R

563


E3-13
t-BuNHC(O)
4-Cl
H
4,4-diMe-c-Hex
t-Bu
S

587


 


E3-14
t-BuNHC(O)
4-Cl
H
4,4-diMe-c-Hex




S

601


 


E3-15
t-BuNHC(O)
2,4-diF
H
4,4-diMe-c-Hex




S

603


 


E3-16
n-BuNHC(O)
4-Cl
H
Cis-4-Me-c-
CH(CH3)2
S

559






Hex


E3-17
EtMeNC(O)
4-Cl
H
Cis-4-Me-c-Hex
CH(CH3)2
S

545


E3-18
EtNHC(S)
4-Cl
H
4,4-diMe-c-Hex
CH(CH3)2
S

561


E3-19
EtNHC(S)
4-Cl
H
Cis-4-Me-c-
CH(CH3)2
S

547






Hex


E3-20
MeNHC(S)
4-Cl
H
Cis-4-Me-c-
CH(CH3)2
S

533






Hex


E3-21
EtNHC(O)
4-Cl
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
S
588


E3-22
EtNHC(O)
2,4-diF
C(O)NH2
cis-4-Me-c-Hex
CH(CH3)2
S
S
576


E3-23
t-BuNHC(O)
2,4-diF
C(O)NH2
cis-4-Me-c-Hex
CH(CH3)2
S
S
604


E3-24
PrNHC(O)
2,4-diF
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
S
604


 


E3-25
EtNHC(O)
2,4-diF
C(O)NH2
4,4-diMe-c-Hex




S
S
618


 


E3-26
EtNHC(O)
2,4-diF
C(O)NH2
cis-4-Me-c-Hex




S
S
604


 


E3-27
EtNHC(O)
2,4-diF
C(O)NH2
cis-4-Me-c-Hex




S
S
604


 


E3-28
EtNHC(O)
2,4-diF
C(O)N(CH3)2
cis-4-Me-c-Hex
t-Bu
S
S
618


E3-29
EtNHC(O)
4-Cl
C(O)N(CH3)2
cis-4-Me-c-Hex
t-Bu
S
S
616


E3-30
MeNHC(S)
2,4-diF
C(O)N(CH3)2
cis-4-Me-c-Hex
t-Bu
S
S
620


E3-31
EtNHC(S)
2,4-diF
C(O)N(CH3)2
cis-4-Me-c-Hex
t-Bu
S
S
634


E3-32
MeNHC(S)
4-Cl
C(O)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
632


E3-33
EtNHC(S)
4-Cl
C(O)N(CH3)2
cis-4-Me-c-Hex
t-Bu
S
S
632


E3-34
EtNHC(O)
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
632


E3-35
EtNHC(S)
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
648


E3-36
EtNHC(O)
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
C(CH3)2CH2OH
S
S
648


E3-37
EtNHC(O)
4-Cl
C(O)N(CH3)2
4,4-diMe-c-Hex
C(CH3)2CH2OH
S
S
646









EXAMPLE E4-1
(4S)-1-({[(3S,4R)-1-acetyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide




The title compound was prepared according to the procedure described in Step F of Example A1 using (4S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide (84 mg, 0.15 mmol) prepared in Example E1-1 and AcOH via amide coupling reaction.
MS[M+H]=601(M+1)
1H N (500 MHz, CDCl3) 7.30 (d, 2H), 7.24 (d, 2H), 4.71 (t, 1H), 4.29-4.19 (m, 1H), 4.16-4.09 (m, 1H), 4.03-3.79 (m, br, 3H), 3.78-3.60 (m, br, 2H), 3.59-3.50 (m, 1H), 3.37-3.29 (m, 1H), 3.06 (s, 3H), 2.96 (s, 3H), 2.91-2.69 (m, br, 2H), 2.14 (s, 3H), 2.09-1.95 (m, 1H), 1.63-1.04 (m, 8H), 1.18 (s, 9H), 0.95 (s, 3H), 0.94 (s, 3H)
EXAMPLE E4-2 ̃14
The following Examples were prepared according to the procedure described in Example E4-1, using the intermediates which are prepared in a series of Example A, B, C, D by the reactions between appropriate compounds among Preparation Example A1, A2, A4, A9 and appropriate amines.







TABLE 13













 























MS


Example
R1
R2′
R3′
R4
R5′
*
**
(M + 1)





E4-2
Ac
4-Cl
H
4,4-diMe-c-Hex
C(CH3)2CH2OH
S

546


E4-3
Ac
4-Cl
H
4,4-diMe-c-Hex
CH(CH3)2
S

516


E4-4
Ac
4-Cl
H
4,4-diMe-c-Hex
C(CH3)3
S

530


 


E4-5
Ac
4-Cl
H
4,4-diMe-c-Hex




S

544


 


E4-6
Ac
4-Cl
H
cis-4-Me-c-Hex
SO2CH3
S

538


E4-7
(CH3)2CHC(O)
4-Cl
H
4,4-diMe-c-Hex
C(CH3)3
S

558


 


E4-8
(CH3)2CHC(O)
4-Cl
H
4,4-diMe-c-Hex




S

572


 


E4-9
CF3C(O)
4-Cl
H
4,4-diMe-c-Hex
C(CH3)3
S

584


E4-10
Ac
4-Cl
C(O)NH2
cis-4-Me-c-Hex
t-Bu
S
S
559


E4-11
CH(CH3)2C(O)
4-Cl
C(O)NH2
cis-4-Me-c-Hex
CH(CH3)2
S
S
573


E4-12
CH3CH2C(O)
4-Cl
C(O)NH2
cis-4-Me-c-Hex
CH(CH3)2
S
S
559


E4-13
t-BuC(O)
4-Cl
C(O)NH2
cis-4-Me-c-Hex
CH(CH3)2
S
S
587


E4-14
CH(CH3)2C(O)
4-Cl
C(O)NH2
4,4-diMe-c-Hex
t-Bu
S
S
601









EXAMPLE E5-1
(4S)-1-({[(3S,4R)-4-(4-chlorophenyl)-1-cyclopropylpyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide HCl salt




To a solution of (4S)-1-[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide (100 mg, 0.18 mmol) prepared in Example E1-1 in DCE (5 ml) was added 1-ethoxycyclopropoxytrimethylsilane (47 mg, 0.27 mmol) and sodium-cyanoborohydride (23 mg, 0.36 mmol), added a catalytic amount of acetic acid, and the solution was stirred at 80° C. for 2 h. After the reaction finished, the solvent was concentrated in vacuo, and extracted with a saturated NaHCO3 aqueous solution and EtOAc. The organic solution was dried over MgSO4, concentrated in vacuo, and the residue was purified by HPLC. This TFA salt of the compound was treated according to the procedure described in Step G of Example A1 to give the title compound.
MS[M+H]=599(M+1)
1H NMR (400 MHz, CDCl3) 7.57 (d, 2H), 7.32 (d, 2H), 4.70 (t, 1H), 4.35-4.22 (m, 2H), 3.95-3.90 (m, 2H), 3.81-3.69 (m, 1H), 3.67-3.54 (m, 2H), 3.42-3.29 (m, 2H), 3.22-3.11 (m, 1H), 2.99 (s, 3H), 2.95 (s, 3H), 2.82-2.68 (m, 1H), 2.15-1.79 (m, 2H), 1.61-1.39 (m, 4H), 1.31-1.15 (m, 4H), 1.22 (s, 9H), 0.95 (s, 3H), 0.91 (s, 3H), 0.82-0.65 (m, 4H),
EXAMPLE E5-2
(4S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(tetrahydro-2H-pyran-4-yl)pyrrolidine-3-yl]carbonyl}-4-{(4,4-dimethylcyclohexyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-N-ethyl-N-methyl-L-prolineamide HCl salt




(4S)-4-[(4,4-dimethylcyclohexyl)(tetrahydrofuran-2-ylcarbonyl)amino]-N-ethyl-N-m ethyl-L-prolineamide (100 mg, 0.26 mmol) prepared in Step D of Example A2 and (3S,4R)-1-(tert-butoxycarbonyl)-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid prepared in Preparation Example A9-9 were reacted according to the procedure described in Step F of Example A1, and then according to that in Step E of Example A1. This compound was reacted with tetrahydro-4H-pyran-4-one via reductive amination as described in Step A of Example A1, and purified by HPLC. This TFA salt of the compound was treated according to the procedure described in Step G of Example A1 to give the title compound (139 mg, 80%).
MS[M+H]=671(M+1)
1H NMR (500 MHz, CDCl3) 7.66-7.52 (m, 21), 7.37-7.27 (m, 2H), 4.73-4.62 (m, 1H), 4.52-4.39 (m, 1H), 4.32-4.16 (m, 1H), 4.15-3.69 (m, br, 10H), 3.59-3.12 (m, br, 10H), 3.00-2.88 (m, 3H), 2.23-2.80 (m, br, 8H), 1.65-1.04 (m, 11H), 0.98-0.86 (m, 6H)
EXAMPLE E5-3 ̃21
The following Examples were prepared according to the procedure described in Example E5-1,2, using the intermediates which are prepared in a series of Example A, B, C, D by the reactions between appropriate compounds among Preparation Example A1, A2, A4, A9 and appropriate amines.







TABLE 14













 























MS


Example
R1
R2′
R3′
R4
R5′
*
**
(M + 1)





E5-3
c-Pr
4-Cl
H
4,4-diMe-c-Hex
C(CH3)2CH2
S

544







OH


E5-4
n-Bu
4-Cl
H
cis-4-Me-c-Hex
CH(CH3)2
S

516


E5-5
i-Pr
4-Cl
H
4,4-diMe-c-Hex
t-Bu
S

530


E5-6
CF3CH2
4-Cl
H
4,4-diMe-c-Hex
t-Bu
S

570


E5-7
c-Pr
4-Cl
H
4,4-diMe-c-Hex
CH(CH3)2
S

514


E5-8
c-Pr
4-Cl
H
4,4-diMe-c-Hex
t-Bu
S

528


E5-9
c-Bu
4-Cl
H
cis-4-Me-c-Hex
t-Bu
S

528


E5-10
c-Pen
4-Cl
H
cis-4-Me-c-Hex
CH(CH3)2
S

528


E5-11
i-Pr
2,4-diF
C(O)N(CH3)2
4,4-diF-c-Hex
t-Bu
S
S
611


E5-12
i-Pr
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
C(CH3)2CH2
S
S
619







OH


E5-13
c-Bu
4-Cl
C(O)N(CH3)2
4,4-diMe-c-Hex
C(CH3)2CH2
S
S
629







OH


E5-14
c-Pen
4-Cl
C(O)N(CH3)2
4,4-diMe-c-Hex
C(CH3)2CH2
S
S
643







OH


E5-15
c-Pr
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
601


E5-16
c-Pen
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
629


E5-17
c-Pr
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
CH(CH3)2
S
S
587


E5-18
c-Pen
4-Cl
C(O)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
627


E5-19
i-Pr
2,4-diF
C(O)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
603


E5-20
c-Pr
2,4-diF
C(S)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
617


E5-21
i-Pr
2,4-diF
C(S)N(CH3)2
4,4-diMe-c-Hex
t-Bu
S
S
619









EXAMPLE E6
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(methylsulfonyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2-methyl-N-(cis-4-methylcyclohexyl)propaneamide




To a solution of N-[(3S)-1{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]-N-(cis-4-methylcyclohexyl)-2-methylpropaneamide TFA salt (124 mg, 0.2 mmol) prepared in Example E1-2 in DCM (3 ml) was added TEA (50 mg, 0.5 mmol), and added methanesulfonylchloride (27.4 mg, 0.24 mmol) at 0° C., and stirred at rt for 30 min. After the reaction finished, the solvent was concentrated in vacuo, the residue extracted with water and EtOAc, and the organic layer was dried over MgSO4. The residue was purified by HPLC to give the title compound (82.8 mg, 77%).
MS[M+H]=538(M+1)
1H NMR (400 MHz, CDCl3) 7.40-7.10 (m, 4H), 3.87-3.50 (m, 6H), 3.47-3.21 (m, 3H), 2.84 (s, 3H), 2.80-2.69 (m, 2H), 2.60-2.33 (m, 2H), 1.78-1.57 (m, 8H), 1.50-1.21 (m, 9H), 0.95 (d, 3H)
EXAMPLE E7-1
(3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(cis-4-methylcyclohexyl)(2-methylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide




To a solution of phosgene (148 mg, 1.5 mmol) and TEA (30 mg, 0.3 mmol) in DCM (5 ml) was slowly added dropwise N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl)-N-(cis-4-methylcyclohexyl)-2-methylpropaneamide TFA salt (90 mg, 0.15 mmol) prepared in Example E1-2, and stirred at rt for 30 min, and concentrated in vacuo to remove phosgene. To the residue was added DCM (5 ml) and TEA (30 mg, 0.3 mmol), and added dropwise 2,2,2-trifluoroethylamine (20 mg, 0.2 mmol), and stirred at rt for 1 h. After the reaction finished, the solvent was concentrated in vacuo, and the residue was extracted with EtOAc and water, and dried over MgSO4. The residue was purified by HPLC to give the title compound (53.4 mg, 67%).
MS[M+H]=585(M+1)
1H NMR (500 MHz, CDCl3) 7.35-7.28 (m, 2H), 7.22-7.11 (m, 2H), 4.06-3.93 (m, 1H), 3.91-3.71 (m, 5H), 3.70-3.46 (m, 5H), 3.44-3.10 (m, 4H), 2.86-2.66 (m, 2H), 2.55-2.45 (m, 1H), 2.02-1.92 (m, 1H), 1.79-1.56 (m, 5H), 1.51-1.39 (m, 2H), 1.10-1.03 (d, 6H), 1.02-0.96 (m, 3H)
EXAMPLE E7-2 ̃3
The following Examples were prepared according to the procedure described in Example E7-1, using the intermediates which are prepared in a series of Example A, B, C, D by the reactions between appropriate compounds among Preparation Example A1, A2, A4, A9 and appropriate amines.







TABLE 15













 

















MS


Example
R1
R2′
R4
*
(M + 1)





E7-2
CF3CH2NHC(O)
4-Cl
4,4-diMe-c-Hex
S
613


E7-3
CF3CH2NHC(O)
4-Cl
cis-4-Me-c-Hex
S
599









EXAMPLE E8-1
methyl(3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)pyrrolidine-1-carboxylate




To a solution of N-[(3S)-1-{[(3S,4R))-4-(4-chlorophenyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide (93 mg, 0.15 mmol) prepared in Example E1-57 and TEA (0.04 ml, 0.3 mmol) in DCM, was added dropwise methylchloroformate (20 mg, 0.22 mmol). The reaction mixture was stirred at rt for 1 h, extracted with EtOAc, washed with excessive amount of water and brine, and the organic solution was dried over MgSO4. The residue was purified by HPLC to give the title compound (76 mg, 90%).
MS[M+H]=562(M+1)
1H NMR (500 MHz, CDCl3) 7.30-7.15 (m, 4H), 4.00-3.33 (m, 13H), 3.32-3.22 (m, 1H), 3.21-3.11 (m, 1H), 2.78-2.68 (m, 0.6H), 2.61-2.51 (m, 0.6H), 2.51-2.40 (m, 0.4H), 1.98-1.89 (m, 0.4H), 1.86-1.68 (m, 1H), 1.67-1.35 (m, 7H), 1.32-1.14 (m, 8H), 0.93 (s, 6H)
EXAMPLE E8-2 ̃5
The following Examples were prepared according to the procedure described in Example E8-1, using the intermediates which are prepared in a series of Example A, B, C, D by the reactions between appropriate compounds among Preparation Example A1, A2, A4, A9 and appropriate amines.







TABLE 16













 

















MS


Example
R1
R4
R5′
*
(M + 1)





E8-2
MeOC(O)
4,4-diMe-c-Hex
CH(CH3)2
S
532


E8-3
MeOC(O)
cis-4-Me-c-Hex
t-Bu
S
532


E8-4
EtOC(O)
cis-4-Me-c-Hex
CH(CH3)2
S
532


E8-5
PhCH2OC(O)
cis-4-Me-c-Hex
CH(CH3)2
S
594









EXAMPLE E9
N-[(3S)-1-{[(3S,4R)-1-[amino(imino)methyl]-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2-methyl-N-(cis-4-methylcyclohexyl)propaneamide TFA salt




To a solution of N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]-N-(cis-4-methylcyclohexyl)-2-methylpropaneamide (248 mg, 0.4 mmol) prepared in Example E1-2 in THF (5 ml) was added N,N-bis-Boc-1-guanylpyrazole (186 mg, 0.6 mmol), and stirred at rt for 12 h. After the reaction finished, the solvent was concentrated in vacuo, the residue was extracted with water and EtOAc, and the organic layer was dried over MgSO4, DCM (3 ml) was added, TFA (1 ml) was added, and stirred at 40° C. for 10 h. The solvent was concentrated in vacuo, and the residue was purified by HPLC to give the title compound (190 mg, 77%).
MS[M+H]=502(M+1)
1H NMR (500 MHz, CDCl3) 7.34-7.28 (m, 2H), 7.25-7.23 (m, 1H), 7.15-7.11 (m, 1H), 4.06-3.93 (m, 1H), 3.91-3.71 (m, 5H), 3.69-3.12 (m, 7H), 2.86-2.66 (m, 2H), 2.55-2.45 (m, 1H), 2.02-1.92 (m, 1H), 1.79-1.56 (m, 5H), 1.51-1.39 (m, 2H), 1.10-1.03 (m, 6H), 1.02-0.96 (m, 3H)
EXAMPLE E10
N-[(3S)-1-({(3S,4R)-4-(4-chlorophenyl)-1-[(ethylamino)(imino)methyl]pyrrolidine-3-yl}carbonyl)pyrrolidine-3-yl]2-methyl-N-(cis-4-methylcyclohexyl)propaneamide TFA salt




Step A: N-[(3S)-1-{[(3S,4R)-4-(4-cholorphenyl)-1-cyanopyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]2-methyl-N-(cis-4-methylcyclohexyl)propaneamide
To a solution of N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]-N-(cis-4-methylcyclohexyl)-2-methylpropaneamide (120 mg, 0.21 mmol) prepared in Example E1-2 in ethanol (5 ml) was added cyanogen bromide (33 mg, 0.31 mmol) and NaHCO3 (88 mg, 1.05 mmol), and stirred at rt for 1 h. The reaction solution was concentrated in vacuo, extracted with water and EtOAc, and the organic layer was dried over MgSO4. The organic solution was concentrated to give the title compound, which was used in next step without further purification.
MS[M+H]=485(M+1)
Step B: N-[(3S)-1-({(3S,4R)-4-(4-chlorophenyl)-1-[(ethylamino)(imino)methyl]pyrrolidine-3-yl}carbonyl)pyrrolidine-3-yl]-2-methyl-N-(cis-4-methylcyclohexyl)propaneamide TEA salt
To a solution of the compound of Step A in hexafluoroisopropanol (2 ml) was added TEA (1 ml) and excessive amount of ethylamine hydrochloride, and heated to 70° C. The reaction solution was stirred for 5 h, concentrated in vacuo, and purified by HPLC to give the title compound (98.7 mg, 73%).
MS[M+H]=530(M+1)
1H NMR (500 MHz, CDCl3) 7.35-7.28 (m, 2H), 7.25-7.22 (m, 1H), 7.15-7.11 (m, 1H), 4.06-3.93 (m, 1H), 3.91-3.71 (m, 51), 3.70-3.46 (m, 3H), 3.44-3.10 (m, 6H), 2.86-2.66 (m, 2H), 2.55-2.45 (m, 1H), 2.02-1.92 (m, 1H), 1.79-1.56 (m, 5H), 1.51-1.39 (m, 2H), 1.35-1.23 (m, 3H), 1.10-1.03 (m, 6H), 1.02-0.96 (m, 3H)
EXAMPLE E11
N-[(3S)-1-{[(3S,4R)-1-[(acetylamino)(imino)methyl]-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2-methyl-N-(cis-4-methylcyclohexyl)propaneamide




To a solution of N-[(3S)-1-{[(3S,4R)-1-[amino(imino)methyl]-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2-methyl-N-(cis-4-methylcyclohexyl)propaneamide TFA salt (185 mg, 0.3 mmol) prepared in Example E9 in DCM (3 ml) was added acetic acid anhydride (46 mg, 0.45 mmol) and TEA (71 mg, 0.7 mmol), and stirred at rt for 6 h. After the reaction finished, the solvent was concentrated in vacuo, extracted with water and EtOAc, and the organic layer was dried over MgSO4. The organic solution was concentrated in vacuo, and purified by HPLC to give the title compound (139 mg, 85%).
MS[M+H]=544(M+1)
1H NMR (500 MHz, CDCl3) 7.38-7.10 (m, 41), 4.21-4.05 (m, 1H), 3.95-3.57 (m, 3H), 3.56-3.42 (m, 2H), 3.40-3.04 (m, 3H), 2.75-2.62 (m, 1H), 2.54-2.40 (m, 1H), 2.36-2.21 (m, 2H), 2.01-1.89 (m, 1H), 1.80-1.51 (m, 6H), 1.48-1.34 (m, 3H), 1.33-1.22 (m, 1H), 1.13-0.90 (m, 1H)
EXAMPLE E12-1
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-phenylpyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-propaneamide




To a solution of N-[(3S)-1-{([(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide (124 mg, 0.2 mmol) prepared in Example E1-57 in toluene (5 ml) was added bromobenzene (31 mg, 2 mmol), and carried out the procedure described in Step D of Example D1 to give the title compound (90 mg, 78%).
MS[M+H]=580(M+1)
1H NMR (500 MHz, CDCl3) 7.55-7.47 (m, 2H), 7.41-7.32 (m, 2H), 7.28-7.11 (m, 3H), 3.95-3.20 (m, 12H), 3.01-2.93 (m, 0.4H), 2.75-2.68 (m, 0.6H), 2.48-2.38 (m, 0.6H), 2.18-2.08 (m, 0.4H), 1.86-1.68 (m, 1H), 1.67-1.35 (m, 7H), 1.32-1.14 (m, 8H), 0.94 (s, 3H), 0.91 (s, 3H)
EXAMPLE E12-2 ̃6
The following Examples were prepared according to the procedure described in Example E12-1, using the intermediates which are prepared in a series of Example A, B, C, D by the reactions between appropriate compounds among Preparation Example A1, A2, A4, A9 and appropriate amines.







TABLE 17













 












Ex-




MS


ample
R1
R4
R5′
*
(M + 1)





E12-2
Ph
4,4-diMe-c-Hex
CH(CH3)2
S
550


 


E12-3




4,4-diMe-c-Hex




S
579


 


E12-4




cis-4-Me-c-Hex
t-Bu
S
551


 


E12-5




cis-4-Me-c-Hex
CH(CH3)2
S
538


 


E12-6




cis-4-Me-c-Hex
CH(CH3)2
S
543









EXAMPLE E13-1
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(4,5-dihydro-1H-imidazole-2-yl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide TFA salt




To a solution of N-[(3S)-1-{[(3S,4R) (4-chlorophenyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide (124 mg, 0.2 mmol) prepared in Example E1-57 in acetonitrile was added 1-(4,5-dihydro-1H-imidazole-2-yl)-3,5-diethyl-1H-pyrazole hydrobromide (73.5 mg, 0.3 mmol) and TEA (40 mg, 0.4 mmol), and stirred at 90° C. for 5 h. After the reaction finished, the solvent was concentrated in vacuo, extracted with water and EtOAc, and the organic solution was dried over MgSO4. The residue was purified by HPLC to give the title compound (114 mg, 83%).
MS[M+H]=572(M+1)
1H NMR (500 MHz, CDCl3) 7.33-7.15 (m, 4H), 4.01-3.12 (m, 12H), 2.85-2.78 (m, 2H), 2.78-2.71 (m, 0.6H), 2.61-2.53 (m, 0.6H), 2.53-2.43 (m, 0.4H), 2.00-1.91 (m, 0.4H), 1.74-1.65 (m, 3H), 1.58-1.32 (m, 7H), 1.32-1.14 (m, 8H), 0.94 (s, 6H)
EXAMPLE E13-2
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(4,5-dihydro-1H-imidazole-2-yl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide TFA salt




The title compound was prepared according to the procedure described in Example E13-1 using N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]-N-(cis-4-methylcyclohexyl)-2-methylpropaneamide prepared in Example E1-2.
MS[M+H]=528(M+1)
Functional Assay
Physiological activity of the compounds of the present invention was assessed by measuring agonistic activity as well as binding activity for melanocortin receptors according to the following assays.
1. Luciferase Assay.
Cell lines expressing human melanocortin receptor 4 (MC4R) were dissociated from tissue culture dishes by rinsing with Ca++, Mg++ free DPBS, treated with 1× Trypsin/EDTA solution for 1 min at 37° C., and resuspended with DMRM (GIBCO-BRL) supplemented with 10% FBS. The cells were counted and diluted with DMEM supplemented with 10% FBS and 200 ug/ml of Geneticin to 5×110 cells/ml. 90 ul of cell suspension was plated onto each well of 96-well black and clear bottom culture plates (Costar). After the incubation for 24 h in the atmosphere of 6% CO2 at 37° C., 10 ul of NDP-MSH and test compounds diluted in DMSO were added to each well. The final DMSO concentration was 1%. After 4 h of incubation in the atmosphere of 6% CO2 at 37° C., 50 ul of Bright-Glo (Promega) was added to each well. Luciferase activity was measured by using L-Max luminometer (Molecular Device). The amount of luciferase activity induced by treatment with NDP-MSH was defined as 100% to obtain the relative efficacy of test compounds. The EC0.5 MSH was defined as the concentration of test compounds that results in half maximal activity of NDP-MSH. The EC50 was defined as the concentration of test compound that results in half maximal activity of its own.
2. cAMP Accumulation Assay.
Cell lines expressing human melanocortin receptor 4 (MC4R) were grown in F150 mm culture dishes in DMEM (GIBCO-BRL) supplemented with 10% FBS, 200 ug/ml Geneticin (GIBCO-BRL), and antibiotics (penicillin and streptomycin) (GIBCO-BRL) in an atmosphere of 6% CO2 at 37° C. When the cells were fully grown, the cells were washed once with 10 ml of Ca++, Mg++ free DPBS. The cells were incubated with 8 ml of Ca++, Mg++ free DPBS for 15 30 min at 37° C. until the cells were easily detached by triturating with pipette. The cells were harvested into 50 ml of conical tubes, and spun at 1500 rpm for 5 min. The supernatant was discarded, and the cells were resuspended in 8 ml of Ca++, Mg++ free DPBS, and spun at 1500 rpm for 5 min. The supernatant was discarded, and the pellets were resuspended in 3 ml of membrane preparation buffer (10 mM Tris pH 7.4; 0.32M sucrose; 4 ug/ml leupeptin; 10 uM phosphoramidon; 40 ug/ml bacitracin; 5 ug/ml aprotinin). The pellets were homogenized with dounce homogenizer (Bellco with type “B” glass pestle) using 20 strokes. The homogenate was centrifuged at 1300×g at 4° C. for 10 min. The supernatants were collected, and the pellets were resuspended in membrane preparation buffer, and homogenization and centrifugation were repeated. All of the supernatants were collected and centrifuged at 40,000 rpm (Beckman XL-100K Ultracentrifuge, Rotor 45 Ti, 50 ml centrifuge tube) at 4° C. for 15 min. The pellets were resuspended in membrane preparation buffer, and protein was determined by BCA assay kit (PIERCE). Aliquots were placed in tubes and stored at −80° C.
20 ul of NDP-MSH or test compounds diluted in DMSO were added onto each well of 96-well V-plate. 20 ul of 750 ug/ml membrane fraction in MP buffer was added onto each well. After the reaction was performed at rt for 15 min, cAMP was measured using cAMP (3H) assay Kit (Amersham, cat. No. TRK 432). The amount of cAMP produced by the treatment with test compound was compared to that produced in the response to NDP-MSH which was defined as 100% agonist. The EC50 was defined as the concentration of test compound that results in half maximal activity of its own.
INDUSTRIAL APPLICABILITY
As can be seen from the above results, the compounds according to the present invention showed agonistic activity at each MCR. In particular, the compounds according to the present invention showed excellent agonistic activity at MC4R as illustrated in Table shown below.










TABLE 18







Example
EC50(nM)



















A1
13



A2
16



A3
12



A4
3



A5
33



A6
24



A7
24



A9
45



A75
79



A90
30



A96
38



A99
69



A109
54



B4
16



B8
29



B28
14



B33
65



C1
38



C2
11



C3
15



C5
6



C9
41



C12
95



C13
40



C14
66



C24
22



D1
47



E1-14
23



E1-23
21



E2-2
7



E2-3
45



E5-2
5



E10
4

## Claims

1. A compound of the following formula 1, pharmaceutically acceptable salt or stereoisomer thereof:



wherein
R1 represents hydrogen, amidino, C1-C4-alkylamidino, C1-C4-alkanoylamidino, C1-C10-alkyl, C3-C7-cycloalkyl, C6-C10-aryl, heterocycle, heteroaryl, C1-C6-alkylcarbonyl, C3-C7-cycloalkylcarbonyl, C1-C4-alkoxycarbonyl, C6-C10-aryl-C1-C4-alkoxycarbonyl, —SO2—C1-C4-alkyl, —C(O)—N(R6)(R7) or —C(S)—N(R6)(R7),
wherein,
R6 and R7 each independently represents hydrogen, C1-C6-alkyl or C3-C7-cycloalkyl,
alkyl, cycloalkyl, heterocycle, aryl or heteroaryl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, amino, C1-C4-alkyl, trifluoromethyl, hydroxy, C1-C4-alkoxy and oxo,
R2 represents C6-C10-aryl or heteroaryl, each of which is unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of halogen, hydroxy, C1-C4-alkyl, C1-C4-alkoxy, cyano and amino,
R3 represents hydrogen, cyano, C1-C6-alkyl, C3-C7-cycloalkyl, C2-C6-alkenyl, monocyclic heterocycle, monocyclic heteroaryl, —C(O)—R8 or —C(S)—R8,
wherein, R8 represents hydroxy, C1-C4-alkyl, C1-C4-alkyloxy or N(R9)(R10),
R9 and R10 each independently represents hydrogen, C1-C6-alkyl, C3-C7-cycloalkyl, C1-C4-alkyloxy, phenyl or heteroaryl,
R9 and R10 may combine each other to form single ring or two rings, or further comprise oxygen atom or sulfur atom,
wherein, alkyl, cycloalkyl, heterocycle, phenyl or heteroaryl is unsubstituted or substituted with a substituent selected from the group consisting of methyl, trifluoromethyl, hydroxy, hydroxyimino, amino, acetylamino, (C1-C4-alkyl)amino and (C1-C4-alkyl)(C1-C4-alkyl)amino,
R4 represents C3-C8-cycloalkyl, C6-C10-aryl, heteroaryl or heterocycle,
wherein, C6-C10-aryl or heteroaryl is unsubstituted or mono- or poly-substituted with a substituent selected from the group consisting of halogen, hydroxy, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy and amino,
cycloalkyl or heterocycle is unsubstituted or mono- or poly-substituted with a substituent selected from the group consisting of halogen, hydroxy, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy and oxo,
R5 represents hydrogen, C1-C6-alkyl, —C(O)—R11, C1-C6-alkylsulfonyl, C6-C10-arylsulfonyl, —(CH2)p—C6-C10-aryl, —(CH2)p-heteroaryl or —(CH2)p—C3-C8-cycloalkyl,
wherein, p represents 1 or 2,
R11 represents C1-C10-alkyl, C2-C6-alkenyl, C3-C8-cycloalkyl, C3-C8-cycloalkenyl, amino, C1-C4-alkylamino, (C1-C4-alkyl)(C1-C4-alkyl)amino, C6-C10-aryl, heteroaryl, or heterocycle,
wherein, alkyl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, mercapto, C1-C4-alkoxy, C1-C3-alkylcarboxy, amino, dimethylamino, C1-C4-alkylcarbonylamino, cyano, carbamoyl, dimethylcarbamoyl, hydroxyimino and oxo,
aryl or heteroaryl is unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of halogen, hydroxy, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy and amino,
cycloalkyl, cycloalkenyl or heterocycle is unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of halogen, hydroxy, amino, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy and oxo.

2. The compound of claim 1, wherein
R1 represents hydrogen, amidino, C1-C4-alkylamidino, C1-C4-alkanoylamidino, C1-C6-alkyl; C3-C7-cycloalkyl, phenyl, monocyclic heterocycle, monocyclic heteroaryl, C1-C6-alkylcarbonyl, trifluoroacetyl, C1-C4-alkoxycarbonyl, C6-C1-C4-alkoxycarbonyl, —SO2—C1-C4-alkyl, carbamoyl, C1-C6-alkylcarbamoyl, (C1-C6-alkyl) (C1-C6-alkyl)carbamoyl, thiocarbamoyl, C1-C6-alkylthiocarbamoyl or (C1-C6-alkyl)(C1-C6-alkyl)thiocarbamoyl,
wherein, alkyl is unsubstituted or substituted with trifluoromethyl,
pharmaceutically acceptable salt or stereoisomer thereof.

3. The compound of claim 2, wherein
R1 represents hydrogen, amidino, methylamidino, ethylamidino, acetylamidino, methyl, ethyl, trifluoroethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxazolynyl, imidazolynyl, thiazolynyl, piperidinyl, tetrahydropyranyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, pyridinyl, acetyl, trifluoroacetyl, propionyl, butyryl, isobutyryl, pivaloyl, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, methylsulfonyl, carbamoyl, methylcarbamoyl, ethylcarbamoyl, trifluoroethylcarbamoyl, propylcarbamoyl, isopropylcarbamoyl, butylcarbamoyl, t-butylcarbamoyl, thiocarbamoyl, methylthiocarbamoyl, ethylthiocarbamoyl or methylethylcarbamoyl,
pharmaceutically acceptable salt or stereoisomer thereof.

4. The compound of claim 1, wherein
R2 represents phenyl unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of F, Cl and methyl,
pharmaceutically acceptable salt or stereoisomer thereof.

5. The compound of claim 4, wherein
R2 represents phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-methylphenyl or 2,4-difluorophenyl,
pharmaceutically acceptable salt or stereoisomer thereof.

6. The compound of claim 1, wherein
R3 represents hydrogen, cyano, C1-C4-alkyl, C2-C4-alkenyl, —CH2C(CH3)2CH2OH, oxazolyl, thiazolyl, oxazolynyl, thiazolynyl, carboxy, C1-C4-alkylcarbonyl, C1-C4-alkyloxycarbonyl, carbamoyl, thiocarbamoyl, C1-C4-alkylcarbamoyl, (C1-C4-alkyl) (C1-C4-alkyl)carbamoyl, (C1-C4-alkyl) (C1-C4-alkyloxy)carbamoyl, C1-C4-alkylthiocarbamoyl or (C1-C4-alkyl)(C1-C4-alkyl)thiocarbamoyl, phenylcarbamoyl, heteroarylcarbamoyl, azetidinecarbonyl, pyrrolidinecarbonyl, piperidinecarbonyl or morpholinecarbonyl,
wherein alkyl is unsubstituted or substituted with a substituent selected from the group consisting of hydroxy, hydroxyimino, amino, (C1-C4-alkyl)amino and (C1-C4-alkyl)(C1-C4-alkyl)amino,
pharmaceutically acceptable salt or stereoisomer thereof.

7. The compound of claim 6, wherein
R3 represents hydrogen, cyano, methyl, ethyl, propyl, allyl, —CHNOH, hydroxymethyl, —CH(CH3)OH, aminomethyl, dimethylaminomethyl, oxazolyl, thiazolyl, oxazolynyl, thiazolynyl, carboxy, acetyl, propanoyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, t-butoxycarbonyl, carbamoyl, thiocarbamoyl, ethylcarbamoyl, t-butylcarbamoyl, dimethylcarbamoyl, methylethylcarbamoyl, methylmethoxycarbamoyl, dimethylthiocarbamoyl, phenylcarbamoyl, heteroarylcarbamoyl, —C(O)NH(CH2)2NH2, azetidinecarbonyl, pyrrolidinecarbonyl, piperidinecarbonyl or morpholinecarbonyl,
pharmaceutically acceptable salt or stereoisomer thereof.

8. The compound of claim 1, wherein
R4 represents C4-C7-cycloalkyl or monocyclic heterocycle unsubstituted or mono- or poly-substituted with a substituent selected from the group consisting of halogen, hydroxy, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy and oxo; or phenyl or monocyclic heteroaryl unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of halogen, hydroxy, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy and amino,
pharmaceutically acceptable salt or stereoisomer thereof.

9. The compound of claim 8, wherein
R4 represents cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, 4,4-dimethylcyclohexyl, 4,4-difluorocyclohexyl, 4-trifluoromethylcyclohexyl, 3,4-tetramethylcyclopentyl, tetrahydropyranyl, pyridinyl, N-methylpyridinyl or phenyl,
wherein, phenyl is unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of F, Cl, methyl and methoxy,
pharmaceutically acceptable salt or stereoisomer thereof.

10. The compound of claim 1, wherein
R5 represents hydrogen, C1-C6-alkyl, —CO—R11, C1-C6-alkylsulfonyl, —CH2—C6-C10-aryl, —CH2-heteroaryl or —CH2—C3-C8-cycloalkyl,
wherein, R11 represents C1-C6-alkyl, difluoromethyl, trifluoromethyl, C2-C6-alkenyl, C3-C8-cycloalkyl, C3-C8-cycloalkenyl, amino, C1-C4-alkylamino or (C1-C4-alkyl)(C1-C4-alkyl)amino, phenyl, monocyclic heteroaryl, or monocyclic heterocycle,
wherein, alkyl is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, mercapto, C1-C4-alkoxy, acetoxy, amino, acetylamino, cyano, carbamoyl, dimethylcarbamoyl, hydroxyimino and oxo
phenyl or heteroaryl is unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of F, hydroxy, methyl, trifluoromethyl, methoxy and amino,
cycloalkyl, cycloalkenyl or heterocycle is unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of C1-C4-alkyl, C1-C4-alkoxy and oxo,
pharmaceutically acceptable salt or stereoisomer thereof.

11. The compound of claim 10, wherein
R5 represents hydrogen, C1-C5-alkyl, trifluoromethyl, C1-C6-alkylcarbonyl, trifluoroacetyl, acryloyl, methacryloyl, C3-C8-cycloalkylcarbonyl, C3-C8-cycloalkenylcarbonyl, carbamoyl, C1-C4-alkylcarbamoyl, (C1-C4-alkyl)(C1-C4-alkyl)carbamoyl, methanesulfonyl, ethanesulfonyl, propanesulfonyl, benzoyl, hydroxybenzoyl, aminobenzoyl, monocyclic heteroarylcarbonyl, heterocyclecarbonyl, benzyl, —CH2-monocyclic heteroaryl, or —CH2—C3-C8-cycloalkyl,
wherein C1-C5-alkyl, or C1-C6-alkylcarbonyl is unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of F, hydroxy, mercapto, methoxy, ethoxy, acetoxy, amino, methylcarbonylamino, cyano, carbamoyl, hydroxyimino and oxo,
pharmaceutically acceptable salt or stereoisomer thereof.

12. The compound of claim 11, wherein
R5 represents hydrogen, methyl, ethyl, propyl, isobutyl, hydroxyethyl, —CH2C(CH3)2CH2OH, —CH2C(CH3)2CH(CH3)OH, —CH2CH2NHC(O)CH3, aminoethyl, acetyl, trifluoroacetyl, hydroxyacetyl, methoxyacetyl, ethoxyacetyl, propionyl, ethoxypropionyl, isobutyryl, cyanoisobutyryl, hydroxyisobutyryl, carbamoylisobutyryl, 3,3-dimethylbutanoyl, pivaloyl, fluoropivaloyl, difluoropivaloyl, hydroxypivaloyl, mercaptopivaloyl, dihydroxypivaloyl, methoxypivaloyl, ethoxypivaloyl, aminopivaloyl, dimethylaminopivaloyl, hydroxyiminopivaloyl, acetylisobutyryl, —C(O)C(CH3)2CH(CH3)OH, —C(O)C(CH3)2C(CH3)2OH, acryloyl, methacryloyl, cyclopentanecarbonyl, cyclohexylenecarbonyl, carbamoyl, dimethylcarbamoyl, methanesulfonylcarbonyl, benzoyl, thiopenecarbonyl, furoyl, oxazolecarbonyl, thiazolecarbonyl, imidazolecarbonyl, pyrazolecarbonyl, tetrahydrofuroyl, dihydrofuroyl, tetrahydropyrancarbonyl, morpholinecarbonyl, methanesulfonyl, benzyl, furanmethyl, thiazolemethyl or imidazolemethyl,
pharmaceutically acceptable salt or stereoisomer thereof.

13. The compound of claim 1, wherein
R1 represents hydrogen, amidino, methylamidino, ethylamidino, acetylamidino, methyl, ethyl, trifluoroethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, oxazolynyl, imidazolynyl, thiazolynyl, piperidinyl, tetrahydropyranyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, pyridinyl, acetyl, trifluoroacetyl, propionyl, butyryl, isobutyryl, pivaloyl, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, methylsulfonyl, carbamoyl, methylcarbamoyl, ethylcarbamoyl, trifluoroethylcarbamoyl, propylcarbamoyl, isopropylcarbamoyl, butylcarbamoyl, t-butylcarbamoyl, thiocarbamoyl, methylthiocarbamoyl, ethylthiocarbamoyl or methylethylcarbamoyl,
R2 represents phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-methylphenyl or 2,4-difluorophenyl,
R3 represents hydrogen, cyano, methyl, ethyl, propyl, allyl, —CHNOH, hydroxymethyl, —CH(CH3)OH, aminomethyl, dimethylaminomethyl, oxazolyl, thiazolyl, oxazolynyl, thiazolynyl, carboxy, acetyl, propanoyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, t-butoxycarbonyl, carbamoyl, thiocarbamoyl, ethylcarbamoyl, t-butylcarbamoyl, dimethylcarbamoyl, methylethylcarbamoyl, methylmethoxycarbamoyl, dimethylthiocarbamoyl, phenylcarbamoyl, hetero arylcarbamoyl, —C(O)NH(CH2)2NH2, azetidinecarbonyl, pyrrolidinecarbonyl, piperidinecarbonyl or morpholinecarbonyl,
R4 represents cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-methylcyclohexyl, 4,4-dimethylcyclohexyl, 4,4-difluorocyclohexyl, 4-trifluoromethylcyclohexyl, 3,4-tetramethylcyclopentyl, tetrahydropyranyl, pyridinyl, N-methylpyridinyl or phenyl,
wherein, phenyl is unsubstituted or mono- or di-substituted with a substituent selected from the group consisting of F, Cl, methyl and methoxy,
R5 hydrogen, methyl, ethyl, propyl, isobutyl, hydroxyethyl, —CH2C(CH3)2CH2OH, —CH2C(CH3)2CH(CH3)OH, —CH2CH2NHC(O)CH3, aminoethyl, acetyl, trifluoroacetyl, hydroxyacetyl, methoxyacetyl, ethoxyacetyl, propionyl, ethoxypropionyl, isobutyryl, cyanoisobutyryl, hydroxyisobutyryl, carbamoylisobutyryl, 3,3-dimethylbutanoyl, pivaloyl, fluoropivaloyl, difluoropivaloyl, hydroxypivaloyl, mercaptopivaloyl, dihydroxypivaloyl, methoxypivaloyl, ethoxypivaloyl, aminopivaloyl, dimethylaminopivaloyl, hydroxyiminopivaloyl, acetylisobutyryl, —C(O)C(CH3)2CH(CH3)OH, —C(O)C(CH3)2C(CH3)2OH, acryloyl, methacryloyl, cyclopentanecarbonyl, cyclohexylenecarbonyl, carbamoyl, dimethylcarbamoyl, methanesulfonylcarbonyl, benzoyl, thiopenecarbonyl, furoyl, oxazolecarbonyl, thiazolecarbonyl, imidazolecarbonyl, pyrazolecarbonyl, tetrahydrofuroyl, dihydrofuroyl, tetrahydropyrancarbonyl, morpholinecarbonyl, methanesulfonyl, benzyl, furanmethyl, thiazolemethyl or imidazolemethyl,
pharmaceutically acceptable salt or stereoisomer thereof.

14. The compound of claim 13, which is selected from the following group:
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{(4,4-dimethylcyclohexyl) [(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-N,N-ethylmethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{(4,4-dimethylcyclohexyl) [(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-N-ethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(2,2-dimethylpropanoyl)amino]-N-ethyl-L-prolineamide
(4S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-methylpyrrolidine-3-yl]carbonyl}-4-[(2,2-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]-L-prolineamide
N-[(3S)-1-{[(3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide
N-[(3S)-1-{[(3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(methylsulfonyl)amino]-N,N-dimethyl-L-prolineamide
N-[(3S)-1-{[(3S,4R)-1-t-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl] (4,4-dimethylcyclohexyl)amino}-2,2-dimethylpropane-1-ol
(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-N-isobutyl-N-(cis-4-methylcyclohexyl)pyrrolidine-3-amine
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(cis-4-methylcyclohexyl)(tetrahydro-2H-pyran-4-ylcarbonyl)amino]-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenylpyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-thienylcarbonyl)amino]-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(isobutyryl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2,-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,2,-dimethylpropanoyl)(cis-4-methylcyclohexyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2,-dimethylpropanoyl)amino]-N-ethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2,-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2,-dimethylpropanoyl)amino]-N-isopropyl-L-prolineamide
N-[(3S,5S)-5-(azetidine-1-ylcarbonyl)-1-[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyepyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,5-dihydrofuran-3-ylcarbonyl)(4,4-dimethylcyclohexyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2,-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl) [(2S)-tetrahydrofuran-2-ylcarbonyl]amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(3-hydroxy-2,2,-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2,-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-furoyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-furoyl)amino]-N-ethyl-N-methyl-L-prolineamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-[(4,4-difluorocyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl) [(2S)-tetrahydrofuran-2-ylcarbonyl]amino]-N-ethyl-N-methyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(2,2,-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-N-ethyl-4-[(3-hydroxy-2,2,-dimethylpropanoyl)(cis 4-methylcyclohexylamino]-N-methyl-L-prolineamide
N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-{[ethyl(methyl)amino]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-[(3S,5S-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(pyrrolidine-1-ylcarbonyl)pyrrolidine-3-yl]-N-(4,4-difluorocyclohexyl)-2,2-dimethylpropaneamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-N-ethyl-N-methyl-4-{spiro[2,5]oct-6-yl[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-L-prolineamide
N-[(3S,5S-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(morpholine-4-ylcarbonyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)acetamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)[(2R)-tetrahydrofuran-2-ylcarbonyl]amino]-N-ethyl-N-methyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2,-dimethylpropanoyl)amino]-N-ethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2,-dimethylpropanoyl)amino]-N-phenyl-L-prolineamide
(2S)—N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)tetrahydrofuran-2-carboxamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-[(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2-methyl-N-(cis-4-(trifluoromethyl)cyclohexyl]propaneamide
(2S)—N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)tetrahydrofuran-2-carboxamide
N-[(35)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)tetrahydrofuran-3-carboxamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-cycloheptyl-3-hydroxy-2,2-dimethylpropaneamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{(4,4-dimethylcyclohexyl)(methylsulfonyl)amino}-N-ethyl-N-methyl-L-prolineamide
(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-N-(4,4-dimethylcyclohexyl)-N-3-furylpyrrolidine-3-amine
N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(4,5-dihydro-1,3-oxazole-2-yl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3 carbonyl-5-[(dimethylamino)carbonothionyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2-methylpropaneamide
N-[(3S,5R)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-(1,3-thiazole-2-yl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl-5-(hydroxymethyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-methylpyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-{(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(E)-(hydroxyimino)methyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-[(3S,5S)-5-(aminoethyl)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-[(3S,5S)-5-[(acetylamino)methyl]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-dichlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-dichlorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)methyl]pyrrolidine-3-yl}-]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-cyanopyrrolidine-3-yl]-2,2-dimethyl-N-(cis-4-methylcyclohexyl)propaneamide
N-[(3S,5R)-5-acetyl-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(1-hydroxymethyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
(4S)-4-[acetyl(4,4-dimethylcyclohexyl)amino]-N-(2-aminoethyl)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-L-prolineamide
methyl (45)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-L-prolinate
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-L-proline
N-[(3S,5R)-5-(aminocarbothioyl-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-{(3S,5R)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)carbonothionyl]pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-[(3S,5R)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-propionylpyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-propionylpyrrolidine-3-yl]-N-(4,4-difluorocyclohexyl)-2,2-dimethylpropaneamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylmalonamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-methoxy-2,2-dimethylpropaneamide
(3E)-N-[(3S)-1-[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-(hydroxyimino)-2,2-dimethylpropaneamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylbutanamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethyl-3-oxobutanamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2,3-trimethylbutanamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-fluoro-2,2-dimethylpropaneamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3,3-difluoro-2,2-dimethylpropaneamide
N-[(3S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-[(4,4-difluorocyclohexyl)(3-methoxy-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
(4S)-4-[(3-amino-2,2-dimethylpropanoyl)(4,4-dimethylcyclohexyl)amino]-1-{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{[3-(dimethylamino)-2,2-dimethylpropanoyl] (4,4-dimethylcyclohexyl)amino}-N,N-dimethyl-L-prolineamide
N-{(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)carbonyl]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylmalonamide
S-(3-{[(3S,5S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-5-{[ethyl(methyl)amino]carbonyl}pyrrolidine-3-yl] (4,4-dimethylcyclohexyl)amino}-2,2-dimethyl-3-oxopropyl)ethanethioate
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-mercapto-2,2-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-text-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluoro cyclohexyl)(3-methoxy-2,2,-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-difluorocyclohexyl)(3-ethoxy-2,2,-dimethylpropanoyl)amino]-N-ethyl-N-methyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,4-difluorophenyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
(45)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,2,-dimethylpropanoyl)(4-methoxyphenyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{(2,2,-dimethylpropanoyl) [4-(trifluoromethyl)phenyl]amino}-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,2-dimethylpropanoyl)(4-methylphenyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-tert-butyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-{(2,4-difluorophenyl)[(2S)-tetrahydrofuran-2-ylcarbonyl]amino]-N—N-dimethyl-L-prolineamide
(4S)-1-[(3S,4R)-4-(4-chlorophenyl)pyrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
(2S)—N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)tetrahydrofuran-2-carboxamide
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(cis-4-methyl cyclohexyl)-3-furamide
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(cis-4-methylcyclohexyl)-2,5-dihydrofuran-3-carboxamide
(4S)—N-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(2,2,-dimethylpropanoyl) (cis-4-methylcyclohexyl)amino]-D-prolineamide
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-5-(1-hydroxymethyl)pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
(4S)-1-{[(3S,4R)-1-(aminocarbonyl)-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
(3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)pyrrolidine-1-carboxamide
(3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)pyrrolidine-1-carboxamide
(4S)-1-({[(3S,4R)-4-(4-chlorophenyl)-1-(ethylamino)carbonyl]pyrrolidine-3-yl}carbonyl)-4-[(4,4-dimethyl cyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-[(ethylamino)carbonothionyl]pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-difluorocyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide
(3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)-N-ethylpyrrolidine-1-carboxamide
(3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)-N-ethylpyrrolidine-1-carboxamide
(3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(2,4-difluorophenyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)-N-ethylpyrrolidine-1-carboxamide
(3R,4S)-3-(4-chlorophenyl)-N-ethyl-4-({(3S)-3-[isobutyryl(cis-4-methylcyclohexyl)amino]pyrrolidine-1-yl}carbonyl)-N-methylpyrrolidine-1-carboxamide
(4S)-1-({[(3S,4R)-1-acetyl-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-isobutyrylpyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethyl cyclohexyl)-2,2-dimethylpropaneamide
(4S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-isobutyrylpyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-L-prolineamide
(4S)-1-([(3S,4R)-4-(4-chlorophenyl)1-cyclopropylpyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(tetrahydro-2H-pyran-4-yl)pyrrolidine-3-yl]carbonyl}-4-{(4,4-dimethylcyclohexyl) [(2S)-tetrahydrofuran-2-ylcarbonyl]amino}-N-ethyl-N-methyl-L-prolineamide
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(2,2,2-trifluoroethyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
(4S)-1-{[(3S,4R)-4-(2,4-difluorophenyl)-1-isobutyrylpyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-cyclobutylpyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
(4S)-1-{[(3S,4R)-1-cyclopentyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide
N-{(3S,5S)-1-{[(3S,4R)-4-(2,4-difluorophenyl)-1-isobutyrylpyrrolidine-3-yl]carbonyl}-5-[(dimethylamino)carbonothio]pyrrolidine-3-yl}-N-(4,4-dimethylcyclohexyl)-2,2-dimethylpropaneamide
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(methylsulfonyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2-methyl-N-(cis-4-methylcyclohexyl)propaneamide
(3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(cis-4-methylcyclohexyl)(2-methylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
(3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)-N-(2,2,2-trifluoromethyl)pyrrolidine-1-carboxamide
methyl(3R,4S)-3-(4-chlorophenyl)-4-({(3S)-3-[(4,4-dimethylcyclohexyl)(3-hydroxy-2,2-dimethylpropanoyl)amino]pyrrolidine-1-yl}carbonyl)pyrrolidine-1-carboxylate
N-[(3S)-1-{[(3S,4R)-1-[amino(imino)methyl]-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2-methyl-N-(cis-4-methylcyclohexyl)propaneamide
N-[(3S)-1-({(3S,4R)-4-(4-chlorophenyl)-1-[(ethylamino)(imino)methyl]pyrrolidine-3-yl}carbonyl)pyrrolidine-3-yl}2-methyl-N-(cis-4-methylcyclohexyl)propaneamide
N-[(3S)-1-{[(3S,4R)-1-acetylamino)(imino)methyl]-4-(4-chlorophenyl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2-methyl-N-(cis-4-methylcyclohexyl)propaneamide
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-phenylpyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-propaneamide
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-pyridine-2-ylpyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-2,2-dimethyl-N-(cis-4-methylcyclohexyl)propaneamide
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(4,5-dihydro-1H-imidazole-2-yl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide
N-[(3S)-1-{[(3S,4R)-4-(4-chlorophenyl)-1-(4,5-dihydro-1H-imidazole-2-yl)pyrrolidine-3-yl]carbonyl}pyrrolidine-3-yl]-N-(4,4-dimethylcyclohexyl)-3-hydroxy-2,2-dimethylpropaneamide,
pharmaceutically acceptable salt or stereoisomer thereof.

15. A melanocortin receptor agonistic composition comprising the compound of formula 1 as defined in claim 1, pharmaceutically acceptable salt or stereoisomer thereof as active ingredient, together with pharmaceutically acceptable carrier.

16. The composition of claim 15 for the treatment of obesity.

17. The composition of claim 15 for the treatment of diabetes.

18. The composition of claim 15 for the treatment of inflammation.

19. The composition of claim 15 for the treatment of erectile dysfunction.